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Summary  
Hypertension is a leading cause of death and disability worldwide. Despite 
effective treatment regimens the mortality among hypertensive subjects are 
much higher than that of normal individuals. Several studies have been carried 
out to identify prognostic factors that have predictive value for mortality in the 
general population. New biomarkers that are readily available and cost-effective 
are important in risk stratification and management of hypertension. While 
important prognostic information can be learned from routine blood tests that 
are often conducted in hypertension clinics, the usefulness of these markers in 
predicting survival are not studied in detail. The thesis aims to explain the 
relationship between such inexpensive and commonly available markers and 
survival in a hypertensive population.  
The thesis is divided into five main results chapters (chapters 3 to 7) based on 
studies conducted to assess the independent role of blood pressure variability 
(BPV), haematocrit, serum phosphate, serum electrolytes and indices of liver 
dysfunction or injury in predicting mortality in hypertensive patients. The study 
settings (Glasgow Blood Pressure Clinic) provided an opportunity to examine 
these relationships in a treated hypertensive cohort of more than 15,000, 
predominantly white population, from the West of Scotland. The hypertension 
clinic database was linked with the electronic records of General Register Office 
for Scotland. This electronic linking allowed extraction of primary cause of death 
data (if patients died during the course of follow-up) according to the 
International Classification of Diseases, 10th Revision, Version for 2007 (ICD-10), 
codes. The type of mortality was ascertained (namely; ischaemic heart disease, 
stroke, cardiovascular, non-cardiovascular and all-cause) from the ICD-10 codes. 
The independent relationships between predictor variables of interests and 
mortality were estimated after employing appropriate survival models. The main 
study findings are summarised below.  
Blood pressure variability and mortality: Long term average BPV is an 
independent predictor of mortality. Longitudinal changes in BPV also predict 
mortality independent of underlying mean BP. While sustained high variability 
increases mortality, sustained low variability decreases mortality in this 
hypertensive cohort. The findings indicate that BPV is likely a fundamental 
   3 
physiologic trait and it is a marker of early mortality. Visit-to-visit BPV is an 
important prognostic indicator of long-term mortality, and physicians should be 
made aware that long term clinic BPV should not be disregarded as random 
fluctuation between visits. 
Haematocrit and mortality: Haematocrit (Hct) is the proportion of blood volume 
occupied by red blood cells. It is associated with follow-up BP and is an 
independent predictor of mortality in the hypertensive population. There are 
distinct differences both in terms of the strength and magnitude of the 
association of Hct and mortality between men and women that have not 
previously been known. While Hct is associated with CV mortality in men ('U' 
shaped, non-linear), it is more closely associated with non-CV mortality in 
women ('U' shaped, non-linear). In the assessment and management of newly 
diagnosed hypertensive patients, Hct levels should be taken into consideration 
as an important risk predictor.  
Serum phosphate and mortality: Inorganic phosphate is an important mineral 
that is directly linked to energy metabolism, bone mineralisation, signal 
transduction, storage and translation of genetic information and maintenance of 
lipid membrane structure. A positive linear association between serum 
phosphate and mortality is reported in the present study. Deprivation status, 
serum calcium and serum alkaline phosphatase levels do not attenuate the 
mortality risk associated with serum phosphate in men and women.  While serum 
phosphate is associated with CV mortality in men, it is more closely associated 
with non-CV mortality in women.  
Serum electrolytes and mortality: Electrolytes, especially sodium, chloride, 
potassium and bicarbonates, play a vital role in maintaining homeostasis within 
the human body. While the relationship with all-cause mortality is non-linear 
across the entire range of serum chloride, there is a linear increase in mortality 
with decrease in serum chloride level below 100 mEq/L.  The relationship 
between serum chloride and mortality is independent of serum sodium and 
bicarbonate levels. While serum potassium shows a non-linear "U" shaped 
relationship with mortality, serum bicarbonate shows a positive linear 
association.  
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Indices of liver dysfunction or liver injury and mortality: Serum albumin, 
bilirubin, alanine transaminase (ALT), aspartate transaminase (AST), gamma-
glutamyl transferase (GGT) and alakaline phosphatase (ALP) are widely used 
markers of liver function or injury to liver cells. These markers of liver function 
or injury to liver cells independently predict mortality outcomes in the 
hypertensive population. While there is a linear association of both GGT and ALP 
with mortality outcomes, it is a more complex, non-linear and ‘U’ shaped 
association for AST. Both ALT and bilirubin show inverse linear association with 
mortality. Age and body mass index significantly influence the relationship 
between ALT and mortality.  
Strengths and limitations: The strengths of the studies conducted as part of this 
thesis include; a large cohort of nearly 15,000 hypertensive adults, a real life 
clinical setting, 35 years of follow-up with median survival time of 32 years, the 
ability to link predictor variables with differing causes of mortality outcomes, 
and adjustment for several potential confounding factors. Exclusion of 
individuals without predictor variables assessed at baseline and the bias 
introduced by the missing covariates in the adjusted Cox-proportional hazard 
models are the major weaknesses.  
Future recommendations:  Although the above mentioned inexpensive markers 
predict mortality in hypertensive population, the mechanism involved in their 
association with mortality is not clear. Future studies are required to explain the 
missing links. Usefulness of inclusion of these markers in predicting mortality 
should be tested in an independent population.  
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1  Introduction  
1.1 Elevated blood pressure as a risk factor: Historical 
perspectives   
Reverend Stephen Hales, an English clergy, is considered to be the first person 
to measure arterial blood pressure (BP) in horses in the first half of 18th century 
1. Sphygmomanometers were introduced in the late 19th century by Riva-Rocci 
and Korotkov 2. Diastolic blood pressure (DBP) measurements were made 
possible after the vital description of sounds associated with the appearance of 
the pulse wave by Korotkov 3. The Hawksley random zero sphygmomanometer 
was introduced later as an alternative to reduce the potential for digit 
preference associated with using the standard devices 4.  Later in the 20th 
century aneroid (mechanical) and electronic devises replaced the mercury 
manometer mainly because of the health hazards associated with mercury use 
and disposal 5. Recently, ambulatory blood-pressure monitoring (ABPM) has been 
recognised as a superior option for the cost-effective diagnosis of hypertension 
in adults 6.  
Richard Bright (1827) and Ludwig Traube (1856) described the association 
between “increased arterial pulse tension” with cardiac and renal conditions 
such as “dropsy” and “nephritis” 2 3. High tension in the arterial system was 
recognised as a condition prior to the commencement of any kidney damage or 
appearance of albumin in urine in the late 19th century by Fred Mahomed 2 3. 
Clifford Allbutt (1986) and Henri Huchard subsequently demonstrated that 
hypertension might occur without overt renal disease and might precede 
arteriosclerosis 5 7. In the early 20th century Otto Frank named the condition 
“essential hypertension” which implied that the elevation of BP was a 
compensatory reaction to overcome ischaemia of the tissue caused by 
constricted arterioles 3 8.  In the tenth edition of Osler’s medical text book in 
1925, the normal systolic blood pressure (SBP) was described as 120-130 mmHg 
and 130-150 mmHg if over age 50 9.  
Insurance companies in the United States of America (USA) started measuring BP 
using sphygmomanometer in the early 20th century 5. The first evidence of an 
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age related increase in BP, and the relationship between elevated BP and 
mortality were published by the Actuarial Society of USA in 1925 10. 
Subsequently, a series of reports by the Actuarial Society of USA documented a 
positive association between elevated BP and mortality 5 11 12. A sharp increase in 
mortality associated with an incremental increase in BP was also documented in 
1959 by the Build and Blood Pressure Studies 13. Sir George Pickering in 1960 
highlighted hypertension as a “quantitative trait” with a continuous positive 
relationship between BP over the whole range and mortality 14.   
The main limitation of the Actuarial Society of USA data was that it represented 
only those individuals who applied for and who were issued a life insurance 
policy. Later epidemiological studies in the general population such as the large 
Multiple Risk Factor Intervention Trial (MRFIT) and data from Framingham Heart 
Study (FHS) corroborated and extended the basic conclusions of the Actuarial 
Society reports. The MRFIT cohort (1993), reported a graded and continuous 
influence of both systolic and diastolic BP on coronary heart disease (CHD) 
mortality and end-stage renal disease 15. Later in the year 2001, the FHS 
investigators confirmed the incremental increase in mortality associated with 
increase in BP even within the non-hypertension range 16. A large meta-analysis 
in 2002, involving data for more than one million adults further strengthened the 
concept of a positive, graded relationship between BP and mortality 17. This 
meta-analysis reported that there was no evidence of an abnormal BP threshold 
and the mortality increased progressively throughout the range of BP. Since BP is 
normally distributed in the population with the majority of individuals in the 
middle of the distribution and the risk operates across the continuum of BP, a 
large number of events arise from the 'moderate' middle of the distribution than 
from the 'high-risk' tail.  
1.2 Evolution of hypertension definitions  
Defining hypertension is extremely difficult due to the ‘quantitative’ 
relationship between BP and morbidity or mortality. The operational definition 
of hypertension is the level at which the benefits of action exceed those of 
inaction 18. As discussed in the previous section, a significant proportion of the 
adverse cardiac outcomes and mortality occur in individuals in the middle of the 
BP distribution. Having said that, a threshold BP level along with the assessment 
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of the global cardiovascular risk may be useful in clinical practice for screening 
high risk patients and initiating beneficial therapy. For this very reason clinical 
guidelines for detection, evaluation and treatment of hypertension have been 
modified several times in the last few decades.  
The first report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC-1) in 1976 agreed DBP as 
the basis for detection and treatment of high BP. It was consistent with the 
prevailing belief that DBP contributes to greater cardiovascular (CV) risk than 
SBP and rising SBP is an inconsequential part of the aging process 19. Although 
SBP was incorporated into BP staging as early as in 1984 (JNC III), it was used in 
the proper definition of hypertension for consideration of therapy only in the 5th 
JNC guidelines in 1993 20-24. A Clinical Advisory Statement issued in the year 2000 
25, after evaluating the accumulating evidence on the importance of SBP 26-29, 
recommended SBP as the principal measure for the detection, evaluation and 
the treatment of hypertension in both middle-aged and older adults.  JNC-6 
published in the year 1999 30, and the subsequent guidelines from European 31 32 
(guidelines Committee, 2003), World Health Organization-International Society 
of Hypertension 33 (WHO/ISH Writing Group, 2003) and the British Hypertension 
Societies 34 35 classified BP above 140 mmHg systolic and 90 mmHg diastolic as 
hypertension.   In 2003, JNC 7 36-38 defined normal BP as SBP below 120 mmHg 
and DBP below 80 mmHg. While individuals with SBP 140-159 mmHg and/or DBP 
90-99 mmHg were classified as stage 1 hypertension, those at or above SBP 160 
mmHg and/or DBP 100 mmHg were classified as stage 2 hypertension. Thus, 
hypertension was defined as SBP 140 mmHg or greater and/or DBP 90 mmHg or 
greater. Furthermore, a new category named “pre-hypertension” was defined as 
SBP between 120 and 139 mmHg and DBP between 80 and 90 mmHg. Various JNC 
classifications since 1976 are shown in figure 1-1 and figure 1-2. The United 
Kingdom’s National Institute for Health and Clinical Excellence (NICE) 2011 
hypertension guideline document also recommends the same criteria for 
hypertension classification 39. However, NICE recommends using ABPM or home 
blood pressure monitoring (HBPM) in patients with clinic BP > 140/90 mmHg with 
no evidence of target organ damage to confirm the diagnosis of hypertension 39 
and an ABPM/HBPM of <135/85 is classified as normal BP.  
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Figure 1-1: Joint National Committee (JNC) blood pressure classifications for systolic blood 
pressure.  
Adapted from Giles 2003 40. ISH=Isolated Systolic Hypertension. Systolic blood pressure is 
not part of JNC I and JNC II staging.  
 
Figure 1-2: Joint National Committee (JNC) blood pressure classifications for diastolic 
blood pressure.  
Adapted from Giles 2003 40. HTN=Hypertension.  
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Subtypes of hypertension include isolated systolic hypertension (ISH), isolated 
diastolic hypertension (IDH), white coat hypertension (elevated office BP but 
normal home BP) and masked hypertension (normal office BP but elevated mean 
arterial BP). ISH is the dominant form of hypertension in the elderly especially 
after the sixth decade of life 28 41 42. White coat hypertension is defined as BP 
that, if measured by a physician or a nurse, is persistently > 140 mmHg systolic, 
> 90 mmHg diastolic, or both, whereas out-of-office BP is within the normal 
range (i.e., <125-130 mmHg systolic and <80 mmHg diastolic for 24-h mean BP, 
or <135/85 mmHg for home BP) 43. The European Society of Hypertension and 
European Society of Cardiology guidelines often use the term “isolated clinic 
hypertension” for white-coat-hypertension. Masked hypertension was first 
described by Pickering 44 and it was defined as a clinic BP of <140/90 mmHg, and 
a 24-h or home BP value above normal values. 
1.3 Historical perspectives in the pathogenesis of 
primary hypertension  
In 1844 Richard Bright attributed hypertension to intrinsic renal disease 2. 
Subsequently several others demonstrated that hypertension may occur without 
overt renal disease. Sir William Osler in 1912 misinterpreted hypertension as a 
purely mechanical affair, a necessity and discouraged early attempts to develop 
drugs to lower BP 45. Later, Pickering 46 suggested that hypertension might 
simply reflect the right end of a normal Gaussian curve for BP in the population, 
and thus might not be a true ‘disease’.  
Goldblatt postulated that essential hypertension is primarily a disease of the 
pre-glomerular renal arterioles, leading to ischaemic renal injury and the release 
of some factors that would raise systemic vascular resistance and BP 47.  This 
concept was also supported by the observations of Perera who showed that renal 
arteriolar changes progressively became more severe depending on the 
magnitude of BP and duration 48.  Although elevated SBP is considered as an 
essential component of aging, Jim Henry in 1969 described several societies 
where age related change was negligible 49. Henry correlated the annual rate of 
increase in BP with “social tension score” in different societies. Later, 
hypertension was considered as a disease of adaptation to stress 50 or exposure 
to Western civilization 51. Page’s “mosaic theory” 52 explains the aetiology of 
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hypertension where essential hypertension was designated as a disease of 
control or regulation that was influenced by many known and unknown factors.  
Guyton postulated a theory of “hierarchy of pressure control systems” that 
provides both short-term damping and long-term control of arterial pressure and 
involves cardiovascular reflexes, capillary fluid shifts, vascular compliance and 
hormones 53. Based on the relationship of plasma renin activity to 24-hour urine 
sodium excretion, Bunner et al 54 identified two forms of vasoconstriction in 
essential hypertension namely renin-angiotensin-mediated vasoconstriction (high 
renin) and a volume-mediated vasoconstriction (low renin). Neural mechanisms 
especially the evidence of an activated sympathetic nervous system (SNS) 
leading to increased heart rate, BP and plasma catecholamnes in response to 
stimuli that includes mental stress, exercise, and a cold pressor test are well 
documented 55-58.  
Borst and Borst-De Geus 59 proposed that an acute rise in BP was accompanied by 
a reflex increase in urinary sodium excretion namely ‘pressure natriuresis’. 
Guyton et al 60 further developed this concept using mathematical and computer 
modelling and suggested that most systems that would raise BP, such as 
activation of SNS, would result only in transient elevations and that permanent 
increase in BP would require a resetting of the pressure natriuresis curve. 
Ecological associations of salt intake with BP led to the conclusion that salt 
intake explains the age-related increase in BP 61 62. Insignificant increases of BP 
with age in certain societies as demonstrated in the INTERSALT study further 
strengthened the notion of a causal association of salt intake with BP 63.  
However, in a study conducted in nuns living in Italy, there was a significantly 
lower increase in BP with age and relatively fewer cardiovascular events than 
their counterparts living in the surrounding villages despite the same 24-hour 
sodium excretion in both the groups 64 65. In a study conducted in the Kuna 
Indians, initial residents of the San Blas Islands off the coast of Panama, the 
sodium excretion levels were similar in migrants and non-migrants at different 
levels of BP 66. However, this study was grossly under powered to detect such 
differences. In general, migrant studies or ecological studies consistently show 
that salt intake is associated with increase in BP levels.   
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1.4 Mechanisms of primary hypertension  
Blood pressure is the product of cardiac output and peripheral resistance. 
Changes in any of these two conditions may result in high BP. Hypertension can 
sustain persistently only in response to an increase in cardiac output or a rise in 
peripheral resistance. Thus defects may be present in one or more of the 
multiple factors that affect these two forces and lead to hypertension. Despite 
decades of clinical research, a specific cause for most cases of hypertension is 
not identified except in a minority of individuals who have secondary 
hypertension. Therefore the condition is often referred to as ‘primary’ in 
preference to ‘essential’ hypertension. The increase in BP is usually slow and 
gradual and therefore some of the initiating factors may no longer be apparent 
at the time of diagnosis of hypertension due to various compensatory 
mechanisms that reverse or normalise these factors. The peripheral artery 
resistance often seen in sustained hypertension is generally considered as a 
compensatory mechanism to adjust the raised BP caused by a raised cardiac 
output. Regardless of how hypertension begins, increased peripheral resistance 
ultimately becomes the haemodynamic pattern seen in sustained hypertension. 
Available evidence suggests a complex interplay of neural, renal, hormonal and 
vascular mechanisms (Table 1-1, Page 31) and they are discussed in detail in the 
following sections.          
1.4.1 Neural mechanisms  
In the early 1990’s Julius and his team suggested that a ‘hyperdynamic’ 
circulation resulting from an adrenergically driven increase in cardiac output 
often resulted in elevated BP 67. This elevated BP is sustained by subsequent 
vasoconstriction, vascular remodelling and autoregulation (autoregulation 
further increases vasoconstriction with an appropriately normal cardiac output). 
In animal models, overactivity of the sympathetic nervous system (SNS) often 
leads to elevated BP and it is believed to play a key role in the pathogenesis of 
hypertension 68. However, the inhibitory reflexes arising from baro-receptors of 
the carotid sinus, carotid arch, heart and great veins evoke a reflex increase in 
efferent parasympathetic and decrease in efferent sympathetic activity. These 
reflexes lead to bradycardia and peripheral vasodilatation and often act as a 
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compensatory mechanism to control the increase in BP 68.   Excitatory neural 
reflexes from the activation of renal afferents by ischaemic metabolites and 
activation of sensory afferents of the muscles during exercise evoke reflex 
increases in BP and cardiac output 69.  Activation of the sympathetic nerves to 
the kidneys increases tubular sodium absorption, renin release and renal 
vascular resistance.  
Catecholamines (epinephrine and nor-epinephrine) induce their effects via both 
β-adrenergic and α-adrenergic receptors. While the β-adrenergic stimulation of 
the heart increases ventricular contractility and heart rate, the α-adrenergic 
stimulation of the peripheral vasculature causes vasoconstriction, vascular 
remodelling and hypertrophy 69 70. The renal nerve stimulates vasoconstriction 
via α1 adrenergic receptors, renin release via β1 adrenergic receptors, and 
enhances renal sodium and water re-absorption via α1 adrenergic receptors 
71.  
The early stage of primary hypertension is associated with increased heart rate, 
cardiac output, plasma and urinary nor-epinephrine, regional nor-epinephrine 
spillover, decreased nor-epinephrine uptake, peripheral postganglionic 
sympathetic nerve firing and α-adrenergic receptor mediated vasoconstrictor 
tone in the peripheral circulation all of which indicate sympathetic overactivity 
68 69 72 73. However, the sympathetic overactivity is difficult to quantify in clinical 
settings and plasma norepinephrine levels are an insensitive measure of 
sympathetic overactivity. Invasive radiotracer measurements of regional 
norepineprine spillover suggest that early stages of primary hypertension are 
characterised by sympathetic activation targeted to the kidney, heart, and 
skeletal muscle vasculature 73. The microneurographic measurements (a real-
time measure of sympathetic nerve activity) of muscle sympathetic nerve 
activity (MSNA) show higher levels of MSNA in hypertensive subjects than 
normotensive individuals 68 74. Increased MSNA alone does not cause hypertension 
as it is often accompanied by compensatory decreases in cardiac output and α-
adrenergic receptor sensitivity to norepinephrine 75. However, increased MSNA 
accompanied by impaired norepinephrine reuptake by sympathetic nerve 
terminals can lead to elevated BP and sustained hypertension 76.  
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Table 1-1: Main mechanisms involved in primary hypertension  
Mechanisms  Mediators and specific actions  
Neural  Adrenergically driven hyperdynamic circulation  
  α and β adrenergic stimulation  
  Vascular re-modelling and autoregulation  
  Overactivity of sympathetic nervous system  
  Inhibitory reflexes from baroreceptors of large vessels   
Renal  Renoprival (Glomerular filtration rate dependent)  
  Transport mechanism (re-absorption of sodium from renal 
tubules; action on eNaC)  
  
Renal ischaemia (Vaso-constriction, oxidative stress, 
inflammation) 
  Low nephron numbers  
Hormonal  
Renin angiotensin system (Sodium handling, vascular 
remodelling, inflammation, oxidative stress, Sodium-Calcium 
exchange and increase in cystosolic calcium, pressure-
natriuresis)  
  
Mineralocortocoid receptors (Sodium re-absorption, salt 
appetite, vascular contraction, endothelial dysfucntion, 
inflammation, vascular remodelling) 
  Renal dopaminergic system (Pressure-natriuresis)  
  Insulin  
  Vasopressin  
  Carditonic steroids  
Additional 
vascular 
mechanisms  
Increase in cytosolic calcium, vascular contractility, 
endothelial dysfunction, oxidative stress, eutrophic 
remodelling, hypertrophic remodelling 
  Microvascular rarefaction  
Other 
mechanisms  Obesity related hypertension  
  Uric acid  
  Androgens  
  
Haematocrit, whole blood viscosity and elevated plasma 
fibrinogen  
  
Nicotine, Caffeine, alcohol, high altitude, cold weather and air 
pollution. 
  Vitamin D levels  
  Blood lead levels  
eNaC=epithelial sodium channel  
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1.4.2 Renal mechanisms  
In general kidneys are considered to be both culprits and victims in 
hypertension. Johnson et al 77 propose three primary renal mechanisms in the 
aetiology of hypertension and they are; (a) glomerular filtration rate dependent 
(renoprival mechanism), (b) transport mechanisms (stimulation of sodium re-
absorption in collecting duct), and (c) renal ischaemia (vasoconstriction, 
oxidative stress and inflammation).  
There is a strong association between renal function and hypertension 47. 
Hypertension develops rapidly in animals whose kidneys are removed 
(renoprival) or injured 78. However, hypertension can occur even in the absence 
of clinically evident renal diseases. In humans, hypertension increases with 
worsening glomerular filtration rate and is often seen in individuals with mild 
renal dysfunction 79. The reduction in GFR can lead to sodium retention and 
volume expansion. Since the tubular renal handling is impaired in renal 
dysfunction the excess sodium load due to reduced GFR cannot be compensated 
by reduced tubular re-absorption.  
Renal vasoconstriction mainly in the afferent arteriole limits sodium excretion, 
alters the sodium balance and results in elevated BP 80 81. The vasoconstriction is 
mediated by different mechanisms and involves hyperactive SNS, activation of 
the renin-angiotensin system, endothelial dysfunction with impaired release of 
nitric oxide, hypokalemia, oxidative stress, thromboxane, and by drugs such as 
cyclosporine 82-89. In the long run the multiple episodes of renal vasoconstriction, 
particularly if coupled with local angiotensin II stimulation, can lead to renal 
arteriolar disease.  
The inflammatory cells consisting of the interstitial T cells and macrophages 
infiltrate the renal vessels and produce oxidants and angiotensin II 89 90. 
Intrarenal injury can also activate SNS 91, which further activates renal efferent 
nerves and augments renal vasoconstriction and facilitates sodium retention. 
Continued stimulation of sodium re-absorptive mechanisms leads to impaired 
pressure natriuresis and persistent hypertension 77.  
Low nephron numbers commonly seen in low birth weight infants and those 
suffering from intra-uterine growth retardation leads to hypertension 92-94. In 
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maternal malnutrition models in which rats pups are born with low nephron 
numbers, they develop preglomerular arteriolar disease and tubulointerstitial 
inflammation 95. This suggests that low nephron numbers probably lead to 
hypertension because of its propensity to cause renal microvascular disease and 
inflammation. Young Caucasian individuals with essential hypertension have only 
half the number of nephrons compared with age-matched controls 96.  
1.4.3 Role of sodium and potassium in hypertension  
While a surplus of sodium (the main extracellular cation) increases arterial BP 97-
100, mounting evidence indicates the role of potassium (the main intracellular 
cation) deficit in hypertension 99 101 and its cardiovascular complications. While 
exchangeable sodium (measured by the isotope dilution technique) is increased 
in hypertensive subjects and correlates positively with arterial BP 102, 
exchangeable potassium correlates negatively with arterial pressure 103 104. Since 
human physiology is evolved in a low-sodium and high-potassium environment, 
we are currently under-equipped to manage the exposure of high sodium and 
low potassium diet 99. Prospective data from the third NHANES suggest that a 
higher sodium potassium ratio is associated with significantly increased risk of 
CV and all-cause mortality 105 106.  
In a landmark intervention study on chimpanzees, a high sodium diet increased 
BP rapidly and it was reversed after withdrawal of the sodium chloride 
supplement 107. Interestingly BP rose in only seven out of ten chimpanzees 
potentially due to varying degrees of salt sensitivity.  In dietary intervention 
studies in human beings, a low salt diet caused a moderate to significant 
decrease in BP both among normotensive and hypertensive subjects 108-111. A 
high-salt diet, beyond raising BP, is an independent risk factor for target organ 
damage leading to fatal and non-fatal cardiovascular events that include stroke, 
aortic stiffness, cardiac hypertrophy, diastolic dysfunction and renal failure 112-
114. In a recent meta-analysis of the long term effects of interventions aimed at 
reducing dietary salt on mortality and cardiovascular morbidity, clinically 
significant impact on mortality or cardiovascular morbidity was not evident in 
both normotensive or hypertensive populations 115 116. However, in a subsequent 
meta-analysis conducted after combining the event rates in both normotensive 
and hypertensive subjects, salt reduction was associated with significantly lower 
cardiovascular events 117. Although it is probably not appropriate to combine the 
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studies in normotensive and hypertensive subjects (hypertensive subjects are 
highly selected group) as in the latter meta-analyses, inadequate sample size in 
the intervention studies may be the reason for the absence of clinically 
significant impact in the former meta-analyses. Based on BP response to salt 
reduction at the population level in the USA, the projected effect of dietary salt 
reduction on future deaths were estimated at the population level. Reducing the 
dietary salt by 3 g per day is projected to reduce mortality by 2-12% in all age 
groups, men and women and in blacks and non-blacks (Figure 1-3) 118.  
 
Figure 1-3: Projected annual reduction in mortality (best case scenario) given a dietary salt 
reduction of 3 g per day in the US population. 
Adapted from Bibbins-Domingo et al 2010 118.  
A diet low in potassium (10 to 16 mmol/day) with the usual sodium intake (120-
200 mmol/day) causes sodium retention and elevation of BP 119 120. The long-
term effects of potassium depletion are to stimulate the activity and expression 
of the renal sodium pump that leads to sodium retention 121 122. In animal studies 
a high potassium diet even within the high sodium environment lowered BP and 
reduced the risk of stroke and stroke-related death 123.  A high potassium diet 
prevents cardiac hypertrophy, mesenteric vascular damage and renal injury 124. 
A meta-analysis of intervention studies evaluating the effects of an increased 
potassium intake on BP in human beings concluded that potassium 
supplementation lowered BP both in hypertensive and normotensive subjects 125. 
Potassium supplementation in hypertensive subjects can reduce the need for 
anti-hypertensive medication 126 and it exerts a powerful and dose-dependent 
inhibitory effect on sodium sensitivity 127.  
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How does sodium increases BP? There is no clear explanation on the mechanisms 
by which altered sodium levels influence BP. The potential mechanisms include 
expansion of plasma volume, increase in cardiac output, vasoconstriction, and 
vascular remodelling. Although increased cardiac output may initiate rises in BP, 
small vessel vasoconstriction and large-vessel stiffness are essential to sustain 
the elevated BP.  
Rodriguez-Iturbe and his colleagues elaborate both volume-dependent and 
volume-independent mechanisms in salt-dependent hypertension 128.  
Autoregulation and endogenous-ouabian-like compounds have been suggested to 
be involved in the volume-dependent pathway. Autoregulation is the process by 
which the small arteries constrict in response to an increased cardiac output. 
The resultant increase in cardiac after load returns cardiac output to normal but 
increases systemic vascular resistance and BP 59 67 129 130. Endogenous ouabain-
like inhibitors (EOs), an endogenous “digitalis-like factor” identical to ouabain or 
a stereoisomer of ouabian, are released from adrenal glomerulosa cells in 
response to salt retention and inhibit Na/K-ATPase in vascular smooth muscles 
and cardiac muscles 131-133. The resultant increase in sodium flux drives the Na-
Ca-exchanger (NCX) to increase cytosolic Ca2+ and enhances vasoconstriction, 
cardiac contractility and Ca2+ dependent cardiac and vascular hypertrophy 134. 
Volume independent mechanisms include angiotensin-mediated CNS effects, 
increase in SNS activity, hypertrophy in cardiac myoblasts and contractility of 
vascular smooth muscles, increase in production of nuclear factor-κB (pro-
inflammatory cytokines), increase in expression of angiotensin II type 1 receptor 
(AT1) in renal tissue and increase in transforming growth factor β production 
128.  
Re-absorption of the filtered sodium is enhanced in primary hypertension mainly 
because of the stimulation of several sodium transporters and the sodium pump. 
The activity of the sodium-hydrogen exchanger type 3 is enhanced in the 
proximal tubule and in the thick ascending limb of the loop of Henle in animal 
models with hypertension 135. Potassium depletion further enhances sodium-
hydrogen exchanger type 3 by inducing intracellular acidosis and by stimulating 
the SNS and the RAAS 136.  
Pressure-natriuresis is the mechanism by which renal excretion of sodium and 
water increases when BP rises. This leads to shrinking fluid volume and return to 
normal BP in normotensive people 130 137. While salt-resistant hypertension is 
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characterised by a shift in pressure-natriuresis curve towards the right, the salt 
sensitive hypertension is accompanied by an exaggerated increase in BP with 
increase in salt intake (changing the slope of the curve) 138 139. The renal 
function curve depicting the effect on mean arterial BP is shown in figure 1-4. 
The resetting of the pressure-natriuresis is mediated by changes in tubular 
sodium transport with unchanged glomerular filtration rate 137. Renal medulla is 
the key site in which pressure-natriuresis occurs. An imbalance between an 
overactive RAAS and a defective nitric oxide (NO) pathway is involved in 
resetting of the pressure-natriuresis 140. AT1 receptors in the kidney stimulate 
renal medullary vasoconstriction and increase sodium re-absorption 140. Studies 
have also demonstrated that angiotensin II alters pressure-natriuresis 139. 
Angiotensin II triggers calcium signal in the pericytes of the descending vasa 
recta and promotes vasoconstriction. It also acts on the tubular epithelial cells 
of the thick ascending limb and releases NO. This offsets the angiotensin II 
dependent vasoconstriction. Any imbalance between the vasoconstrictor and the 
dilator factors (tubule-vascular crosswalk) can cause medullary ischaemia, 
impaired pressure-natriuresis and salt induced hypertension 140. While AT1 
receptors promote sodium retention, AT2 receptors promote natriuresis which is 
mediated partly by release of NO 141.  
 
Figure 1-4: Renal function curve showing the effect of mean arterial blood pressure (MABP) 
on renal sodium excretion.  
A: the equilibrium pressure that is maintained through adjustment in sodium balance. B: on 
sustained increases in salt intake, function curve shifts to the left to give a higher level of 
excretion at any given pressure. C: if these adjustments fail, curve shifts to the right so that 
a higher equilibrium pressure is required to match sodium output to input (Adapted from 
Mullins et al 2006 142) 
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Stimulation of dopamine receptors (D1) enhances natriuresis and in animal 
studies the dopaminergic system explains part of the sodium excretion seen with 
salt loading 143. Both the D1 receptor-g-protein coupling defect and the 
decreased generation of dopamine could lead to renal sodium retention and 
hypertension 144. Dopamine simultaneously inhibits Na/K-ATPase activity 145 146 
and the Na+/H+ exchanger 147 148 within the renal tubule system. This results in 
decrease in sodium transport and re-absorption. A cytoskeletal protein named α-
adducin modulates Na/K-ATPase activity in renal epithelial cells and the 
polymorphisms within the adducin gene are associated with high BP 149. 
Furthermore in adducin dependent hypertension, the renal dopamine system is 
unable to inhibit Na/K-ATPase activity and thereby decrease renal sodium re-
absorption 150.  
Endothelin, a potent endothelium derived vasoconstrictor, causes natriuresis 151. 
Endothelin is plentiful in the renal medulla and protects against salt induced 
hypertension. While the vasodilatory effect of endothelin is mediated by 
endothelin B receptor (ETB), the vasoconstrictor effect of endothelin is 
mediated by endothelin A receptor (ETA). A high salt diet influences endothelin 
expression in the renal medulla and changes the renal medullary blood flow via 
PGE2 and NO 152.  
Renal inflammation is very often associated with renal medullary ischaemia and 
it is believed to be involved in the initiation and progression of experimental 
salt-sensitive hypertension 128. However, whether it is a cause or effect of salt-
sensitive hypertension or the renal medullary ischaemia is still not clear. 
Nocturia is very often a clinical sign of abnormal pressure-natriuresis and 
hypertensives have more nocturia that probably reflect the resetting of 
natriuresis 153. It is suggested that the fluid retained peripherally during daytime 
can lead to central volume expansion at night. The resulting elevated nocturnal 
BP compels the pressure-natriuresis 154.  
The extrarenal mechanisms involved in resetting the natriuresis and implicated 
in causing salt-sensitive hypertension involve activation of renal sympathetic 
nerves 71, α-melanocyte stimulating hormone which exacerbates salt-sensitive 
hypertension via stimulation of the central melanocortin system and activation 
of SNA 155, and dysfunction of the natriuretic peptides 156. Interstitial tissue 
macrophages regulate lymphatic fluid drainage and salt-dependent volume by 
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affecting the vascular-endothelial growth-factor-C-dependent buffering 
mechanisms 157.  
A homeostasis of sodium and potassium plays an important role in control of BP. 
In the following section the mechanisms by which potassium controls BP are 
explained. Potassium deficiency inhibits the sodium pump of arterial and 
arteriolar vascular smooth muscle cells and thereby increases the intracellular 
sodium 158. Furthermore, hypokalemia inhibits potassium channels in the cell 
membrane and depolarises the membrane. This in turn activates voltage-
dependent calcium channels in the membrane and in the sarcoplasmic reticulum 
and promotes the sodium calcium exchange 159 160. The excess cytosolic calcium 
increases the contraction of the vascular smooth muscles. By contrast, an 
increase in serum potassium hyperpolarises the endothelial cell, decreases the 
cytosolic calcium and promotes vasodilation 161 162. Furthermore, a potassium 
rich diet decreases cardiovascular risk by inhibiting arterial thrombosis, 
atherosclerosis, and medial hypertrophy of the arterial wall 163-165.  
Potassium depletion depresses the baro-receptor sensitivity and thereby affects 
this compensatory mechanism in the control of increase in BP 166. Furthermore, 
the decrease in baro-receptor sensitivity is restored when adequate potassium is 
supplemented. While potassium depletion inhibits insulin secretion, potassium 
infusion increases insulin secretion by changing the membrane potential of 
pancreatic beta cells 167 168. The increase in insulin promotes endothelium-
dependent vasodilation in skeletal muscles by influencing the release of NO 169 
170.  
1.4.4 Hormonal mechanisms  
Multiple hormonal mechanisms including the renin-angiotensin system (RAS), 
mineralocorticoid and mineralocorticoid receptors, the renal dopaminergic 
system, insulin, vasopressin and carditonic steroids have been demonstrated to 
play a role in primary hypertension. The renin-angiotensin-aldosterone system 
(RAAS) activation is probably the most important hormonal mechanism 
contributing to increases in BP and hypertension 171. The following section briefly 
describes these hormonal mechanisms in control of BP. Some of these hormonal 
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mechanisms are also involved in salt induced hypertension and they are 
described in the previous section (Section 1.4.3).  
Renin produced by the renal juxtaglomerular cells cleaves angiotensinogen to 
angiotensin I and it is then converted to angiotensin II by angiotensin-converting 
enzyme (ACE). Chymase in the heart and systemic arteries also provides an 
alternative pathway for conversion of angiontensin I to angiotensin II. The 
interaction of angiontensin II with G protein coupled AT1 receptors activates 
several cellular processes that contribute to elevated BP and hypertension 172.  
The earliest pathophysiologic change seen in primary hypertension is probably 
the process of vascular remodelling. Vascular remodelling in primary 
hypertension is characterised by increases in the media to lumen ratio resulting 
from vascular smooth muscle (VSM) cell growth, apoptosis, elongation of cells, 
and altered composition of extracellular matrix 173. Angiotensin II initiates 
vascular remodelling by stimulating both VSM cell hyperplasia and hypertrophy 
174. Furthermore, Angiotensin II is considered to be an inflammatory mediator in 
the vasculature and induces its effects by oxidative stress 175 176. Angiotensin II 
stimulates the formation of intracellular reactive oxygen species, including 
superoxide anion, hydrogen peroxide, hydroxyl free radical and peroxynitrite 177 
178. Angiotensin II evokes enhanced vasoconstriction and in patients with primary 
hypertension, AT1 receptor blockade reduces both BP and arterial resistance 
179. 
Harrison et al proposed a new mechanism that involves T-cell stimulation by 
angiotensin II and CNS activation in the pathogenesis of hypertension 180. The 
activated T cells release tumour necrosis factor (TNFα) and other diverse 
inflammatory stimuli, further activates vascular and renal nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and leads to local production of 
reactive oxygen species, vasoconstriction and vascular remodelling 180.  The 
cellular level changes induced by Angiotensin II are also associated with many 
signal pathways, including tyrosine kinase, mitogen-activated protein kinase, 
RhoA/Rho kinase and increased generation of reactive oxygen species 181-188. 
Interactions between these pathways are highly complex and dysregulation at 
any level could manifest as pathophysiologic vascular changes in hypertension. 
However, it is still not clear whether Angiotensin II plays a primary initiating role 
in hypertension or whether it simply mediates the vascular damage.  
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Kidney cross-transplantation experiments suggest that AT1 receptors exclusively 
in the kidney regulate BP 189. The proximal tubule AT1 receptors are critical for 
the sodium retaining action of Angiotensin II and its influence on BP. While the 
inappropriate activation of intrarenal RAS prevents the kidney from maintaining 
normal sodium balance 190 191, the inhibition of intrarenal RAS markedly reduces 
glomerular filtration rate, and sodium excretion 192 193. Furthermore, an 
inappropriately active intrarenal RAS causes renal vascular, glomerular and 
tubule-interstitial injury and fibrosis 194.  
Aldosterone is produced in the adrenal zona glomerulosa in response to 
Angiotensin II, potassium and adrenocorticotropin (ACTH). Aldosterone promotes 
unidirectional sodium flux, and an increase in extracellular fluid volume that 
leads to elevated BP 195. Interaction of aldosterone with mineralocorticoid 
receptors in the renal collecting duct cells recruits sodium channels from the 
cytosol to the surface of the renal epithelium. The epithelial sodium channels 
increase sodium absorption leading to expansion of plasma volume and increase 
in BP. Suppression of serum aldosterone increases endocytosis, de-phosporilate 
the epithelial membrane, diminish the epithelial sodium channels and sodium re-
absorption 196. In large epidemiological studies such as the Framingham study a 
17% increase in risk of hypertension was observed for each quartile increase in 
plasma aldosterone 197. While aldosterone influences the vascular contractility, 
it acts on the CNS and increases salt appetite 198. Increased concentration of 
aldosterone in combination with high sodium intake induces myocardial 
interstitial fibrosis 199 200. Aldosterone induced oxidative stress, endothelial 
dysfunction, inflammation, vascular remodelling and fibrosis in the vasculature, 
heart and kidneys are mediated via the mineralocorticoid receptor and sodium 
201-203. Aldosterone also induces progressive renal and cerebrovascular damage 204 
205. However, the adverse effects of aldosterone are only seen in the presence of 
a high-sodium diet 206.  
1.4.5 Additional vascular mechanisms  
Application of Poiseuille’s law 207 suggests that BP is directly related to the first 
power of cardiac output and inversely proportional to the fourth power of blood 
vessel radius. In addition to changes in cardiac output, alterations in small 
changes in the diameter of both the small and large arteries therefore play an 
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important role in the pathogenesis of elevated BP and hypertension. The neural 
and hormonal mechanisms involved in the sodium calcium exchange (NCX) and 
the role of sodium and potassium intake in controlling the cytosolic calcium are 
described in detail in the previous sections. An increase in cytosolic calcium is 
the final common pathway that mediates contraction of vascular smooth 
muscles.  
Endothelial cell dysfunction characterised by the impaired release of endothelial 
derived relaxing factors such as NO and enhanced release of endothelial derived 
constricting, proinflammatory, prothrombotic and growth factors (endothelin, 
thromboxane, and TGF-α) are involved in the pathogenesis of primary 
hypertension 208 209. Overproduction of superoxide anion and other reactive 
oxygen species (oxidative stress) activate signalling molecules that lead to cell 
growth, fibrosis inflammation and eventually vascular remodelling 208 210. While 
the RAAS mediated inward eutrophic remodelling initiated by vasoconstriction is 
the dominant mechanism in small arteries, hypertrophic remodelling mediated 
by SNS and angiotensin II with increase in size of vascular smooth muscle cells, 
accumulation of extracellular matrix proteins such as collagen and fibronectin 
due to activation of TGF-α is the dominant mechanism of remodelling in larger 
arteries 171.  
Elevated BP and hypertension are commonly accompanied by microvascular 
rarefaction i.e., reduced number or combined length of small vessels in a given 
volume of tissue. Both functional rarefaction (decreased capillary recruitment 
during metabolic demand) mediated by reactive oxygen species and anatomic 
rarefaction (vascular smooth muscle cell death and vessel dropout) mediated by 
apoptosis are believed to be involved in the pathogensis of hypertension 211.  
1.4.6 Other factors or mechanisms related to hypertension  
Primary hypertension is multi-factorial and several distinct and related 
mechanisms are involved in its pathogenesis. Overweight and obesity in children 
appears to be the lead contributor to essential hypertension prevalence in 
children and adolescents 212 213. The mechanisms of obesity-related hypertension 
are discussed briefly in the following section.  
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Several mechanisms are involved in the characteristic haemodynamic pattern of 
volume expansion, increased cardiac output, and systemic vascular resistance 
seen in obesity related hypertension. Sympathetic overactivity 214-216, selective 
leptin release 217 218, adipokines including leptin, free fatty acids and angiotensin 
II 219, RAAS overactivity, reactive oxygen species and NO deficiency 219, T cell 
activation 220 221, and the overactivation of endocannabinoid pathway 222 are 
some of the mechanisms associated with obesity related hypertension. Obesity 
and associated increase in adipose tissue results in decrease in adiponectin 
levels and increase in leptin levels.  The imbalance between the prohypertensive 
and antihypertensive adipokines mediates cell proliferation, endothelial 
dysfunction, inflammatory reaction, oxidative stress and thrombosis in the 
vascular structure 219. Furthermore, the reduced insulin sensitivity often seen in 
obesity is directly associated with elevated BP and hypertension 219.  
Large epidemiological studies suggest that increased uric acid levels predict the 
development of hypertension 223-225. A one month treatment with allopurinol, the 
xanthine oxidase inhibitor,  reduced BP in a randomised, double blind, and 
placebo controlled trial 226.  However, conclusive evidence supporting the use of 
allopurinol in reducing the risk of developing hypertension is lacking 227.  
While androgens increase BP and risk of primary hypertension 228 229, the impact 
of oestrogen on BP is not very clear 229. Up-regulation of thromboxane A2 
expression, NE, and angiontensin II are involved in the androgen mediated 
vasoconstriction and hypertension 228.  
Various haemorheological factors are associated with elevated BP 230 and include 
increased haematocrit 231 and whole blood viscosity 232, elevated plasma 
fibrinogen 233 and plasminogen activator inhibitor, increased tissue plasminogen 
activator antigen levels 234, and T cell activation 180.  
Nicotine in tobacco especially in smoking form acutely raises BP by stimulating 
the release of NE from sympathetic nerve terminals 235. Nicotine in cigarette 
smoke also impairs NO dependent vasodilatation both by increasing oxidative 
stress and increasing the plasma levels of an endogenous NOS inhibitor 
asymmetric dimethyl arginine (ADMA) 236.  However, the effect of each cigarette 
is transient and is over within 30 minutes. Although a vasoconstriction mediated 
by nicotine causes acute but transient increase in systolic BP, it is followed by a 
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decrease in BP as a consequence of depressant effects played chronically by 
nicotine itself. Nicotine along with carbon monoxide from the tobacco smoke 
may act directly on the arterial wall and in the long run causes structurally 
irreversible alterations and sustained hypertension 237.  
Caffeine in coffee or other beverages acutely raises BP by blocking the 
vasodilatory adenosine receptors and also by increasing plasma NE 238. Although 
the risk of hypertension did not vary with coffee consumption in the Nurses’ 
Health Study, the risk increased steeply when caffeine was consumed in soft 
drinks 239. While regular caffeine intake increases BP, when ingested through 
coffee, the BP effect of caffeine was small 240. In a meta-analysis in hypertensive 
individuals, caffeine intake produced an acute increase in BP for ≥3 hours with 
no longer-term association between coffee consumption and increased BP 241. 
Cytochrome P-450 metabolises caffeine in the liver in the human body and it is 
known that people carrying a polymorphism of the P-450 gene (CYP12A) are at 
excess risk for a future myocardial infarction if they are heavy coffee drinkers 
242.  
The relationship between alcohol consumption and BP levels is not very clear. 
While alcohol can raise BP due to increases in SNA, it can reduce BP due to 
vasodilatation 243. In binge drinkers the risk of hypertension is relatively high due 
to sympathetic activation with each intervening period of alcohol withdrawal 244. 
Interestingly, in large epidemiological studies a J-shaped relationship is observed 
between alcohol intake and risk of hypertension 245 246. However, the risk of 
hypertension was higher even in light drinkers among Japanese men 247. While a 
J-shaped association was observed between alcohol intake and risk of 
hypertension in women in the Women’s Health Study, a positive linear 
association was observed in men in the Physicians’ Health Study 248. A linear 
gene-dose effect with the gene encoding alcohol dehydrogenase (ALDH2) gene 
with no evidence of an initial J-climb is reported in Japanese men 243.  
Sympathetic activation in cold weather 249 and high altitude 250 may raise BP. 
Cumulative exposure to decreasing ambient and apparent temperature may 
increase BP 251. Decrease in outdoor temperature increases BP in both men and 
women 252. Seasonal variation in BP correlates with outdoor temperature, with 
each 10 degree Celsius drop in outdoor temperature is associated with a 
5.7mmHg increase in SBP in Chinese adults aged 30-79 years 253.  In a study of 
Chapter 1 Introduction 44 
ABPM measurements in more than six thousand patients, normal room 
temperature was associated with lower day-time BP and higher night-time BP 
249.  
Vitamin D deficiency is linked to hypertension and in many prospective studies 
25-hydroxy-vitamin D2 has been independently associated with an increased risk 
of hypertension 254-256. However in a large randomised trial of over 36000 
postmenopausal women, calcium and vitamin D supplements had no effect on BP 
or on the risk of developing hypertension 257.  
While occupational lead exposure is associated with renal damage and 
hypertension 258, other epidemiological studies indicate a positive but modest 
association between blood lead levels with BP and incident hypertension 259. In 
the NHANES 1999-2006, blood lead levels (BLL) were significantly correlated with 
higher SBP among black men and women, but not white or Mexican-American 
participants 260. Cumulative environmental lead exposure in mothers is a 
predisposing factor to higher BP levels in female offspring 261.  
Short-term exposure to air pollution rapidly increased DBP under experimental 
settings in normotensive subjects 262. Long-term exposure to particulate matter 
increased arterial BP in a population-based study of individuals in the age group 
of 45-75 years 263. The particulate matter activates the excitatory neural 
reflexes in the lungs and increases SNA. Furthermore, the smallest particles can 
also enter the systemic circulation, cause oxidative stress and vascular 
inflammation 264 265.  
1.5 Natural history of primary hypertension  
1.5.1 Tracking of blood pressure from childhood to adulthood  
High BP in children is a long-term health problem and a systematic review in 
diverse populations showed strong evidence for BP tracking from childhood into 
adulthood 266. In the Fels Longitudinal study, childhood BP levels predicted 
hypertension in adulthood 267. Data on association of childhood BP with 
cardiovascular events in later adulthood are lacking. However, intermediate 
markers of target organ damage, such as left ventricular hypertrophy (LVH) 268-
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271, increased carotid intima-media thickness (cIMT) 272-274, and retinal vascular 
changes 275 are more common in children and adolescents with high BP.  
1.5.2 Pre-hypertension  
In the Framingham cohort, hypertension developed in 5%, 18% and 37% of 
individuals with baseline BP less than 120/80 mmHg, BP less than 130/85 mmHg 
and BP between 130-139 and/OR 85-89 mmHg, respectively over a four year 
interval 16. Pre-hypertension was associated with increased left ventricular mass 
(LVM) and carotid intima-media thickness (cIMT) in adolescents and young adults 
276. Target organ damages in pre-hypertension in adults include left ventricular 
hypertrophy 277-279, coronary calcification 280, reduced coronary flow reserve 281, 
progression of coronary atherosclerosis 282, increases in IHD and stroke 283 284, 
poor cognitive function 285, retinal vascular changes 286, proteinuria 287 288, and 
renal arteriosclerosis 289.  
1.5.3 Established hypertension  
Long-term observations of hypertensive patients reveal premature deaths in this 
group of patients with an average of 15-20 years less than normal life 
expectancy 48. Adolescent BP and BP tracking into young adulthood are 
associated with subclinical atherosclerosis 290. Atherosclerosis leads to 
premature morbidity and mortality in hypertensive patients more often than in 
the general population. While hypertension doubles the risk for CHD, it triples 
the risk for congestive heart failure (CHF) 291. Brain micro-bleeds are reported 
more often in individuals with hypertension 292. Individuals with hypertension are 
at 3-4 times greater risk of stroke 293.  Left ventricular hypertrophy seen very 
often in hypertensive patients is strongly related to subsequent cardiovascular 
mortality 294 295.    
1.5.4 Resistant hypertension   
Resistant hypertension is defined as failure to achieve BP goal in patients who 
are adhering to full tolerated doses of an appropriate three-drug regimen that 
includes a diuretic 296 297. In a retrospective cohort analysis conducted among 
over 0.2 million patients with incident hypertension, 1.9% developed resistant 
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hypertension during a median follow-up period of 1.7 years with the incidence 
rate of 0.7 cases per 100 person-years of follow-up 298. While non-compliance 
with treatment is considered as the foremost reason for resistant hypertension, 
there are other reasons such as secondary hypertension, fluid retention resulting 
from kidney failure that influences hypertension control. Choice of anti-
hypertensive therapy, baseline SBP and associated co-morbidities also influence 
development of resistant hypertension 299.  
While comparing the clinical outcomes in hypertensive population, a 
retrospective electronic clinical records review found greater risk for CHD and 
congestive heart failure (CHF) in individuals with resistant hypertension in 
comparison to non-resistant hypertension 300.  There was no difference in total 
cardiovascular events between the two groups in this study. However in another 
retrospective cohort analysis, there was a 47% increase in risk (HR=1.47, 95% CI: 
1.33-1.62) of cardiovascular events in patients with resistant hypertension 298.  
1.5.5 Natural history of sub-types of hypertension  
Subtypes of hypertension such as isolated systolic hypertension (ISH) and isolated 
diastolic hypertension (IDH) have different prognostic implications 41 301 302.  For 
example, individuals with IDH were 23 times more likely to develop systolic 
hypertension in comparison to individuals with optimum BP (<120/80 mmHg) 
during a ten year follow-up 302. Furthermore, subjects with IDH at baseline have 
high likelihood of developing a cluster of features of increased cardiovascular 
risk such as insulin resistance and other metabolic abnormalities. Rise in SBP and 
widening of pulse pressure are typical changes associated with aging and 
associated with mortality outcomes in elderly patients with ISH 303. ISH is 
associated with a 2.7 times greater risk of strokes than seen in individuals with 
normal blood pressure 304. However, data on long-term natural history and the 
clinical importance of ISH and IDH in young individuals are scarce.   
1.6 Global burden of hypertension   
Hypertension is a significant global public health problem and remains as the 
most common risk factor for cardiovascular morbidity and mortality. Worldwide 
hypertension affects approximately 1 in 4 adult individuals which translates to 
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nearly one billion in absolute numbers in the year 2000 and this is expected to 
grow to >1.5 billion by 2025 305. While in higher income regions hypertension was 
predicted to grow by 70 million people from 2000 to 2025, it was >500 million in 
lower-income regions during the same period. The lifetime risk of hypertension 
is estimated to be approximately 90% among individuals who are non-
hypertensive at 55-65 years and survived to age 80-85 years 306. Demographic 
changes in populations, progress in economic development, globalisation, 
increase in food availability and reduction in physical activity are considered to 
be the major determinants of this rapid rise in hypertension 307.  
Burden of hypertension using the most recent global, regional and country-wise 
data are summarised in the following section. The global burden of disease 
(GBD) estimates for year 2004 and 2008 are the principle data sources 308. The 
disease and injury outcomes caused by hypertension are quantified in terms of 
deaths and disability-adjusted life year (DALYs) for 2004, as described in a 
recently released WHO report 309. DALY is a time-based measure that combines 
years of life lost due to premature mortality and years of life lost due to time 
lived in states of less than full health 310. For population estimates, the GBD 
2004 uses the 2006 revision of the 2004 population estimates for WHO Member 
States prepared by the UN Population Division 311.  
1.6.1 Prevalence of hypertension  
Of the 189 WHO member countries with available data312, age standardised 
prevalence of hypertension in men aged 25 years or more was lowest and highest 
in United States of America (17.0%) and Niger (50.3%), respectively.   Consistent 
with the mean SBP levels, the prevalence of hypertension in women aged 25 
years or more was lowest in the Republic of Korea (13.1%) and highest in Sao 
Tome and Principe (42.4%). The age standardised hypertension prevalences for 
the year 2008 in all WHO member countries are summarised in figure 1-5. 
There are distinct regional variations in prevalence of hypertension.  Although 
the average BP is decreasing worldwide since 1980 at the rate of 1mmHg SBP per 
decade, the change in BP is different across regions and countries in a global 
analysis of data covering 5.4 million participants 313. However, the number of 
people with uncontrolled hypertension increased from 605 million (537-680 
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million) in 1980, to 978 million (921-1040 million) in 2008 313. The increase in 
hypertension prevalence is mainly attributable to increase in average SBP in the 
African, and South East Asian regions. SBP is currently highest in the low-income 
and middle-income countries 313.  
1.6.2 Mortality and morbidity attributable to high blood pressure  
Overall high BP is responsible for 7.6 million premature deaths (13.5% of all 
deaths) and 92 million disability adjusted life years (DALYs) lost (6% of all) 
worldwide, annually 293.  Furthermore, 54% of all stroke and nearly half (47%) of 
all ischaemic heart disease (IHD) were attributable to non-optimal BP 293.  Of the 
7.6 million deaths attributable to high BP worldwide, 4 million were in women. 
While the high BP associated population attributable fraction (PAF) of total 
mortality worldwide was nearly 12.8% (highest among all other risk factors) 314, 
they were 11.4% and 14.3% in men and women respectively as per the WHO 2004 
estimates. The revised estimates of mortality attributable to leading risk factors 
are summarised in figure 1-6.  
High BP is associated with significant mortality in all regions of the world with 
the PAF ranging from 4.6% in the African region to 14.46% in the Western Pacific 
region. Although the mortality rates are falling in both hypertensive men and 
women in industrialised countries 315, hypertension still remains as a major 
contributor to overall mortality. Among the WHO regions, European region tops 
the chart with 2.5 million deaths attributable to high BP followed by Western 
Pacific (1.8 million deaths) and South East Asian Region (1.4 million). Low 
Income and Lower Middle Income countries contribute nearly 4.9 million deaths 
attributable to high BP. The region wise mortality statistics attributable to high 
BP are summarised in figure 1-7. 
In terms of disability adjusted life years lost (DALYs), the overall PAF associated 
with high BP was 3.7% worldwide (3.9% and 3.6% in men and women, 
respectively). The DALYs lost due to high BP was highest in the European region 
followed by South East Asian region and Western Pacific Region (Figure 1-7). 
Nearly 70% of the total DALYs burden attributable to high BP was from Low 
Income and Lower Middle Income countries. 
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Figure 1-5: World map showing age standardised prevalence range of hypertension in 
women (Panel A) and men (Panel B).  
Data source: WHO Global Burden of Disease database 312.    
 
Figure 1-6: Mortality attributable to 19 leading risk factors, 2004 estimates. 
Adapted from WHO publication  312. Countries grouped into income regions by gross 
national income per capita; low income (USD 825 or less), middle income (USD 826-10065) 
and high income (USD 10066 or more).  
Chapter 1 Introduction 50 
 
Figure 1-7: The region wise mortality and morbidity statistics attributable to high blood 
pressure (Numbers are in thousands).   
AFR=African Region, AMR=American Region, EMR=Eastern Mediterranean Region,  
EUR=European Region, SEAR=South East Asian Region, and WPR=Western Pacific Region. 
HIC=High Income Countries, LIC=Low Income Countries, LMIC=Lower Middle Income 
Countries, and UMIC=Upper Middle Income Countries. Data source: WHO Global Burden of 
Disease database 312.    
 
1.7 Predictors of adverse outcomes in hypertension  
1.7.1 Blood pressure and mortality outcomes  
Elevated BP as a leading factor associated with cardiovascular mortality and 
morbidity is well established 17. In hypertensive individuals treated in clinical 
practice, SBP is a good predictor of CVD and coronary heart disease (CHD) 316 317. 
A sustained SBP reduction of 12 mmHg over ten years in individuals with stage 1 
hypertension and one additional cardiovascular risk factors is adequate to 
prevent 1 death for every 11 patients treated 318. The latest United Kingdom 
National Institute for Health and Clinical Excellence (NICE)-2011 hypertension 
guideline recommends anti-hypertensive drug therapy to people under the age 
of 80 years with stage I hypertension (BP≥140/90 mmHg and <160/100 mmHg) 
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who have any of the following conditions; (a) target organ damage, (b) 
established CVD, (c) diabetes, (d) renal diseases and (e) a 10 year CHD risk 
equivalent of 20% or greater 319. It also recommends pharmacological treatment 
for people at any age with stage II hypertension irrespective of accompanying 
risk conditions.  
Randomised controlled trials of anti-hypertensive agents have unequivocally 
proved the causal role of elevated BP on CVD events and mortality outcomes 320. 
However, sub-optimal adherence to anti-hypertensive therapy and poor BP 
control are observed in a substantial proportion of patients with hypertension 321 
322. As per the latest available estimates in the Unites States of America (USA), 
approximately 30% of adults are unaware of their hypertension, >40% of 
individuals with hypertension are not on treatment and two-thirds of treated 
hypertensive patients are not being controlled to the desired BP levels of 
<140/90 mmHg 36.  The corresponding rates in England are 34%, 46% and 48%, 
respectively 323. The awareness, treatment and control rates of hypertension are 
even lower in middle income and lower middle income countries 324.  
In general, lower BP values are associated with better clinical outcomes in 
treated hypertensive patients and all major anti-hypertensive classes can 
effectively lower BP. Effects of antihypertensive treatment on total mortality in 
trials comparing new (CCBs, ACEIs, ARBs and alpha blockers) with old (diuretics 
and β blockers) antihypertensive drugs show no differences in outcomes between 
the drug groups (Figure 1-8) 325. Similarly, the Blood Pressure Lowering 
Treatment Trialists’ collaborative group’s assessment on the comparative effects 
of different BP-lowering regimens suggests no major difference between drug 
classes in terms of cardiovascular prevention 326 327. Tolerability of anti-
hypertensive therapy influences discontinuation of treatment during follow-up 
and hence treatment outcomes. While ARBs have the lowest discontinuation 
rate, it is highest in diuretics and beta blockers. Alpha blockers and calcium 
channel blockers also report significantly higher rate of discontinuation in 
comparison to ACEI 328. In general, 50% of patients with hypertension do not take 
all of their prescribed medications due to various reasons 329. Poor adherence to 
BP medications can lead to inadequate BP control 330 and adverse clinical 
outcomes.  
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Figure 1-8: Effects of antihypertensive treatment on all-cause mortality in trials comparing 
new with old antihypertensive drugs.  
Solid squares represent the odds ratios in trials and have a size proportional to the number 
of events. The 95% confidence intervals for individual trials are denoted by lines and those 
for the pooled odds ratios by diamonds. Adapted from Staessen et al 2003 325. ALLHAT/Aml 
(Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial – amlodipine 
versus chlorthalidone), ALLHAT/Dox (Antihypertensive and Lipid-Lowering treatment to 
prevent Heart Attack Trial – doxazosin versus chlorthalidone), ALLHAT/Lis 
(Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial – lisinopril 
versus chlorthalidone), LIFE (Losartan Intervention For Endpoint reduction in hypertension 
study), MIDAS (Multicenter Isradipine Diuretic Atherosclerosis Study), STOP2/ACEIs 
(angiotensin-converting-enzyme inhibitor arm of STOP2), STOP2/CCBs (calcium-channel 
blocker arm of STOP2), NORDIL (NOrdic DILtiazem study), INSIGHT (International Nifedipine 
GITS Study – Intervention as a Goal for Hypertension Treatment), ELSA (European 
Lacidipine Study on Atherosclerosis), CONVINCE (Controlled ONset Verapamil 
INvestigation of Cardiovascular Endpoints Trial), STOP2/ACEIs (angiotensin-converting-
enzyme inhibitor arm of STOP2), CAPPP (CAptopril Prevention Project), ANBP2 (Australian 
comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based 
treatment of hypertension in the elderly), HYVET/AD (HYpertension in the Very Elderly pilot 
trial – ACE inhibition versus diuretic treatment), SCOPE (Study on COgnition and Prognosis 
in the Elderly).  
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Recent pooled data suggest that various classes of anti-hypertensive agents are 
not equivalent in their ability to protect against target organ damages and 
adverse mortality and morbidity outcomes 331. Although all antihypertensive drug 
classes reduce cardiovascular disease morbidity and mortality, clinical trials in 
the last two decades demonstrate a class effect especially in specific baseline 
demographic and clinical conditions such as ethnicity, diabetes, left ventricular 
hypertrophy, heart failure, atrial fibrillation, previous myocardial infarction, 
stroke, peripheral artery diseases, proteinuria and renal dysfunction 331 332. While 
renin angiontensin system (RAS) blockers are the preferred choice of drugs in 
hypertensive subjects with heart failure, microalbuminuria, renal dysfunction, 
end stage renal disease (ESRD), recurrent atrial fibrillation, metabolic syndrome 
and diabetes mellitus, calcium antagonists (CA) are the preferred choice of anti-
hypertensive agents in asymptomatic atherosclerosis, peripheral artery disease, 
and pregnancy. Similarly, diuretics are the preferred choice of first line anti-
hypertensive treatment in heart failure, isolated systolic hypertension in the 
elderly and among hypertensive blacks 331 332. Heart failure is also a compelling 
indication for use of aldosterone antagonists especially among patients with 
severe left ventricular dysfunction 36 333. Although, effective BP control can be 
achieved in almost all of hypertensive patients, majority of them will require 
two or more anti-hypertensive agents 36.  
Despite similar BP control in the treatment arms of the losartan intervention for 
endpoint reduction (LIFE) study among patients with essential hypertension and 
LVH, losartan (angiotensin receptor blocker, ARB) was clearly superior to 
atenolol (beta blocker, BB) in reducing cardiovascular morbidity and mortality 
334. In the Anglo-Scandinavian cardiac outcomes (ASCOT-BPLA) trial the 
amlodipine-based regimen reduced the relative risk of cardiovascular events 
more effectively than the atenolol-based regimen in both older and younger 
patients 335. However, the achieved BP difference alone could not explain the 
greater risk reduction in the amlodipine (CA) based regimen with added 
perindropil (ACEI) in comparison to the atenolol (BB) based regimen 336. Better 
BP control was partially responsible for the lower incidence of fatal and non-
fatal myocardial infarction in the amlodipine (CA) based regimen in comparison 
to the valsartan (ARB) based regimen in the valsartan antihypertensive long-term 
use evaluation (VALUE) trial 337. More recent data suggest significant differences 
in outcomes even in combination therapies with different anti-hypertensive 
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agents. For example, the avoiding cardiovascular events through combination 
therapy in patients living with systolic hypertension (ACCOMPLISH) trial stopped 
prematurely due to favourable outcomes in the benazepril-amlodipine fixed dose 
regimen group in comparison to the benazepril-thiazide fixed dose regimen 
group 338. Although the BP reduction was better in the ACEI-CA (ACE-inhibitor, 
Calcium antagonists) group in the ACCOMPLISH trial, the clinical benefit 
observed in this group was beyond the clinical benefits explained by BP 
reduction achieved. Even though there are different explanations for the 
disparity observed between anti-hypertensive drug classes in their ability to 
protect against target organ damage, none of them fully explain the clinical 
benefits observed in some anti-hypertensive classes in comparison to other 
agents.  
The effect of anti-hypertensive agents on central aortic BP has been suggested 
as one of the mechanisms that influences outcomes. For example, in the conduit 
artery functional endpoint (CAFE) study central aortic BP was significantly lower 
in the amlodipine based arm than in the atenolol-thiazide arm 339. The 
difference in central aortic BP between the treatments arms in the CAFÉ study 
partially explain the preference of amlodipine based regimen in reducing the 
composite outcome of total cardiovascular events, CV procedures and the 
development of renal impairment. In the ASCOT-BPLA trial sub-study, 
differences in magnitude of wave reflection index (WRI) account for differential 
effects of amlodipine and atenolol based regimens (lower carotid systolic BP in 
people randomized to amlodipine based regimen) on central BP 340. 
Furthermore, higher WRI predicts future cardiovascular events independent of 
brachial BP and other conventional risk factors in the ASCOT-BPLA sub-study 341.  
1.7.2 Blood pressure variability and mortality outcomes  
Contrary to the normal BP hypothesis that extensively relies on effect of anti-
hypertensive agents in reducing the mean office BP during follow-up, several 
other mechanisms influence the CV outcomes.  In the Pressioni Arterios 
Monitorate e Loro Associazioni (PAMELA) study among the general adult 
population of Italy, the steepest increase in mortality rate was observed with 24-
hour SBP measurement in comparison to risk associated with home and office 
SBP 342. Increases in SBP during night-time and the mean difference between 
day-time and night-time DBP were associated with CVD mortality 343 344. Even a 
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morning surge in BP alone independently predicts stroke 345-347. For example in 
the International Database on Ambulatory BP in relation to Cardiovascular 
Outcome (IDACO ) study, a morning surge exceeding the 90th percentile of the 
population, was an independent risk factor for mortality and CV events 348. The 
average of several readings from ABPM predicts risk of vascular events better 
than one-office based BP reading 349 350. Masked hypertension (normal office BP 
but raised BP at home or on ambulatory BP monitoring) is associated with 
increased risk of vascular events 351 352. The accumulating data suggest that out-
of-office measures such as self-measured BP at home, ambulatory BP and central 
pressure are more closely associated with risk of target organ damage and 
adverse CVD outcomes than office-based BP 43 353-356. In the ASCOT-BPLA trial 
nocturnal ambulatory BP readings provide complimentary and incremental utility 
over clinic BP in the prediction of cardiovascular risk 357.  
Visit-to-visit variability in BP is significantly associated with increase in risk of 
all-cause mortality 358. Independent of mean SBP, visit-to-visit office SBP and 
maximum SBP predict future stroke events 359.  Anti-hypertensive drug classes 
like calcium antagonists (CA) and beta blockers (BB) have differential effects on 
BP variability which partially accounts for the disparity in observed effect on risk 
of stroke and the expected effect based on mean BP 360. Treatments that affect 
the greatest reductions in BP variability (for example; CA)  are associated with 
the greatest reductions in risk of stroke and coronary heart disease in the 
secondary analysis of data from major randomised controlled trials of 
antihypertensive treatment and of secondary stroke prevention 361. The 
comparison of estimated relationship between usual BP and stroke risk with 
relations based on actual measured mean SBP across seven clinic visits in the 
pooled analysis of the UK and Dutch transient ischaemic attacks (TIA) trials 
suggests that the usual clinic BP substantially overestimates the risk of stroke 
among individuals with variable BP 362. Effects of anti-hypertensive drugs on SBP 
variability are dose-dependent and even persist when used in combinations. High 
dose of a CA alone or in combination with other agents is therefore effective in 
prevention of stroke 363. The International Verapamil SR-Trandolapril (INVEST) 
trial results suggest that consistent BP control (BP control in >75% follow-up 
visits) reduces the composite primary outcome of deaths, non-fatal MI and non-
fatal stroke 342. Although patients with consistently normal SBP have very few 
vascular events, those with high variability and normal mean SBP are at 
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increased risk. However, the results of post-hoc analyses can be considered as 
only hypothesis generating and prospective studies in real life settings are 
required to test these hypotheses. Therefore, hypertension treatment guidelines 
often ignore residual variability in clinic BP in treated hypertensive patients 362.  
1.7.3 Magnitude of blood pressure reduction and cardiovascular 
risk  
The magnitude of BP reduction achieved is an important determinant of 
favourable cardiovascular outcomes in hypertensive populations 326. However, a 
recent systematic review concluded that treating to lower than standard DBP 
goals does not always reduce mortality or morbidity 364. Moreover in the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) trial, there was no 
significant reduction in CV events in the intensive treatment group targeting a 
SBP<120 mmHg compared to targeting <140mmHg 365. Furthermore, serious 
adverse events were more common in the intensive treatment group. In patients 
with CHD lowering of DBP to <55 or 60 mmHg was associated with an increase in 
CV events, including myocardial infarction 366. Consistent with the available 
evidence, the UK NICE 2011 hypertension guideline document does not 
recommend such intensive pharmacological treatment of hypertension 319.  
1.7.4 Race, ethnicity and CVD outcomes in hypertension  
In general, patients of African origin are less responsive to β-blockers, ACEIs, 
and ARBs as monotherapy and more responsive to CCBs and diuretics 367-371. 
However, a systematic review of racial differences in the efficacy of anti-
hypertensive therapy for the prevention of CV outcomes in hypertensive subjects 
suggests no major differences between the ethnic groups 372. While Anti-
hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) reports a greater magnitude of benefit for 'blacks' on diuretic therapy 
compared with 'non-blacks' 373, post hoc analyses of The Losartan Intervention 
for Endpoint Reduction (LIFE) trial on usefulness of angiotensin-receptor blockers 
(ARBs) as first-line antihypertensive agents suggests poor outcomes in 'Blacks, in 
comparison to non-blacks 374. However, no large outcome studies have been 
carried out with ARBs in sufficiently large number of African Americans, South 
Asians and Chinese to make any valid conclusions. 
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In the BP lowering arm of the Anglo-Scandanavian Cardiac Outcomes Trial 
(ASCOT-BPLA), black patients were significantly less responsive to atenolol 
monotherapy. Although the BP response to CA monotherapy did not differ by 
ethnic groups, black patients had lesser BP response on addition of perindropil as 
second line agent to CA in comparison to whites 375.  In the African American 
Study of Kidney Disease and Hypertension, African American patients treated 
with the ACEI ramipril had a significantly lower incidence of the primary 
composite end point (glomerular filtration rate reduction, end-stage renal 
disease, or death) than African Americans treated with the calcium channel 
blocker amlodipine 376.  Conversely, African Americans and Asians have 3-4 fold 
higher risk of angioedema 377 attributable to ACEIs than Caucasians.  
1.7.5 Clustering of CVD risk factors with hypertension   
Clustering of cardiovascular risk factors with hypertension is common and 
increases the risk of adverse cardiovascular outcome 378 379. Clustering of risk 
factors with hypertension significantly inflates health care costs and the cost 
rises incrementally with additional number of risk factors as a consequence of 
relatively higher incidence of cardiovascular events and mortality outcomes 380. 
1.7.6 Hypertension and Chronic Kidney Disease  
Chronic Kidney Disease (CKD) is a major determinant of cardiovascular mortality 
and morbidity outcomes in patients with hypertension 381. It is important to note 
that while kidney dysfunction leads to hypertension (cause), hypertension is a 
leading factor in promotion of progressive loss of renal function (consequence)  
382. Hypertension is considered as a major risk factor for both diabetic and non-
diabetic CKD 383. More than one quarter of the population with hypertension in 
the United States have concomitant CKD 384. Often, hypertensive individuals with 
CKD report significantly poorer BP control 385 and it leads to adverse CVD 
outcomes. Furthermore, lowering of SBP to targets less than 130 mmHg reduces 
both cardiovascular risk and the progression of CKD in proteinuric cases 386. 
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1.8 Other potential biomarkers/predictors of mortality in 
hypertension   
Haematocrit, heamoglobin and basic metabolic profile are commonly ordered, 
relatively inexpensive laboratory tests that contain potentially important health 
information and are readily accessible in almost all practice settings. 
Furthermore, the elements of the tests are quantitative and easily electronically 
encoded, and have international standards for measurement. The following 
section describes the relationship between haematocrit and basic metabolic 
profile with CVD and mortality outcomes. Studies in the general population and 
in special population groups are reviewed in detail with the objective to study 
some of the important findings in a hypertensive population.  
1.8.1 Association between RBC indices and mortality  
Haemoglobin is the iron-containing oxygen transport metallo-protien in the red 
blood cells (RBC) of human beings and in most of the other vertebrates. The 
prognostic value of haemoglobin within the normal reference range was 
examined in a 20 year follow-up study (Tromso Study) of 6541 men aged 
between 20-49 years 387. A U-shaped relationship between quintiles of 
haemoglobin and all-cause mortality (excess risk in quintile 1 and quintile 5) was 
reported and the relationship was more pronounced in smokers in comparison to 
non-smokers.  
Haematocrit (Hct), the proportion of blood volume occupied by red blood cells 
(RBC), is a major determinant of blood viscosity, BP, venous return, cardiac 
output and platelet adhesiveness 388-392. Several prospective studies have 
established associations between Hct and risk of cardiovascular disease, 
including coronary heart disease (CHD) and stroke 393-397.   A ‘J’ or ‘U’ shaped 
relationship between Hct and all-cause mortality (with significantly higher 
mortality rates among those with Hct in the lowest and highest quartile) has 
been reported among women, while an inverse relationship between Hct and all-
cause mortality was seen in men in the Framingham Heart Study 395. In contrast, 
a population based 17 years follow-up study reported a U-shaped relationship 
between Hct and CHD mortality (with the lowest CHD mortality rates being seen 
among those with Hct in the middle tertile and higher rates among those with 
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Hct in the upper tertile) in males, and a positive linear relationship in females 
(with linear increase in CHD mortality from those with Hct in the lowest tertile 
to highest tertile) 393. In a 28 year follow-up study among men aged 55 years, 
borderline polycythemia (Hct>0.50), was associated with a 1.8 fold increase in 
CHD death even after adjustment for established coronary risk factors 396. In the 
Northwick Park heart Study, after 30 years of follow-up haematocrit was found 
to be associated with CHD mortality 398. Major study findings are summarized in 
table 1-2.  
Table 1-2: Haematocrit and risk of coronary heart disease  
Studies  Details  Comparison  Effect size 
Danesh, 
2000 394 
 
 
 
Meta-analyses of 
prospective cohort 
studies (N=8020 in 
general population and 
N=1162 with pre-existing 
CVD). 
Hct (Tertile 1 Vs 
tertile 3) and CHD 
 
 
 
General population: 
RR=1.16, 95% CI: 1.05-1.29. 
Pre-existing CVD: RR=1.81, 
95% CI: 1.19-2.76.  
 
Brown, 
2001 393 
 
 
NHANES II Mortality 
study, 16.8 years of 
follow-up, 8896 adults.  
 
Hct (Tertile 1 Vs 
tertile 3) and CHD 
mortality. 
 
  
Men: No association. 
Women: HR=1.3, 95% CI: 
0.9-1.90. Women younger 
than 65 years: HR=2.2, 95% 
CI: 1.0-4.6.  
Kunnas, 
2009 396 
 
TAMRISK study, 28 years 
follow-up in 650 men 
aged over 55 years.  
Hct<50% Vs Hct≥50% 
and CHD mortality.  HR=1.8, 95% CI: 1.1-2.7.  
Pizzi, 
2010 398 
 
NPHS-I, 30 year follow-
up in 3108 individuals 
over 30 years.  
RR per 1 SD increase 
in PCV and CHD 
mortality.  
RR=1.17, 95% CI: 1.00-1.37.  
 
 
CHD=Coronary Heart Disease, CI=Confidence Interval, CVD=Cardiovascular Disease, 
Hct=Haematocrit, HR=Hazard Ratio, NHANES=National Health and Nutrition Examination 
Survey, NPHS= Northwick Park Heart Study, PCV=Packed Cell Volume, RR=Relative Risk, 
SD=standard deviation, TAMRISK= The Tampere Adult Population Cardiovascular Risk 
Study.  
1.8.2 Renal function indices and mortality  
Estimated glomerular filtration rate (eGFR) is a biomarker of chronic kidney 
disease (CKD) and the 2002 Kidney Disease Outcomes Quality Research Initiative 
guidelines 399 define CKD as a persistent kidney damage marked by albuminuria 
or reduced GFR and assign disease stages on the basis of GFR. Several studies in 
the general population report the association between low eGFR and adverse 
clinical outcomes including all-cause mortality 400-404. While individuals with 
eGFR<60 mL/min have an approximate 16% increase in CV mortality, it is more 
than 30% in individuals with eGFR<30 mL/min 405. Similarly, the presence of 
microalbuminuria and macroalbuminuria increase the risk of CV mortality by 50% 
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and 350%, respectively 406. In a meta-analysis involving more than 100,000 
participants from general population cohorts, eGFR<60 mL/min and albumin 
creatinine ratio of >1.1 mg/mmol are independent predictors of mortality 407. In 
a recent collaborative meta-analysis, the hazard ratio (HR) for cardio-vascular 
disease mortality and all-cause mortality were significantly elevated among 
individuals with eGFR<60 mL/min/1.73m2) in comparison to individuals with 
eGFR>95 mL/min/1.73m2 408.  
1.8.3 Serum uric acid and mortality  
A positive association of elevated serum uric acid with all-cause mortality was 
observed in the World Health Organization (WHO) Monitoring Trends and 
Determinants in Cardiovascular Diseases (MONICA) Augsburg cohort of men in the 
age group of 45-64 years 409. In the MONICA/KORA- (Cooperative Health Research 
in the Region Augsburg) cohort study, elevated serum uric acid was 
independently associated with both CV and all-cause mortality 410. Elevated 
serum uric acid levels independently predicted the risk of CV mortality in the 
NHANES follow-up study of 5926 subjects 411. In 10,615 Japanese individuals from 
a cohort of atomic bomb survivors, elevated serum uric acid was independently 
associated with CV mortality in women and all-cause mortality in both men and 
women 412. In a large prospective cohort of 83683 Austrian men followed-up for a 
median of 14 years, serum uric acid was independently related to mortality from 
congestive heart failure (CHF) and stroke. However, after adjustment for 
potential confounding factors serum uric acid was not significantly associated 
with deaths from CHD 413. Similarly in a large cohort of 28613 elderly Austrian 
post-menopausal women followed-up for a median of 15 years, serum uric acid 
independently predicted all major forms of death from CVD 414. The HR for all-
cause mortality [1.22, 95% CI; 1.09-1.37] and CHD mortality (1.29, 95% CI; 1.05-
1.58) were increased in the upper serum uric acid quintile in comparison to the 
first quintile in a cohort of middle-aged workers (9125 men) free of CHD at entry 
415. However, fatal stroke showed a U-shaped relationship as both the upper and 
bottom quintiles were associated with excess risk 415. Hyperuricemia was an 
independent risk factor of mortality from all causes, total CVD, and ischaemic 
stroke after adjustment for multiple CV risk factors in a prospective cohort study 
of 41,879 Taiwanese men and 48,514 women aged ≥35 years 416. In a meta-
analysis involving 402,997 adults, hyperuricemia was associated with an 
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increased risk of CHD incidence and mortality even after adjustment for 
potential confounding factors. However, the relationship was significant only 
among women 417. Similarly, in a meta-analysis involving 238,449 adults, 
hyperuricemia was associated with modest increase in risk of both stroke 
incidence and mortality 418. 
Serum uric acid levels show a 'J-shaped' association (elevated mortality risk in 
the lowest and highest quintiles) with all-cause mortality in haemodialysis 
patients 419. In a follow-up study of 1,017 patients with angiographically proven 
coronary artery disease, serum uric acid was an independent predictor of 
mortality 420. Similarly, in another follow-up study of 647 consecutive patients 
with angiographically proven significant coronary artery disease, serum uric acid 
was an independent predictor of all-cause mortality with no significant 
association with CV mortality 421 422. In the sub-analysis of Japanese Coronary 
Artery Disease (JCAD) study involving 8832 patients with severe coronary artery 
stenosis, elevated uric acid was an independent predictor of CV events and all-
cause mortality 423. In the Bezafibrate Infarction Prevention [BIP] study, elevated 
uric acid was significantly associated with the primary end-point of fatal or 
nonfatal myocardial infarction or sudden cardiac death 424. Hyperuricemia after 
acute myocardial infarction is associated with the development of heart failure 
and independently predicts mortality 425. Furthermore, serum uric acid 
independently predicts deaths in patients at high risk of CVD 426. 
In a follow-up study of 560 consecutive patients with an acute heart failure 
event admitted in a single university centre, serum uric acid level independently 
predicted all-cause mortality 427. The relative risk (RR) of all-cause mortality was 
2.13 (95% CI, 1.78-2.55) for serum uric acid>6.5 mg/dL compared with serum 
uric acid<6.5 mg/dL  in a meta-regression analysis involving 1456 heart failure 
patients with a median ejection fraction of 32% 428.  
In hypertensive patients, serum uric acid is independently associated with left 
ventricular mass and the combination of hyperuricemia with left ventricular 
hypertrophy is an independent and powerful predictor of CVD 429. In the 
Fremantle Diabetes Study participants (1,268 participants with Type 2 Diabetes 
and Southern European Ancestry), after a mean follow-up of four years serum 
uric acid did not independently predict CVD or all-cause mortality 430. In 
contrast, independent of several potential confounding factors higher serum uric 
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acid levels increased the risk of cardiovascular mortality in Type 2 Diabetic 
patients. However, the relationship was not statistically significant for all-cause 
mortality 431. In a recent study in Type 2 Diabetes patients 432, higher levels of 
serum UA above 7.70 mg/dl was associated with increased mortality. 
1.8.4 Serum phosphate and mortality  
Hyperphosphatemia (plasma inorganic phosphate concentration >5mg/dl or 
1.6mmol/l) is associated with vascular calcification, CVD morbidity and 
mortality in populations with CKD 433-440. In a meta-analysis on quality of 
evidence for the association between levels of serum phosphorus and CV 
mortality in individuals with CKD, the risk of death increased 18% for every 1-
mg/dL increase in serum phosphorus 441. Summary of main cohort studies on 
serum phosphate and mortality outcomes are shown in table 1-3 on page 63.   
Mechanistic studies suggest that higher phosphate levels could lead to vascular 
calcification and CVD 442 443. In post-myocardial infarction statin trials 444, BP 
lowering trials 445 among diabetic patients and in medical out-patients 446 serum 
phosphate was significantly associated with cardiovascular events and mortality. 
Furthermore, in a population based cohort of 13,340 subjects free of overt 
cardiovascular and renal diseases in the age group of 45-64 years, serum 
phosphorus was positively associated with carotid intima-media thickness 
independent of traditional risk factors in men 447. In the Bogalusa Heart Study, 
among asymptomatic young adults, serum phosphate within the normal range 
was found to be significantly associated with carotid intima-media thickness 
with smoking potentiating this adverse association 448.  
Recent studies in the general population also indicate significant association 
between elevated phosphate and CVD events or mortality 449-451. The elevated 
risk of cardiovascular events linked to hyperphosphatemia in individuals with 
CKD are actually similar to those linked to higher-normal phosphate in non-
uremic populations 452. However, any prospective interventional data showing 
improved CVD and mortality outcomes are lacking and additional research is 
required to confirm a causal association between phosphorous and CVD 453.  
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Table 1-3: Serum phosphate and mortality outcomes  
Studies  Details  Comparison  Effect 
size 
Tonelli, 2005 444 
 
 
 
Post-hoc analyses of CARE study 
(4127 participants with prior MI, 
5 years follow-up).  
1 mg/dl increase 
in serum 
phosphate and risk 
of mortality.  
RR=1.27, 
95% CI: 
1.02-
1.58.  
 
Foley, 2008 450 
 
 
15762 ARIC study participants 
with 12.6 years of follow-up.  
Phosphate per 0.5 
mg/dl increase and 
mortality.  
HR=1.12, 
95% CI: 
1.07-
1.17.  
Chonchol, 2009 445 Post-hoc analyses of Appropriate 
Blood Pressure Control in 
Diabetes Study (950 participants 
with diabetes, 4.8 years of 
follow-up) 
Serum phosphorus 
>3.9 mg/dl Vs low 
serum phosphorus 
and cardiovascular 
deaths (time 
dependent model) 
HR=4.25, 
95% CI: 
1.15-
16.55.  
Abramowitz, 2010 
446 
 
 
Retrospective cohort study of 
10743 outpatient attendees with 
GFR≥60 ml/min (6.8 years of 
follow-up).  
Highest Vs lowest 
quartile of 
phosphate and 
mortality.  
HR=1.29, 
95% CI: 
1.07-
1.55.  
Larsson, 2010 451 Community based cohort of 2176 
men (30 years follow-up).  
 
Phosphate per 1 SD 
increase and 
mortality.  
HR=1.06, 
95% CI: 
1.01-
1.12.  
Slinin, 2011 454 
 
 
Post-hoc analyses of 7259 
postmenopausal women with 
osteoporosis in the MORE study 
with 4 years of follow-up.  
Phosphate per 1 SD 
increase and 
mortality.  
HR=1.00, 
95% CI: 
0.80-
1.25.  
Palmer, 2011 441 
 
 
 
Meta-analyses in individuals with 
chronic kidney diseases. 47 
cohort studies included with 
327644 individuals. 
1 mg/dl increase 
in serum 
phosphate and 
mortality. 
RR=1.18, 
95% CI: 
1.12-
1.25. 
SD=Standard Deviation, MORE=Multiple Outcomes of Raloxifene Evaluation, 
ARIC=Atherosclerosis Risk in Communities, HR=Hazard Ratio, RR=Relative Risk, 
CI=Confidence Interval.   
1.8.5 Serum calcium and mortality  
In a meta-analysis on quality of evidence for the association between levels of 
serum calcium and CV mortality in individuals with CKD, there was no 
independent association between serum levels of calcium and the risk of death 
or CV events 441. In the United States Renal Data System Waves 1, 3, and 4 Study 
of 14,829 patients who were on haemodialysis, higher calcium levels were 
associated with fatal or nonfatal cardiovascular events and the association was 
independent of other risk factors 438. Serum calcium and albumin-corrected 
calcium were associated with all-cause mortality in the Dialysis Outcomes and 
Practice Patterns Study (DOPPS), an international study of haemodialysis 
practices and associated outcomes 455. In the CORES Study of 16,173 
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haemodialysis patients, elevated and reduced serum levels of albumin-corrected 
calcium were associated with increase in all-cause mortality 456. In haemodialysis 
patients cumulatively (time-averaged calcium values to reflect the 'cumulative' 
effect of calcium burden over time) high (>10.0 mg/dl) or low calcium (<9.0 
mg/dl) levels were associated with higher death risk 457. In a post hoc data 
analysis from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial of 
raloxifene treatment in 7259 postmenopausal women with osteoporosis, higher 
baseline serum calcium levels were independently associated with 
cardiovascular events 458. Serum calcium was associated with all-cause mortality 
and non-CV mortality in a community-based cohort of 2176 men who were 
followed-up for 30 years 459.   
1.8.6 Serum electrolytes and mortality  
In the CArdiovascular STudy in the ELderly (CASTEL), a population-based study 
performed in Northeast Italy, elevated serum potassium > or = 5 mEq/l was 
associated with incident stroke 460. Higher serum potassium was independently 
associated with increased cardiovascular mortality in the NHANES I 
Epidemiological Follow-up Study 461. Elevated potassium levels > or = 5.2 
mmol/litre were associated with a significant increase in mortality, particularly 
non-CV mortality, even after adjustment for potential confounding factors in a 
prospective study of middle-aged British men who were not on anti-hypertensive 
treatment and followed-up for 11.5 years 462. However, the increased risk of 
mortality associated with elevated potassium was seen only among current 
smokers. Serum electrolytes and mortality outcomes data are summarised in 
table 1-4 on page 65.  
A statistically significant inverse association between serum sodium 
concentration and all-cause mortality was reported in a prospective study of 
1069 consecutive patients who were scheduled to undergo coronary angiography 
for suspected or known coronary atherosclerosis 463. Lower serum sodium levels 
were associated with progressive heart failure deaths 464. In prospective 
evaluation of 3,282 elderly subjects with CHF, lower serum sodium (serum 
sodium level < or = 139 mmol/L) was associated with increased risk of deaths 465. 
In the United Kingdom heart failure evaluation and assessment of risk trial (UK-
heart), increase in serum sodium was associated with all-cause mortality 466. 
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However, there were only 54 deaths during the follow-up period in this study 
and it was underpowered to detect an association between serum sodium and 
mortality.  
Table 1-4: Serum electrolytes and mortality outcomes  
Studies  Details  Comparison  Effect size 
Wannamethee, 
1997 462 
Prospective study of 
7262 middle age British 
men, 11.5 years of 
follow-up. 
SK≥5.2 mmol/L Vs 
SK=3.7-5.1 mmol/L 
and mortality.  
HR=1.7, 95% CI: 1.2-
2.6.  
 
 
Nolan, 1998 466 433 CHF patients in the 
UK-heart trial, 16 
months follow-up.  
1 SD increase in SK 
and mortality.  
HR=1.64, 95% CI: 
1.03-2.63.  
Fang, 2000 461 NHANES-I, 2836 
subjects, 16 years of 
follow-up.  
SK≥4.5 mEq/L Vs 
SK=3.8-4.4 mEq/L 
and mortality.  
HR=1.51, 95% CI: 
1.15-1.97. 
Nolan, 1998 466 433 CHF patients in the 
UK-heart trial, 16 
months follow-up.  
1 SD increase in 
SNa and mortality.  
HR=1.59, 95% CI: 
1.13-2.22.  
Mazza, 2005 
465 
3282 CHF patients aged 
over 65 years, 12 years 
follow-up. 
SNa≤139 mmol/L 
Vs >139 mmol/L 
and mortality.  
RR=1.95, 95% CI: 
1.44-2.63.  
Mehta, 2008 
464 
396 incident heart 
failure patients in two 
UK centres, 10 months 
follow-up.  
High Vs Low SNa 
and mortality.  
HR=0.91, 95% CI: 
0.86-0.97 
Jia, 2009 463 1069 consecutive 
patients who 
underwent coronary 
angiography in a 
Chinese hospital, 3 
years follow-up.  
SNa Quartile 4 Vs 
Quartile 1 and 
mortality.  
HR=0.46, 95% CI: 
0.26-0.81.  
De Bacquer, 
1998 467 
9106 individuals in the 
BIRNH study, 10 years 
follow-up.  
SCl≤100 Vs SCl>100 
mmol/L and 
mortality.  
RR=1.65, 95% CI: 
1.06-2.57 in men and 
RR=2.16, 95% CI: 
1.11-4.22 in women.  
Kovesdy, 2009 
468 
1240 male patients 
with moderate CKD.  
SHCO3 and 
mortality.  
U shaped relationship 
with mortality.  
Menon, 2010 
469  
1881 individuals with 
CKD in the MDRD study.  
SHCO3 Quartile 1 
Vs Quartile 4 and 
mortality.  
HR=1.39, 95% CI: 
1.07-1.18.  
Navaneethan, 
2011 470 
41749 CKD patients. SHCO3 and 
mortality.  
A 'J' shaped 
relationship with 
mortality.  
Raphael, 2011 
471 
1094 patients in the 
AASK trial, 6 years 
follow-up.  
One unit increase 
in SHCO3 and 
mortality.  
HR=0.96, 95% CI: 
0.92-0.88 
AASK=African American Study of Kidney Disease and Hypertension, BINRH=Belgian 
Interuniversity Research on Nutrition and Health, MDRD=Modification of Diet in Renal 
Disease, NHANES=National Health and Nutrition Examination Survey, SK=Serum 
Potassium, SNa=Serum Sodium, SCl=Serum Chloride, SHCO3=Serum Bicarbonate, 
HR=Hazard Ratio, RR=Relative Risk, CI=Confidence Interval, SD=Standard Deviation, 
CHF=Congestive Heart Failure, CKD=Chronic Kidney Disease.  
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Serum chloride level is routinely assessed in clinical laboratories in the 
management of patients with hypertension. However, serum chloride level is 
often ignored in clinical decision making in routine medical practice. In a ten 
year follow-up study of >9100 participants aged 25-74 years, free of 
symptomatic coronary heart disease at baseline, the estimated adjusted hazard 
ratio for CV death in subjects with a serum chloride level ≤100 mmol/l in 
comparison to those with levels above that limit was 1.65 (95% CI; 1.06-2.57) 
and 2.16 (95% CI; 1.11-4.22) in men and women, respectively 467.   
A J-shaped relationship was noted between serum bicarbonate and mortality in 
CKD patients 470. Both lower and higher serum bicarbonates were associated with 
increased all-cause mortality (U-shaped relationship) in patients with non-
dialysis-dependent CKD  468. In the Modification of Diet in Renal Disease (MDRD) 
Study, although low serum bicarbonate level was associated with all-cause 
mortality the relationship was not independent of baseline glomerular filtration 
rate 469. In the African American Study of Kidney Disease and Hypertension 
(AASK) trial, higher serum bicarbonate level within the normal range was 
associated with better survival and renal outcomes 471.  
1.8.7 Indices of liver dysfunction/injury and mortality  
In a ten year follow-up study of 3704 adults, low serum albumin was associated 
with high mortality in men and women 472.  In dialysis patients the associations 
of serum phosphorus and albumin concentrations with mortality are modified by 
each other over time and the lowest risk was found with concurrent low 
phosphorus and high albumin values 473. In a multivariate analysis, significantly 
higher risk for total mortality was reported in haemodialysis patients with serum 
albumin <3.8 g/dL (odds ratio 5.04, 95% CI; 1.30-19.60] when compared with 
those with albumin >4.1 g/dL. However, serum albumin did not independently 
predict mortality outcomes in a 4 year follow-up study of chronic haemodialysis 
patients 474. In a systematic review of the relationship between laboratory based 
measures and mortality outcomes in haemodialysis patients, serum albumin was 
significantly associated with all-cause mortality 475. 
The independent associations of serum alkaline phosphatase (ALP) and mortality 
are well established.  For example, after adjustment for serum phosphate, 
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hepatic enzymes, and other potential confounders, post- myocardial infarction 
participants with ALP in the third tertile reported a HR of 1.43 (95% CI: 1.08-
1.89) compared with those in the lowest tertile. This association was also 
validated in the US general population 476 and it was independent of the baseline 
prevalence of metabolic syndrome 477. In outpatients with normal kidney 
function ALP is associated with all-cause mortality 478. In the Korean Longitudinal 
study of Health and Aging (KLoSHA), the group with low ALP had better survival 
rates in comparison to the group with high ALP 479.  
Elevated aspartate transaminase (AST) is associated with mortality in ST 
elevation myocardial infarction patients 480. In an elderly cohort of people aged 
75 years and above abnormal AST level was associated with increased risk 
(adjusted HR=1.27, 95% CI: 1.09-1.47) of all-cause mortality 481.  The association 
of AST with mortality outcomes in the general population has not been studied 
in detail.  
Positive linear association between serum ALT on a logarithmic scale and 
mortality is reported in both men and women with prior history of stable CVD 
482. However, in the US general population elevated ALT was associated only 
with liver disease mortality 483. Studies evaluating the association between non-
alcoholic fatty liver diseases (using liver enzyme levels as surrogate markers) and 
mortality in samples from the general population also provide conflicting results 
484-486. An inverse relationship between ALT in the normal range with all-cause 
mortality was reported in three independent populations of middle-to-older 
aged subjects without evidence of clinically significant liver damage and 
independent of traditional risk factors 487.  
Serum GGT is independently associated with mortality. In the US adult 
population, all-cause mortality increased with elevated GGT (HR, 1.5; 95% CI, 
1.2-1.8), as did mortality from liver disease (HR, 13.0; 95% CI, 2.4-71.5), 
neoplasms (HR, 1.5; 95% CI, 1.01-2.2), and diabetes (HR, 3.3; 95% CI, 1.4-7.6) 
483. In the European Prospective Investigation into Cancer and Nutrition study, 
higher GGT plasma-activity was associated with increased all-cause mortality in 
individuals with diabetes 488. In a prospective study of 6997 men aged 40-59 with 
no history of CVD (CHD or stroke) or diabetes drawn from general practices in 
Britain, elevated GGT was associated with significantly increased risk of stroke, 
fatal CHD events and CV mortality independent of established CV risk factors 489.  
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Several other studies also report increased CV mortality with elevated GGT 
levels 490-492.  
Serum bilirubin is inversely associated with both cardiovascular diseases 493-495 
and cancer 496 in cross-sectional epidemiological studies. In the Korean 
Longitudinal study of Health and Aging (KLoSHA), the group with high bilirubin 
had better survival rates in comparison to the group with low bilirubin 479. In a 
large cohort study among over a half million adults from a UK primary care 
research database, 0.1 mg/dl increase in bilirubin decreased the mortality in 
men by 3% (95% CI: 2%-3%) 497.  
1.9 Summary of literature review and rationale for the 
present study  
Hypertension is a leading cause of death and disability worldwide. The patho-
physiology of hypertension is very complex and involves the interplay of multiple 
neural, hormonal, renal and environmental factors. Despite effective treatment 
regimens the mortality among hypertensive subjects is much higher than that of 
normal individuals. Although reduction in clinic BP is an important and a major 
determinant in mortality reduction, several other factors influence survival in 
hypertensive patients.  
Several studies have been carried out to identify prognostic factors that have 
predictive value for mortality in hypertensive populations. However, the search 
for a new biomarker that is readily available and cost-effective is of special 
interests. While important prognostic information can be learned from BP 
measurements and routine blood tests that are often conducted in hypertension 
clinics, the usefulness of these markers in predicting survival have not been 
studied in detail. This thesis aims to study such factors and the specific aim and 
objectives are listed in the following section.  
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1.10 Aim and objectives of the thesis  
1.10.1 Aim  
To assess the independent predictors of long term mortality in hypertensive 
population.   
1.10.2 Objectives  
1. To assess the relationship between long term blood pressure variability 
and mortality in a hypertensive population.   
2. To explain the relationship of haematocrit and mortality in a hypertensive 
population.   
3. To evaluate the relationship between serum phosphate and mortality in a 
hypertensive population.   
4. To assess the relationship between serum electrolytes and mortality in a 
hypertensive population.  
5. To establish the relationship of liver enzymes (serum aspartate 
transaminase-AST, alanine transaminase-ALT, alkaline phosphatase-ALP, 
gamma glutamyl transpeptidase-GGT) and bilirubin with mortality in a 
hypertensive population.   
Chapter 2 Methods 70 
2 Materials and Methods  
2.1 Study setting and study population 
The Glasgow blood pressure clinic (GBPC) provides secondary and tertiary level 
service to individuals with hypertension from the West of Scotland. It was set-up 
in 1968 to record standardised information on patients attending the special 
hypertension clinics at the Western Infirmary, the Royal Infirmary, Stobhill 
Hospital and the Southern General Hospital 498.  All the clinics were held in out-
patient departments. It was initially supervised by an executive committee with 
GB Shaw as its first chairman. A small sub-committee looked after the medical 
records maintenance and computer infrastructure. Patients were referred to the 
specialist hypertension clinic mostly by their general practitioners or by other 
doctors in these hospitals.  The primary objective of the GBPC was to store 
accessible data from a large number of hypertensive patients and to use this 
information for management and research 498. Data from patients attending 
these clinics are stored in a computerised database, which contains information 
on individuals attending the clinic from 1968 to 2011.   Use of the anonymised 
database for research studies is approved by the West of Scotland research 
ethics service (WoSRES) of the National Health Service (11/WS/0083). 
2.2 Collection of data and follow up  
All patients were treated at GBPC until they achieve target BP and are 
maintained at that level for at least three months. In the early days, a document 
management system developed by Kennedy and his colleagues was used to 
record the data collected 499 500. While an initial structured acceptance 
document and a detailed history and examination document were completed at 
the patient's first visit, a shorter structured document was used to record follow-
up data. The results of investigations were entered separately as an additional 
document. The frequency of visits to GBPC mainly depends on individual patients 
BP levels and presence of other co-morbidities.  After completion, the 
acceptance and follow-up documents reach the data processing unit situated at 
the department of Medical Computing, the Western Infirmary. Demographic and 
clinical data on these documents together with the results of the clinical 
investigations were transferred to a main computer file.  
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Magnetic tapes were used to store the data in the initial days and later they 
were reorganised and stored by using the NHS information technology system in 
dedicated computers.   
2.3 Measurements  
Blood pressure measurements were taken manually 3 times, using standardised 
sphygmomanometers at each visit by specialist hypertension nurses; the mean of 
the last 2 measurements was recorded at each visit. All BP measurements used 
in this study were taken in a seated position. The Korotkoff sounds (phase V) 
were taken as DBP. Patients attending the clinic were advised to take their 
regular medications as usual. Height and weight of all patients were measured 
using standardised equipment during each visit. Patients were classified as being 
smokers if they had ever smoked cigarettes. Frequency of consumption of 
alcohol was also recorded.  Alcohol consumption was categorised into two 
groups; ≤ 5 and ≥ 6 standard units per week. 
2.4 Laboratory measurements  
Venous blood samples were collected at baseline and at regular intervals for 
estimation of routine haematological and biochemical indices. Haematocrit (Hct) 
was analysed in the hospital laboratory auto-analyser, which calculates Hct as 
the product of red blood cell count and the erythrocyte mean cell volume. 
Serum electrolytes, creatinine, phosphate, liver enzymes and bilirubin were 
measured routinely in the hypertension clinic using the auto-analysers. 
Estimated glomerular filtration rate (eGFR) was calculated from the baseline 
serum creatinine values using the Modification of Diet in Renal Disease Study 
Group (MDRD) equation 501. The laboratory assays were performed by the central 
laboratory services of the Western Infirmary. All data were electronically 
captured and maintained as a large single database.  The baseline, repeat 
measurements and outcome variables are summarised in table 2-1 on page 72. 
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Table 2-1: Study variables in the Glasgow Blood Pressure Clinic Database.   
Baseline variables  Number of 
individuals 
at baseline  
Repeat 
measure
ments*   
Outcome 
variables  
Age at first visit (Yrs)  16011  Date of 
death (DD 
MM YR)  
 
Primary 
Cause of 
death (ICD 
10 codes).   
 
Sex (Men or Women) 16011  
Date of first visit (DD MM YR)  16011 Y 
Height (Meters)  15405 Y 
Weight (Kg) 15739 Y 
Systolic BP (mmHg)  15727 Y 
Diastolic BP (mmHg) 15727 Y 
Current tobacco use  14665  
Current alcohol use (Frequency of use)  14188  
Co-morbidities (CVD, and Diabetes)  15002  
Heamatocrit (%)  10951 Y 
Serum Creatinine (mg/dl) 11033 Y 
Serum Phosphate (mg/dl)  9820 Y 
Serum AST (U/L) 11258 Y 
Serum ALT (U/L) 10125 Y 
Serum ALP (U/L) 11427 Y 
Serum GGT (U/L) 10555 Y 
Serum Bilirubin (mg/dl) 11037 Y  
Serum Sodium (mEq/L) 13830 Y  
Serum Potassium (mEq/L) 14012 Y  
Serum Chloride (mEq/L) 13430 Y  
Serum Bi-carbonate (mEq/L) 10550 Y  
*3 months and up to 10 years (3-6 months interval). Y=Yes, CVD=cardiovascular disease, 
BP=blood pressure, AST=aspartate transaminase, ALT=alkaline transaminase, ALP 
=alkaline phosphatase, GGT=gamma glutamyl transpeptidase, ICD=international 
classification of disease.   
2.5 Outcome assessment  
Record linkage with the office of the Register General for Scotland allowed 
identification of all deaths and causes of death in clinic attendees. Records kept 
by the General Register Office for Scotland ensured notification of a subject’s 
death (provided that it occurred in the United Kingdom) together with the 
primary cause of death according to the International Classification of Diseases, 
10th Revision, Version for 2007 (ICD-10), codes502 503. Initial validation checks in 
a sample of 300 patients did not find any instance of failure to notify a death 504. 
The International Classification of Diseases (ICD), endorsed by the World Health 
Assembly, is the standard diagnostic tool for epidemiology, health management 
and clinical purposes especially to monitor the incidence and prevalence of 
diseases and other health problems 505. ICD classifies diseases and other health 
problems recorded on many types of health and vital records including death 
certificates and health records. It helps in international comparisons and is used 
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as a standard tool for comparison of national mortality and morbidity statistics 
of the member countries of World Health Organization (WHO) in the global 
burden of disease analyses 506. It is available in the six official languages of WHO 
(Arabic, Chinese, English, French, Russian and Spanish) as well as in 36 other 
languages. The disease classification system is updated regularly, and is 
available as annual list of changes 502. The updates are approved annually at the 
meeting of the Heads of WHO collaborating centres for the Family of 
International Classifications.  
As per ICD-10 convention, diseases of the circulatory system are identified with 
the codes I00-I99 503. Of the diseases of the circulatory system, ischaemic heart 
diseases (IHD) and cerebrovascular diseases are coded as I20-I25 and I60-69, 
respectively. However, transient cerebral ischaemic attacks and related 
syndromes are excluded and classified separately as G45.  The following 
mortality events were considered in the analyses: Cardiovascular deaths (CV 
mortality; ICD-10 codes I00-I99), ischaemic heart disease deaths (IHD mortality; 
ICD-10 codes 120-I25), and stroke deaths (stroke mortality; ICD-10 codes I60-
I69). Deaths other than due to cardiovascular causes were classified as non-
cardiovascular deaths (non-CV mortality). All deaths irrespective of their 
corresponding ICD codes were included in the all-cause mortality category. 
Mortality data were collected up to April 2011.  
2.6 Survival analysis 
Survival analysis was the central statistical method employed for the analysis 
and interpretation of the data. In the context of this thesis, survival analysis 
refers to analysing the time to occurrence of death. The survival time was 
estimated as number of years from the beginning of the follow-up of an 
individual until death occurs. As in most of the survival models the vector of 
survival time was not completely observed 507 and the survival time was right 
censored at 35 years of follow-up allowing a maximum of 35 years for 
participants who had been under follow up for the longest time. Survival 
characteristics are often summarised by quoting survival probabilities or 
cumulative survival at a given time point in the follow-up. Survival probabilities 
are assumed to be the same for subjects recruited early and late into the study. 
The survivor function S(t) provides the probability that a person survives longer 
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than some specific time 't' during the follow-up 508 509. The hazard function h(t) 
gives the instantaneous potential per unit time (one year) for the event to 
occur, given that the individual has survived up to time 't' 509. The most popular 
method used in comparing the survival between different groups is the log rank 
test 510. It takes the whole follow-up period into account in the analyses and test 
the hypothesis that there is no difference between populations being studied in 
the survival probability at any given time point in follow-up. Median survival 
time is another option to summarise survival data. The point in time from the 
time of inclusion in the study where the cumulative survival is 50% is the median 
survival time. However, median survival time derived from raw data is often not 
correct especially when there is censoring. Although it is reliable to interpret 
the median survival time from the survival curves, it cannot be estimated unless 
the survival curve drops below 0.5.  
The relative survival in two groups can be estimated by comparing the observed 
number of events with the expected number of events. The relative risk ratio is 
a measure of how many events have occurred in a study and expressed as 
proportion of events occurring in one group in comparison to the reference 
group. It is often calculated over the average or median duration of the study. A 
hazard ratio (HR) is different from relative risk estimates. In simple terms, the 
HR is the relative probability of an individual reaching a certain point in time 
without experiencing an event in one group compared to the reference group.  
2.6.1 Kaplan-Meier survival analysis  
Initially the Kaplan-Meier (KM) method was employed to summarise the survival 
data separately for all categories of mortality events 508. A plot of the KM 
survival probabilities (KM curve) corresponding to each ordered failure time 
(i.e., one year) are normally plotted as a step function that starts with a 
horizontal line at a survival probability of 1 and then steps down to other 
survival probabilities separately for all categories of the baseline predictor 
variables 511 512. It is recommended to present the survival plots as cumulative 
incidence (mortality) data displaying the proportion of patients with events 
increasing over time 513. This approach was followed for presentation of KM 
curves. To estimate the survival probability at any given time the risk set 
available at that time was used 514. A subject might not be available in the risk 
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set at given time 't' if the subject died prior to time 't' or if the subject did not 
enter into the study at the given time 't'. The general KM formula for survival 
probability at event time t(j) is as follows;  
S(t(j)) =  S(t(j-1))×Pr(T>t(j)|T≥ t(j))   (1)  
In other words, the general KM formula gives the probability of survival past the 
previous failure time t(j-1), multiplied by the conditional probability of surviving 
past time t(j), given survival to at least time t(j). The letter 'T' in the equation 1 
denotes a random variable for a person's survival time in the study where 'T' is 
always equal to or greater than zero and equal to or less than 35 years. To 
determine whether the KM curves for the different categories of baseline 
predictor variable are statistically equivalent, the log-rank test for multiple 
groups was used 510. In general, the log-rank test is a large-sample chi-square 
test where the test statistic provides an overall comparison of the KM curves 
being compared. The test statistic is derived from the observed versus expected 
cell counts over categories of mortality outcomes. The categories for the log-
rank statistic are defined by each of the ordered failure times for the entire set 
of data being analysed. For example, if there are 4 groups based on the baseline 
predictor variable, the log-rank test statistic estimation involved estimation of 
variance and covariance of observed and expected cell count in all four groups. 
Furthermore, the log-rank test statistic would have approximately a large chi-
square distribution with 3 degrees of freedom under the null hypothesis that all 
four groups have common survival time. The estimated power of two-sample 
comparison of survivor functions in log-rank test at different sample sizes and 
hazard ratios are given in table 2-2.  
Table 2-2: Estimated power of two-sample comparison of survivor functions.   
Power N N1 N2 HR Alpha* 
0.85 80 40 40 2.00 0.05 
0.82 100 50 50 1.80 0.05 
0.81 200 100 100 1.50 0.05 
0.83 500 250 250 1.30 0.05 
0.82 1000 500 500 1.20 0.05 
0.88 1200 600 600 1.20 0.05 
0.93 1400 700 700 1.20 0.05 
0.81 3600 1800 1800 1.10 0.05 
N; total number of events, N1 and N2; Number of events in each group, HR=effect size, 
Alpha=two sided significance level. They were generated using 'Stata version 12' which 
implements the Freedman method515 for sample size calculation under the null hypothesis 
that H0=S1(t)=S2(t).  
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There are some weaknesses in the KM method. Since the log rank test is just a 
significance test, an estimate of the effect size (size of the difference between 
groups compared) cannot be generated using this test. The KM method and the 
log rank test can study the effect of one factor at a time and therefore they are 
not often used in multivariate analyses. Additionally, it cannot model a 
continuous predictor variable.   
2.6.2 Cox proportional hazards models 
Since the KM method and the log-rank test can only study the effect of one 
factor at a time, Cox proportional hazards (Cox PH) models 516 were set up to 
analyse the influence of baseline predictor variables on all-cause, CVD, IHD, 
stroke and non-CVD mortality after adjustment for potential confounding 
variables. The Cox PH model assesses the hazard of an event to occur at time 't' 
for an individual with a given specification of a set of variables, provided that 
the individual has not experienced that event up to time 't' 517.   
The Cox PH formula can be written as;  
H(t, X) =h0(t)e∑ 


  (2) 
where X=(predictor variable of interests and other confounding variables).  
The Cox PH model in equation 2 gives the hazard at time 't' as a product of 
baseline hazard involving time 't' (an unspecified arbitrary non-negative function 
of the time) and an exponential expression to the linear sum of βiXi, where the 
sum is over all the explanatory variables and β is an unknown parameter 
reflecting the effect of X on survival. In other words, it models the effect of 
covariates on the hazard rate and leaves the baseline hazard rate unspecified. 
The baseline hazard function is interpreted as the hazard when all covariates are 
zero. This model is a semi-parametric model as it contains finite dimensional 
relative risk parameters (β's) and an infinite dimensional parameter h0(t).  The 
exponential part ensures that the fitted model will always give estimated 
hazards that are non-negative. Cox model does not assume knowledge of 
absolute risk and only estimates relative risk. An additional advantage of Cox 
model over the K-M method is that it can accommodate both discrete and 
continuous measures of event times.   
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A stepwise backward selection of variables was used in the selection of models 
518. Exposure variables with p values less than 0.10 were retained in the model 
and others were excluded. When the linearity of the effect of exposure variable 
on outcome was in doubt, they were divided into groups. In order to ensure an 
equal proportion of individuals at risk at baseline in all groups, often the 
quartiles or quintiles of the exposure variable was taken. Variables with skewed 
distribution were transformed into logarithmic scale to avoid undue influence of 
extreme values on the choice of the model. Finally, if there were strong 
correlations between variables in the model (correlation coefficient of more 
than 0.60), one of them was removed from the model.  
The covariates included were baseline age, gender, body mass index (BMI), 
smoking status, systolic and diastolic blood pressure (SBP and DBP), alcohol use, 
tobacco use, eGFR and cardiovascular co-morbidity. A variable on year of first 
visit strata (epochs) was used to adjust the secular trend in mortality and was 
divided into five categories (first visit 1977 or before, between years 1978-1985, 
1986-1993, 1994-2001, 2002 and after). This variable was included in all models 
to adjust for any secular trend in treatment practices and mortality.  
The Cox's method is a 'semi-parametric' approach and no particular type of 
distribution is assumed for survival. However, there are some strong basic 
assumptions made on the effect of exposure variable on survival.  The main 
assumptions in the basic Cox-PH model are 516 519; (a) the hazard rate of an 
individual at time 't' is proportional to the hazard rate at any other given time 
point in the follow-up period and (b) the exposure variable of interests and other 
covariates contribute linearly to the natural log of the hazard ratio.  
Although the Cox-PH model makes no assumption about the form of baseline 
hazard function (non-parametric part of the model), it assumes a parametric 
form for the effect of predictors on the hazard. Therefore, parameters 
estimates like the maximum likelihood estimates of the Cox model were derived 
by maximising the partial likelihood function (L) 519. The likelihood function is a 
mathematical expression which describes the joint probability of obtaining the 
data actually observed on the subjects in the study as a function of the unknown 
parameters (the β’s) in the model being considered. To maximise the likelihood 
function the partial derivatives of log of 'L' with respect to each parameter in 
the model were carried out using an iteration procedure. In other words, a 
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solution is obtained in a stepwise manner, which starts with guessed value for 
the solution, and then successfully modifies the guessed value until a solution is 
finally obtained. While the HRs were computed by taking the exponential of the 
coefficient of the predictor variable, the statistical inferences of the HRs were 
derived in terms of the maximum likelihood estimates by computing a Wald test 
(a Z statistic known as the Wald statistic) and a likelihood ratio (LR) test. 
Variance is the inverse of the observed information evaluated at the maximum 
partial likelihood estimation. The standard error of β’s derived from the 
resulting variance-covariance matrix is used for estimation of 95% confidence 
limits of the HR.  
Cox-PH model assumes that time to event is a continuous variable. The partial 
likelihood in the Cox-PH model is only valid when there is no ties in the dataset 
i.e., no two subjects have the same event time. In instances where ties are 
present, the Breslow approximation to the partial log likelihood was used 520. 
There are different approaches to manage tied events in the Cox-PH models. 
The most common method used is the exact method. It assumes that ties result 
from imprecise measurement of time and there is a true unknown order of 
events in time. Mathematically the exact method calculates the event 
probability of all possible ordering of events. It is largely a complex computation 
when there are multiple ties and often requires approximation. Breslow520 and 
Efron 521 are approximation to the exact method. Breslow does not perform well 
when the number of ties at a particular time point is a large proportion of the 
number of case at risk. In such situations, Efron is preferred over Breslow.  
The estimated sample size requirements for Cox-PH regression to obtain 80% 
power at different hazard ratios are given in table 2-3. They were generated 
using 'Stata version 12' which implements the Hsieh and Lavori (2000) method522 
for sample size calculation. The 'Stata' command provides options to account for 
possible correlation between a covariate of interest and other predictors and for 
withdrawal of subjects from the study. The required sample size was estimated 
under two assumptions; (a) the predictor variables are independent of each 
other and (b) there is correlation between predictor variables and the multiple 
correlation coefficients is 0.3.    
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Table 2-3: Estimated sample size for Cox regression.   
Power N N1 HR Alpha* 
0.80 3457 4938 1.1 0.05 
0.80 945 1350 1.2 0.05 
0.80 457 652 1.3 0.05 
0.80 278 397 1.4 0.05 
0.80 191 273 1.5 0.05 
0.80 143 204 1.6 0.05 
0.80 112 160 1.7 0.05 
0.80 91 130 1.8 0.05 
0.80 77 109 1.9 0.05 
0.80 66 94 2.0 0.05 
N; number of events, N1; number of events required assuming the covariate of interest is 
correlated with other covariates (r = 0.3), HR; hazard ratio, Alpha=two sided p value.  
2.6.3 Testing proportional hazard assumption  
The proportional hazard (PH) assumption requires that the hazard ratio (HR) is 
constant over time and that the hazard of one individual is proportional to the 
hazard for any other individual, where the proportionality constant is 
independent of time. The PH assumption is tested by comparing the estimated –
ln(-ln) survivor curves of the baseline predictor variable as in the research 
question and also by the goodness-of-fit (GOF) tests 523 524. In general, the log-log 
survival curve is a transformation of an estimated survival curve that results 
from taking the natural log of an estimated survival probability twice. Since the 
log of the survival probability is always a negative number, a second log is taken 
to negate the first log. The PH assumption is violated when the log-log curves 
are not parallel to each other. In the GOF test, Z or large sample chi-square 
statistics were computed for each variable in the model, after adjustment for 
other variables in the model and p values were derived from comparing it with a 
standard normal statistic obtained for each variable in the model.  
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2.6.4 Cox proportional hazard model with restricted spline 
functions 
In the Cox PH model described earlier (2.1.3), the modelled response is the 
hazard rate of death with a log hazard ratio linear in the predictor variables. 
However, this assumption is often violated especially when the effect of 
predictor variables are best represented as non-linear functions. In order to 
model efficiently the non-linear relationship, multivariable Cox-regression 
models with restricted spline functions were used 525. This model can be used as 
a flexible alternative model in case of violation of PH assumption. The Cox PH 
model incorporating an arbitrary covariate effect is of the form;  
 H(t, X) =h0(t)e()   (3) 
where the log hazard ratio function g is an unspecified smooth function of X.  
A spline is a polynomial of degree d or order d+1, on any interval (εi-1, εi). A knot 
is often described as a free parameter for a piecewise linear spline that 
represents a break point in the log hazard function which may be interpreted as 
a threshold value. The 'mvrs' algorithm in ‘Stata’ was used to fit the regression 
spline (RS) Cox PH models with all predictor variables 525. Unlike in the previous 
Cox PH model, the RS Cox PH model provides more flexibility in modelling a 
continuous predictor variable.  
For all the predictor variables, the classical maximising gradient based method 
was employed in the multivariate model with equally spaced knots. In order to 
avoid the problem of local optima, different sets of initial knots values were 
placed on a grid constructed within the range of the variable. Although ten knots 
were placed, the knot localised on the bounds of the interval would not have 
any influence on the estimation. Therefore, in total  = 
!
!()! different 
vectors of knots were used for initialising the algorithm.  
Given the fact that the classical linear model is nested in each spline model, the 
models were compared by using likelihood ratio test. A best fit was arrived 
based on the knot positions by bootstrapping method 525. Since we used all 
predictor variables, the algorithm cycled over each predictors by changing the 
model according to the type-1 error rate of individual variable in the model 
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(excluded when α>0.05). The process stopped after several cycles when there 
was no further change in predictor variables included in the model and their 
spline functions. Finally, the log relative hazard for each predictor variable in 
the multivariable RS model and their 95% point wise confidence interval 
estimates were plotted against actual values of the predictor variable. The 
exponent of the log HR provides the actual HR and its interpretation is same as 
that in the Cox-PH model.  
2.6.5 Stratified Cox proportional hazard model  
The stratified Cox PH model was used to analyse data when one or more of the 
predictor variables violated the PH assumption. The stratified Cox PH model is a 
modification of the Cox-PH model and often used in survival analyses when one 
or more of predictor variables violate the PH assumption 526. While the 
predictors that satisfy the PH assumption are included in the model, predictors 
that do not satisfy the PH assumption are not included in the model and used for 
stratification 524.  
The general stratified Cox PH model can be written as;  
hg(t, X)=H0g(t)(⋯!!)   (4) 
where g=1, 2,..............k*, strata defined from Z predictor variable that do not 
satisfy the PH assumption. This model is designated as a "no-interaction" model 
because of the β coefficients in the model are the same for each subscript g 524.  
However, this model assumes that the β coefficients do not vary over strata. In 
other words, the variables being stratified are assumed not to interact with the 
predictor variables in the model.  The estimated survival curves for each stratum 
in the fitted stratified Cox-PH model will be different due to differences in the 
baseline hazard function for each stratum. Conversely, the β coefficients of the 
X's are the same for each stratum. Hence the baseline hazard ratios are the 
same for each stratum. However if we allow for interaction, then we would 
expect to obtain different β coefficients for each of the stratified categories 524. 
This model allows the underlying hazard function to vary across levels of 
stratification variables. A likelihood ratio test can be performed to compare the 
log likelihood statistics for the interaction model and the non-interaction model 
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under the null hypothesis that the β coefficients of each of these product terms 
are all zero.  
2.7 Analysis of repeat measurement data  
2.7.1  Generalised estimating equation regression  
Generalised estimating equations (GEE) were used to analyse longitudinal 
correlated response data 527 528 such as repeat measurements of BP variables and 
eGFR. The normal linear model assumes that the measurements are independent 
while estimating the variance component. Conversely, the GEE model accounts 
for the correlation between observations in generalised linear regression models 
by use of empirical variance estimator 528.  
The GEE model characterises the marginal expectation (average response of 
observations sharing the same covariates; population averaged effects) as a 
function of covariates.  There are no distributional assumptions in GEE models. It 
avoids the need for multivariate distribution of the longitudinal response 
variable by assuming a functional form for the marginal distribution at each time 
point. The functional form should have a mean zero if the true parameters are 
entered into that estimating function. The GEE model generalise and extend the 
usual likelihood equations for a generalised linear model with a univariate 
response by incorporating the covariance matrix of the vector of response 
variables.  The estimating equations approach of population average model 
provides a more efficient approximation to the truth than mixed effect models 
529. The covariance structure is often treated as a nuisance in the model. While 
the "independence estimating equations", a GEE model with an independent 
working correlation matrix, incorrectly assumes that the observations within 
subject are independent, the sandwich estimator 528 provides a good estimate of 
the covariance in large samples. The main focus in the GEE analysis are to 
estimate the population averaged mean effect and the estimation of inferences 
of the regression coefficients in the model. It allows robust inferences even if 
the underlying correlation structure is incorrectly specified 529.   
In GEE models, the estimated regression coefficient represent the effect of the 
explanatory variables on the population average effect of the response variable. 
In other words it describes the change in population mean given the changes in 
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covariates after accounting for correlation between observations.  For 
quantitative traits, the GEE regression coefficient is interpreted as change in 
mean outcome for a unit change in the exposure in the entire population.   
The major limitations of the GEE are described below. There is no likelihood 
function in GEE as it does not specify completely the joint distribution. Instead it 
uses a quasi-likelihood estimate of the regression coefficient by maximising the 
normality-based likelihood without assuming that the response is normally 
distributed. In quasi-likelihood estimations, the mean response is expressed as a 
parametric function of covariates and the variance is assumed to be a function 
of the mean 530. Therefore, testing the model fit and comparing the models are 
not possible in GEE. GEE requires specifying the covariance structure of the 
correlated response for the appropriate standard error estimations. Empirical 
based standard errors often underestimate the true ones. However, the effect 
can be minimised by increasing the sample size. Although GEE makes less 
computational restrictions on data, it treats missing data as completely missing 
at random. However, this assumption may not hold true in longitudinal repeat 
measurement data especially when the follow-up schedule is not decided in 
advance. In the GBPC, the patient follow-up is partially influenced by the 
presence of other co-morbidities and status of BP control. Patients with other 
co-morbidities and uncontrolled BP may visit the clinic more frequently than 
others. To minimise the bias introduced by irregular follow-up in the analyses, 
the GEE model was restricted to individuals with a minimum number of follow-
up visits (at least 4 annual visits in the first five years).  
2.7.2  Extended Cox proportional hazard model with time 
dependent variables  
In the general Cox PH model, the baseline hazard is a function of time 't' but 
does not involve the predictor variables (X's). However, the exponential function 
involves the X's but does not involve 't'. Hence the X's in this model are generally 
referred as "time independent" X's 524. Under the PH assumption, the hazard for 
one individual is proportional to the hazard for any other individual and the 
proportionality constant is independent of time. However, some of the baseline 
predictor variables are "time-dependent" and change their value with time. In 
such situations, the Cox PH model will be extended to involve interaction terms 
with the predictor variable and some function of time. The basic assumption is 
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that the effect of a time-dependent variable Xj(t) on survival probability at time 
't' depends on the value of this variable at the same time 't', and not on the 
value at an earlier or later time 524. This model is generally referred as "time-
dependent extended Cox PH model". Regular follow-up schedule is essential for 
time dependent Cox PH models 526. As the clinic visits are dependent largely on 
clinical progress and given the fact that repeat measurement data are available 
only in a sub-group of patients, this method was not used in the GBPC data 
analyses.  
2.7.3 Four groups analyses  
The 'four groups' models for contrasting combinations of change in variables 
ranges during follow-up are also considered in the survival analyses 531. Median 
values of initial assessment and final assessment of the same variable were 
taken as the cut-off points to define the 'four groups'. The four groups comprised 
of high-high, high-low, low-high and low-low groups based on initial and final 
values of the variable. In specific cases clinically relevant cut-off were used to 
classify individuals into four groups. The classification details are provided in the 
respective results chapters. They were considered in both the Kaplan-Meier and 
the Cox-PH models to analyse the impact of change in predictor variables during 
the course of follow-up on mortality.  
2.8 Measuring correlation between variables    
Different measures of correlations are described in the literature to describe the 
association between two variables. A perfect correlation occurs when a scatter 
plot of one variable against another one results in a straight line. The methods 
used in the analyses of GBPC data are described in the following section.  
2.8.1  Pearson correlation coefficient  
Pearson's correlation coefficient was used to assess the relationship between two 
quantitative variables. Pearson correlation coefficient (r) is a measure of linear 
association between two variables. The correlation coefficient can assume a 
value anywhere between -1 to +1. The interpretation of correlation coefficient is 
as follows; the larger the correlation coefficient the stronger the linear 
association between two variables 532. The sign of the correlation coefficient 
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indicates the direction of the association. The strength of the association 
between two variables can vary depending on the range of values observed on 
the variables.  
2.8.2  Spearman's rank correlation coefficient  
Spearman's rank correlation (rs) was used to assess the relationship between 
quartiles or quintiles of two variables. It uses ranks of the two variables to 
calculate correlation. While Spearman's correlation assesses monotonic 
relationship, Pearson's correlation  benchmarks linear relationship 532. The 
Spearman's correlation coefficient (rs) also takes values from +1 to -1. The closer 
rs is to zero, the weaker the association between the ranks.  
Correlation coefficients are often used incorrectly to indicate agreement 
between two variables. A systematic error can results in perfect correlation with 
absolutely no agreement. Correlation also depends on the range of the true 
quantity in the sample. The correlation will be greater if the range of the 
quantity is wider. Although the test of significance of the correlation coefficient 
may indicate that the two methods are related (it will be invariably significant in 
large samples with relatively small correlation coefficient), it needs to be 
interpreted with the absolute value of correlation coefficient. Evidently, simple 
correlation is a poor tool with which to assess reproducibility 533.  
2.8.3  Intra-class correlation coefficient  
Intra-class correlation coefficient (ICC) was used to assess the reliability of 
measurements at repeated time points. ICC is a general measurement of 
agreement, where the measurements used are assumed to be parametric (i.e. 
continuous and has a normal distribution).   The coefficient represents 
agreement between two or more evaluation methods on the same set of 
subjects, after corrections for agreement expected by chance 534.  Two-way 
mixed model analysis of variance (ANOVA) with measures of consistency was 
used to generate ICC between different measurements. The advantage of ICC 
over correlation coefficient is that it is adjusted for the effects of the scale of 
measurements 535. However, it is dependent on the range of measurement as in 
the correlation coefficients.  
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The basic assumption in all ICC models as in any other parametric models is that 
the study subjects are a random sample from a larger population. However, this 
is often not the case and it makes the interpretation more difficult. The ICC 
estimates are based on mean squares obtained by applying analysis of variance 
(ANOVA) models to the data. The ICC in general is the proportion of relevant 
variance associated with differences among individuals in the study group 534 and 
it is calculated as the ratio of between-subjects variance to the total variance. 
In other words, the larger the heterogeneity among the subjects, with lower or 
equal random error the easier it is to differentiate between subjects. The values 
of the ICC can theoretically range from 0 to 1. It can be also used to measure 
consistency between different measurements. However, it is difficult to say 
whether one measurement can be used in place of another measurement using 
the ICC 534. 
2.8.4  Cramer's V statistic  
To measure the degree of congruence between different measurements Cramer's 
V statistics was generated. Cramer's V is a post-hoc test to give additional 
information on the significance of findings over and above Chi-square test 536. 
Cramer's V statistic assumes that the marginal differences in rows are similar to 
those for columns and that the change from one category to another is equally 
likely. Cramer's V varies between 0 and 1 and a value close to zero shows little 
association between variables.  
2.9 Statistical software for analyses 
Stata, Version 12.1, StataCorp, Texas, USA was used for data analyses. 
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3 Long-term blood pressure variability and 
mortality  
3.1 Introduction  
Blood pressure is inherently variable and variability of BP in an individual could 
be as important as the magnitude of the BP 537. Even within controlled 
environment, BP is subject to biological variation from beat to beat.  Factors 
such as temperature, weather 249, and physical activity 538 influence blood 
pressure variability (BPV).  Studies also reveal that SBP varies to a greater extent 
than DBP 539. There are mainly two forms of variability—short-term BPV, which is 
the variability of BP over minutes or hours, such as is seen on 24-hour ABPM, and 
long-term BPV, such as is seen with repeated recordings over weeks or months 
(visit-to-visit variability).  
BPV increases with increase in mean BP 538 and it is often ignored as a prognostic 
marker in epidemiological studies.  One of the earliest studies that examined the 
prognostic benefit of BPV was in a group of 286 hypertensive patients who had 
been followed-up for more than three years. In this study the carotid artery 
intima media thickness was higher in individuals with higher SBP variability 
(BPVSBP) compared to individuals with similar mean BP but lower variability 
540. 
In another study conducted among 1433 Japanese men living in Hawaii, there 
was a 100% increase in the risk of incident CHD events in individuals with high 
SBP variability as compared to individuals with low SBP variability 541.  
Recent evidence from post-hoc analysis of large clinical trials and population 
cohorts indicates that long-term visit-to-visit BPV may be an independent 
cardiovascular risk predictor 342 359 542. The association of short-term variability of 
BP (24 hour period) with end-organ damage and cardiovascular events is well 
established 346 543. There is evidence to suggest that visit-to-visit variability in 
SBP has prognostic value, independent of average BP 359 544, and that the 
variability is reproducible and not a random phenomenon 545 546. Long-term intra-
individual BP variability, which reflect BP fluctuations between measurements 
separated by months, has been shown to have poor correlation with concomitant 
24 hour BP variability (correlation coefficient <0.4). Thus the prognostic impact 
associated with these two measures relates to different underlying mechanisms 
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547. This would imply that long-term BPV is a marker of risk that is currently not 
captured by the office and ambulatory BP measurements routinely used in 
clinical practice and may be a fundamental physiologic trait. If BPV is a true 
independent prognostic marker then visit-to-visit BPV during different time-
frames over a long follow-up period should show similar patterns of risk. The 
present study assessed the relationship between BPV measurements at different 
time-points of follow-up and mortality in a treated hypertensive cohort.   
3.2  Methods 
3.2.1 Study Setting and Population 
The study population comprised of all patients attending the Glasgow Blood 
Pressure Clinic (GBPC).  Detailed description of study settings and measurements 
are provided in section 2.1-2.4 of chapter 2. Data from 16,011 attendees are 
stored within a computerised database. Detailed study flow-chart is presented in 
figure 3-1 on page 92.  
3.2.2 Blood Pressure Measurements 
The GBPC employs specialist hypertension nurses, who are experienced and 
highly trained in BP measurement. The procedure requires subjects to rest for 5 
minutes in a seated position before BP is manually measured using standardised 
sphygmomanometers. The procedure is performed 3 times and the mean of the 
second and third measurements is recorded. Heart rate is also recorded. The 
approximate timing of BP measurement was between 9.00am and 11.00am 
during each clinic visit. Consumption of food and drink, and level of physical 
exertion before each clinic appointment could not be controlled. Drug 
substitution, addition and dose adjustment occurred during follow-up and in 
accordance with clinical guidelines. Prescribed medications are cross checked 
with patients at each clinic visit, and they are advised to comply with their 
treatment at all times. However formal concordance testing was unavailable. 
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3.2.3 Blood pressure trait definitions 
In total four time frames for analysis were defined as periods of follow-up from 
the first visit to clinic - year 1 (Y1), years 2-5 (Y2-5), years 5-10 (Y5-10), and 
years 10+ (Y10+).  To be included in each time frame for analysis, subjects were 
required to have a minimum of 3 BP readings at least 30 days apart. Other 
exclusion criteria were extremes of age (<20 and >80 years) and BMI (<15 and 
>50Kg/m2). For each time frame the coefficient of variation (CoeffV) and 
average real variability (ARV) as metrics of BP variability (ARVSBP, ARVDBP, 
CoeffVSBP, CoeffVDBP) were calculated. CoeffV provides a normalized measure 
of variability and ARV takes the order of the BP measurements into account and 
quantifies variability between adjacent readings.  The mean BP was calculated 
for each time frame using a time-weighted average of all BP measurements 
(SBPtw, DBPtw) during the interval, to remove any upward bias of the mean BP 
caused by more frequent appointments when BP was uncontrolled. The formulae 
used for calculating all these metrics are presented in box 1 on page 90. All 
CoeffV values were then multiplied by 100 to produce CoeffV percent.  Finally, 
quartiles of ARV and CoeffV percent were determined for each time period. 
In addition to the above analyses, the study population was divided into 4 groups 
depending on the longitudinal pattern of change in BPV over time. Using a 
threshold ARVSBP of 17 and comparing Y1 and Y2-5, study subjects were 
classified into those who had a persistently high (high-high) or low (low-low) 
BPV, and subjects whose BPV increased (low-high), or decreased (high-low) over 
time. A cut-off of ARVSBP=17 was used as it facilitated the division of the cohort 
into 4 groups with approximately equal sample sizes.  The same categorisation 
procedure was undertaken for DBP using a threshold of ARVDBP=9, again 
comparing Y1 and Y2-5.  Similar analyses were performed excluding Y1, i.e. 
comparing Y2-5 with Y5-10, because Y1 can be considered a period where 
patients would be exposed to intense drug alterations and dose titration of 
antihypertensive agents in order to reach target BP. 
3.2.4 Outcome assessment  
Outcome assessment is explained in detail in section 2.5 of chapter 2.  
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3.2.5 Statistical Analysis 
Summary statistics of baseline participant characteristics were calculated by 
time periods (Y1, Y2-5, Y5-10, and Y10+), stratified by sex. Categorical variables 
are shown as counts and percentages and continuous variables shown as means 
(SD).  ARVSBP and ARVDBP were summarised as mean (SD), stratified by follow-
up period and by categories of baseline covariates. Appropriate statistical 
comparisons were performed using independent 't' tests or analysis of variance 
(ANOVA). 
To measure degree of congruence of BPV classification between time frames, 
Cramer’s V statistics and intra-class correlation coefficients were calculated for 
both SBP and DBP. Cramer's V statistic assumes that the marginal differences in 
rows are similar to those for columns and that the change from one category to 
another is equally likely. The intraclass correlation coefficient provides a scalar 
measure of agreement or concordance between the BPV categories in different 
time-frames. More details are provided in the sections 2.8.3 to 2.8.4. In order to 
assess the relationship between BPV and average blood pressure, Spearman’s 
correlation coefficients (section 2.8.2) were calculated between ARVBP and 
mean BP, and ARVBP and mean BPtw, for each time frame. 
Box 1: Calculation of BP metrics 
 
Coefficient of Variation 
CoeffV = 
"#
$%&'    
Average Real Variability 
ARVBP = 

'
∑ |)*+ − )*+  |'+-  
Time-weighted average BP 
Mean BPtw = ∑ ./01/012 3
'
4-5 ∗ 784 − 89 
BP= Blood Pressure; T= Time; SD= Standard 
deviation; BP = SBP or DBP 
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Survival analyses were performed as explained in section 2.6. The survival data 
were right censored at 35 years of follow-up. Cox proportional hazards (Cox-PH) 
models (section 2.6.2) were used to determine the risk of all-cause mortality, 
IHD, stroke, cardiovascular or non-cardiovascular mortality for each quartile of 
ARVBP, with the lowest quartile serving as the referent. Separate analyses were 
performed for SBP and DBP, and for each follow-up time frame: Y1, Y2-5, Y5-10, 
and Y10+.  Furthermore, all analyses were repeated using CoeffV percent as an 
alternative measure of BP variation.  The models were adjusted for mean SBPtw 
and DBPtw, and baseline cardiovascular risk factors including: age, sex, smoking, 
alcohol consumption, BMI, total cholesterol, prevalent cardiovascular disease 
(CVD), and eGFR.  Furthermore, in analyses of Y1 and Y2-5 a variable on year of 
first visit strata (epochs) was included to adjust the secular trend in mortality 
and was divided into five categories (first visit 1976 or before, between years 
1977-1987, 1988-1997, 1998-2004, 2005 and after).  Log-minus-log plots (section 
2.6.3) were analysed for any suggestion of deviation from the proportional 
hazards assumption 548.  
A sub-group analysis was also performed after stratifying the Y1 and Y2-5 
average real blood pressure variability measurements by mean baseline SBP 
categories (<140 mmHg, 140-160 mmHg and >160 mmHg). The HRs for both all-
cause and cardiovascular mortality were generated using cox-proportional 
hazard models as explained in the previous paragraph.  
The four groups of change in BPV at different time frames were compared 
visually using Kaplan Meier survival plots (as explained in section 2.7.1), and 
statistically using Log Rank tests.  Additionally, Cox proportional hazards models 
were used to determine the risk conferred by membership in one of the four 
groups after adjustment for the covariates described above.   
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Figure 3-1: Study flow chart.   
N=1488 Excluded (age<20 or >80, 
BMI<15 or >50 kg/m2, and death or 
follow-up ended before year 1).  
N=16011 registered 
hypertension patients  
N=14523 
Q1=1761: Q2=1816: 
Q3=1759: Q4=1800 
N=7387 excluded 
(<3 BP readings) 
N=7136 (Year 1) N=11502  
N=8547 
N=6063 
N=3021 Excluded (death or 
follow-up ended before year 
5).  
N=2955 Excluded (death or 
follow-up ended before year 
5).  
N=2484 Excluded (death or 
follow-up ended before year 
10).  
Q1=1448: Q2=1422: 
Q3=1429: Q4=1416 
N=5785 excluded 
(<3 BP readings) 
 
N=5715 (Year 2-5) 
Q1=666: Q2=675 
Q3=678: Q4=666 
N=5862 excluded 
(<3 BP readings) 
 
N=2685 (Year 5-10) 
Q1=321: Q2=324 
Q3=329: Q4=318 
N=4761 excluded 
(<3 BP readings) 
N=1292 (Year 10+) 
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3.3 Results 
3.3.1 Sample baseline demographic characteristics 
At baseline, after exclusions based on age and BMI, 14,523 participants had basic 
demographic information recorded.  Of these, 6952 (47.9%) were males and 6094 
(42.5%) smokers.   The median survival time was 29.32 years. The mean (SD) SBP 
at baseline was 165mmHg (29.19) and the mean (SD) DBP was 98mmHg (20.02).  
The baseline characteristics for each time period, stratified by sex, are 
presented in table 3-1 on page 95. BPV as measured by ARV, CoeffV or SD were 
all higher in Y1 compared to Y2-5 and later. The summary statistics of baseline 
BPV data are presented in table 3-2 on page 95.  
3.3.2 Blood pressure variability and baseline characteristics 
Table 3-3 presents mean (SD) ARVSBP, categorised by follow-up time-frames and 
by baseline characteristics.  ARVSBP was consistently higher during all follow-up 
time-frames in women (p < 0.01), older age (p < 0.001), participants with 
baseline CKD (p < 0.01), and baseline prevalent CVD (p < 0.01).  High baseline 
SBP and high baseline mean SBPtw, were both associated with greater ARVSBP (p 
< 0.001). Table 3-4 (page 97) presents mean (SD) ARVDBP, categorised by follow-
up time-frames and by baseline characteristics.  Albeit with a few exceptions 
and poor consistency across the follow-up period, the ARVDBP results were 
similar to ARVSBP. In contrast with ARVSBP, ARVDBP was not associated with 
sex, and it decreased with age beyond 50 years in Y1 and Y2-5 time periods 
(p<0.001).  Furthermore, among users of alcohol ARVDBP was higher up to five 
years follow-up (p<0.001).   
3.3.3 Agreement between BP variability measurements  
In general there was poor agreement between ARVBP quartiles and different 
time frames though the association was significant. The correlation was higher 
between adjacent time frames but the magnitude of correlation was small 
(ICC<0.3, Cramer’s V <0.3) (Tables 3-5 and 3-6 on page 98). This was similar for 
both SBP and DBP measures. 
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3.3.4 Blood pressure variability and mean blood pressure 
ARVSBP and ARVDBP were moderately correlated with both mean BP and mean 
BPtw, at each follow-up time period (p<0.01; Table 3-7 on page 99).  The 
highest Spearman correlations were observed during Y2-5 (mean SBP (mean 
SBPtw) and ARVSBP = 0.47, mean DBP and ARVDBP = 0.28, mean DBPtw and 
ARVDBP = 0.27).  
3.3.5 Blood pressure variability and mortality  
Data from previous BPV studies suggest that when compared with SD of BP, ARV 
seems to be a more appropriate index for BPV and a better predictor of risk. I 
therefore highlighted the relationship between ARV and mortality in this 
chapter. However, the association between SD and CoeffV of BP with mortality 
are also presented for better clarity. Unadjusted event rates per 1000 person 
years of follow-up, stratified by quartiles of ARV, are presented in tables 3-8 on 
page 100 (SBP) and 3-9 on page 101 (DBP).  For all mortality outcomes the 
number of events increased with increasing BP variability.  The PH assumption 
was tested graphically using log-log survival curves (Figures 3-2 to 3-3 on page 
102). There were no indications of violation of PH assumption. Cox-PH models of 
ARVSBP (Figures 3-4 to 3-5 on pages 103-104) and ARVDBP (Figures 3-6 to 3-7 on 
pages 105-106) are presented as Forest plots. The results of the Cox-PH analysis 
of ARV and CoeffV percent BP for each time period are also presented in tables 
3-10 to 3-14 on pages 107-109.  Increasing quartiles of ARVSBP in Y1 were 
associated with increased risk of all-cause (p for trend <0.001), cardiovascular (p 
for trend <0.001), and IHD mortality (p for trend <0.001) (Figures 3-4 to 3-5 on 
pages 103-104).  The results were consistent during other follow-up time points 
as well. Similarly, increasing quartiles of ARVDBP in Y1 were associated with 
increased risk of all-cause (p for trend <0.01), and cardiovascular mortality (p 
for trend <0.05) (Figure 3-6 on page 105).  However, the results were not 
consistent in the other follow-up time points analysed. Non-CV mortality was 
consistently elevated in higher ARVSBP quartiles in all follow-up time points up 
to year 10 (Figure 3-5 on page 104). CoeffV of SBP quartiles showed a significant 
association with all-cause mortality in all time frames except Y1 (Table 3-10 on 
page 107).   
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Table 3-1: Baseline population characteristics by follow-up period, stratified by sex. 
 
 
Variables  
Year 1 (n=7136) Years 2-5 (n=5715) Years 5-10 (n=2685) Year 10+ (n=1292) 
Men 
n=3518 
Women 
n=3618 
Men 
n=2787 
Women 
n=2928 
Men 
n=1279 
Women 
n=1406 
Men 
n=579 
Women 
n=713 
Age at first visit, years(SD) 51.22 (11.77) 52.90 (13.59) 51.43 (11.12) 52.88 (13.03) 51.03 (10.51) 52.47 (12.18) 49.20 (9.62) 49.60 (11.43) 
Smoker, n (%) 1673 (49.42) 1467 (42.00) 1352 (48.90) 1171 (40.23) 590 (46.17) 553 (39.33) 256 (44.21) 242 (33.94) 
IHD, n (%) 527 (14.98) 449 (12.41) 488 (17.51) 447 (15.27) 301 (23.53) 292 (20.77) 180 (31.09) 159 (22.30) 
CVD, n (%) 876 (25.69) 701 (19.88) 819 (29.45) 692 (23.65) 464 (36.28) 431 (30.65) 248 (42.83) 249 (34.92) 
Alcohol >6 units, n (%) 2544 (77.04) 1641 (48.05) 2043 (75.75) 1351 (47.54) 961 (76.27) 627 (45.53) 435 (75.39) 310 (43.79) 
Cholesterol (mmol/l), mean (SD) 5.92 (1.35) 6.18 (1.36) 5.87 (1.17) 6.18 (1.33) 5.97 (1.17) 6.23 (1.25) 6.10 (1.17) 6.37 (1.27) 
eGFR<60 ml/min/1.73m2, n (%) 657 (20.25) 999 (29.92) 554 (20.28) 846 (29.46) 240 (18.78) 381 (27.10) 87 (15.05) 160 (22.47) 
BMI (kg/m2), mean(SD) 27.47 (4.45) 27.50 (5.63) 27.55 (4.39) 27.55 (5.54) 27.45 (4.14) 27.31 (5.34) 26.87 (3.69) 26.82 (4.99) 
Baseline SBP mmHg, mean (SD) 169.04 (26.66) 173.59 (30.25) 167.25 (27.40) 172.11 (30.21) 167.61 (26.74) 171.41 (30.22) 170.04 (25.80) 172.49 (28.97) 
Baseline DBP mmHg, mean (SD) 102.13 (14.53) 100.14 (15.03) 101.55 (15.01) 99.53 (21.49) 101.85 (14.92) 99.46 (14.58) 102.89 (14.82) 100.28 (14.68) 
SD = standard deviation, IHD = ischaemic heart disease, CVD = cardiovascular disease, eGFR = estimated glomerular filtration rate, BMI = body mass index, 
SBP = systolic blood pressure, DBP = diastolic blood pressure.  
 
Table 3-2: Baseline blood pressure variability summary statistics by follow-up period, stratified by sex.  
 
 
Variables 
Year 1 (n=7136) Years 2-5 (n=5715) Years 5-10 (n=2685) Year 10+ (n=1292) 
Men 
n=3518 
Women 
n=3618 
Men 
n=2787 
Women 
n=2928 
Men 
n=1279 
Women 
n=1406 
Men 
n=579 
Women 
n=713 
ARVSBP, mean (SD) 20.55 (11.29) 21.91 (12.53) 17.21 (9.87) 18.08 (9.94) 16.86 (9.71) 17.85 (9.51) 15.91 (8.04) 17.52 (8.77) 
ARVDBP, mean (SD) 11.57 (6.79) 11.28 (6.74) 9.69 (5.61) 9.54 (5.49) 9.27 (5.11) 9.18 (5.03) 8.67 (4.27) 8.94 (4.53) 
SDSBP, mean (SD) 18.67 (6.53) 19.68 (6.88) 17.48 (6.79) 18.32 (6.70) 17.59 (6.71) 17.96 (6.63) 17.25 (6.52) 18.65 (6.77) 
SDDBP, mean (SD) 10.29 (3.69) 10.23 (3.72) 9.61 (3.75) 9.66 (3.74) 9.44 (3.56) 9.49 (3.60) 9.64 (3.56) 9.97 (3.74) 
CoeffVSBP, mean (SD) 0.121 (0.039) 0.124 (0.040) 0.116 (0.042) 0.119 (0.040) 0.119 (0.044) 0.119 (0.041) 0.117 (0.043) 0.123 (0.043) 
CoeffVDBP, mean (SD) 0.110 (0.038) 0.111 (0.040) 0.105 (0.040) 0.107 (0.040) 0.107 (0.040) 0.108 (0.041) 0.111 (0.042) 0.115 (0.045) 
Mean SBP, mean (SD) 154.38 (17.30) 157.87 (19.08) 149.80 (16.78) 153.04 (17.80) 147.52 (14.90) 150.64 (16.70) 148.05 (14.22) 151.53 (16.06) 
Mean DBP, mean (SD) 93.87 (9.00) 92.78 (9.56) 91.34 (8.90) 90.13 (9.10) 88.54 (7.65) 88.00 (8.23) 87.05 (7.02) 87.06 (7.68) 
Mean SBPtw, mean (SD) 154.70 (19.76) 159.04 (22.13) 148.00 (18.04) 152.00 (19.63) 146.29 (16.74) 149.81 (18.35) 146.07 (14.16) 149.50 (17.17) 
Mean DBPtw, mean (SD) 94.92 (10.40) 93.61 (10.90) 91.37 (9.56) 90.14 (9.99) 88.71 (8.45) 88.22 (8.86) 85.14 (7.29) 85.36 (8.39) 
ARV=average real variability, SD = standard deviation, SBP = systolic blood pressure, DBP = diastolic blood pressure, CoeffV=coefficient of variation, 
tw=time weighted estimates.  
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Table 3-3: Baseline characteristics and average real systolic blood pressure variability.    
Variables  
Year 1 
ARVSBP 
 (n=7136) 
Years 2-5 
ARVSBP   
(n=5715) 
Years 5-10 
ARVSBP   
(n=2685) 
Year 10+ 
ARVSBP   
(n=1292) 
Gender  
    Men, Mean (SD) 20.55 (11.29) 17.21 (9.87) 16.86 (9.71) 15.91 (8.04) 
Women, Mean (SD) 21.91 (12.53) 18.08 (9.94) 17.85 (9.51) 17.52 (8.77) 
P Value (ttest) <0.001 <0.001 0.008 <0.001 
Age Groups 
    20-29, Mean (SD) 16.33 (9.15) 14.90 (8.48) 13.49 (9.04) 13.38 (5.54) 
30-39, Mean (SD) 18.43 (11.19) 16.11 (9.34) 14.79 (8.48) 15.74 (7.84) 
40-49, Mean (SD) 20.50 (11.47) 16.92 (9.60) 17.20 (9.20) 15.99 (7.84) 
50-59, Mean (SD) 22.09 (12.37) 17.96 (9.53) 17.64 (9.48) 17.40 (8.58) 
60-69, Mean (SD) 22.84 (12.12) 19.22 (11.33) 18.50 (10.24) 18.55 (9.88) 
70 above, Mean (SD) 23.32 (12.24) 18.34 (9.13) 20.21 (10.85) 20.16 (10.58) 
P Value (ANOVA) <0.001 <0.001 <0.001 <0.001 
Smoking  
    Smokers, Mean (SD) 21.73 (12.10) 18.00 (9.91) 17.26 (10.18) 16.99 (8.29) 
Non-Smokers, Mean (SD) 20.89 (11.83) 17.40 (9.89) 17.46 (9.19) 16.68 (8.61) 
P Value (t test) 0.004 0.02 0.59 0.53 
Alcohol Use  
    Users, Mean (SD) 21.30 (11.77) 17.82 (10.04) 17.16 (9.57) 16.37 (7.98) 
Non-Users, Mean (SD) 21.40 (12.22) 17.55 (9.72) 17.70 (9.70) 17.42 (9.11) 
P Value (t test) 0.74 0.33 0.16 0.03 
Obesity  
    BMI (<19), Mean (SD) 23.52 (12.70) 21.35 (12.07) 13.49 (9.04) 15.48 (4.06) 
BMI (19-24.99), Mean (SD) 21.68 (11.92) 18.13 (9.55) 14.79 (8.48) 16.79 (7.96) 
BMI (25-29.99), Mean (SD) 21.04 (11.65) 17.83 (10.27) 17.20 (9.20) 16.50 (9.08) 
BMI>30, Mean (SD) 21.01 (12.35) 16.85 (9.58) 20.21 (10.85) 17.41 (8.15) 
P Value (ANOVA) 0.05 <0.001 0.21 0.45 
CKD Status 
    eGFR<60, Mean (SD) 23.42 (12.54)  19.28 (10.24) 18.89 (10.03) 18.27 (9.86) 
eGFR>60, Mean (SD) 20.36 (11.51) 16.96 (9.55) 16.93 (9.45) 16.43 (8.05) 
P Value (t test) <0.001 <0.001 <0.001 0.002 
CVD Status  
    CVD Present  22.75 (12.44) 18.35 (9.44) 17.98 (8.76) 17.64 (8.39) 
CVD Absent  20.86 (11.79) 17.41 (10.07) 17.07 (10.01) 16.28 (8.51) 
P Value (t test) <0.001 0.002 0.02 0.005 
Baseline SBP 
    <160 16.92 (10.44) 14.99 (8.62) 15.60 (8.85) 15.47 (7.74) 
>160 23.75 (12.07) 19.44 (10.34) 18.52 (9.93) 17.54 (8.80) 
P Value (t test) <0.001 <0.001 <0.001 <0.001 
Mean SBPtw     
Low 17.94 (10.12) 14.10 (7.82) 14.41 (8.11) 14.33 (7.40) 
High 24.54 (12.72) 21.21 (10.49) 20.34 (19.80) 19.27 (8.79) 
P Value (t test) <0.001 <0.001 <0.001 <0.001 
SBP=Systolic Blood Pressure, ARV=Average Real Variability, CKD=Chronic Kidney Disease, 
SD=Standard Deviation, BMI=Body Mass Index, CVD=Baseline Cardiovascular Diseases.  
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Table 3-4: Baseline characteristics and average real diastolic blood pressure variability.   
Variables  
Year 1 
ARVDBP  
(n=7135) 
Years 2-5 
ARVDBP   
(n=5714) 
Years 5-10 
ARVDBP  
(n=2684) 
Year 10+ 
ARVDBP   
(n=1292) 
Gender  
    Men, Mean (SD) 11.57 (6.79) 9.69 (5.61) 9.26 (5.11) 8.67 (4.27) 
Women, Mean (SD) 11.28 (6.74) 9.54 (5.49) 9.18 (5.03) 8.94 (4.53) 
P Value (t test) 0.07 0.33 0.65 0.28 
Age Groups 
    20-29, Mean (SD) 11.31 (6.34) 9.57 (5.14) 9.53 (4.79) 8.60 (3.62) 
30-39, Mean (SD) 11.70 (6.88) 10.14 (5.79) 9.23 (5.18) 8.61 (4.38) 
40-49, Mean (SD) 11.71 (6.92) 9.89 (5.57) 9.55 (5.03) 8.84 (4.53) 
50-59, Mean (SD) 11.67 (6.78) 9.72 (5.33) 9.05 (4.93) 8.88 (4.29) 
60-69, Mean (SD) 11.23 (6.78) 9.42 (6.04) 9.17 (5.48) 8.77 (4.55) 
70 above, Mean (SD) 9.83 (6.09) 7.89 (4.42) 8.71 (4.44) 9.65 (5.92) 
P Value (ANOVA) <0.001 <0.001 0.32 0.89 
Smoking  
    Smokers, Mean (SD) 11.58 (6.66) 9.78 (5.65) 9.03 (5.15) 8.92 (4.53) 
Non-Smokers, Mean (SD) 11.30 (6.77) 9.46 (5.46) 9.36 (5.01) 8.76 (4.35) 
P Value (t test) 0.08 0.03 0.09 0.52 
Alcohol Use  
    Users, Mean (SD) 11.89 (6.83) 9.92 (5.62) 9.35 (4.98) 8.65 (4.01) 
Non-Users, Mean (SD) 10.82 (6.50) 9.16 (5.36) 9.04 (5.24) 9.05 (4.93) 
P Value (t test) <0.001 <0.001 0.11 0.10 
Obesity  
    
BMI (<19), Mean (SD) 13.13 (6.82) 10.84 (5.66) 9.23 (4.15) 
10.21 
(5.03) 
BMI (19-24.99), Mean (SD) 11.74 (6.69) 9.85 (5.12) 9.53 (4.81) 9.09 (4.25) 
BMI (25-29.99), Mean (SD) 11.33 (6.72) 9.73 (5.78) 9.22 (5.11) 8.74 (4.65) 
BMI>30, Mean (SD) 11.19 (6.90) 9.20 (5.56) 8.92 (5.27) 8.57 (4.16) 
P Value (ANOVA) 0.003 0.001 0.13 0.89 
CKD Status 
    eGFR<60, Mean (SD) 11.68 (6.95)  9.91 (5.61) 9.54 (5.19) 8.99 (4.27) 
eGFR>60, Mean (SD) 11.22 (6.55) 9.43 (5.43) 9.12 (5.03) 8.76 (4.41) 
P Value (t test) 0.015 0.004 0.068 0.45 
CVD Status  
    CVD Present  11.70 (6.76) 9.88 (5.37) 9.33 (4.82) 8.77 (3.89) 
CVD Absent  11.37 (6.72) 9.52 (5.61) 9.17 (5.19) 8.85 (4.72) 
P Value (t test) 0.092 0.031 0.43 0.74 
Baseline SBP 
    <160 9.99 (6.38) 8.70 (5.27) 8.73 (4.92) 8.57 (4.42) 
>160 12.25 (6.85) 10.22 (5.65) 9.52 (5.08) 8.96 (4.43) 
P Value (t test) <0.001 <0.001 <0.001 0.14 
AV Area DBP     
Low 10.29 (6.16) 8.52 (4.94) 8.64 (4.81) 8.61 (4.31) 
High 12.56 (7.15) 10.71 (5.90) 9.80 (5.25) 9.02 (4.52) 
P Value (t test) <0.001 <0.001 <0.001 0.10 
DBP=Diastolic Blood Pressure, ARV=Average Real Variability, CKD=Chronic Kidney 
Disease, SD=Standard Deviation, BMI=Body Mass Index, CVD=Baseline Cardiovascular 
Diseases. 
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Table 3-5: Dependency between average real blood pressure variability measurements in quartiles (Cramer's V statistics).  
Variables  
Year 1 ARVSBP   
(n=7136) 
Years 2-5 ARVSBP   
(n=5715) 
Years 5-10 ARVSBP   
(n=2685) 
Year 10+ ARVSBP   
(n=1292) 
Year 1 ARVSBP  (n=7136) 1.00 0.161*** 0.118*** 0.113*** 
Years 2-5 ARVSBP (n=5715) 0.161*** 1.00 0.169*** 0.103*** 
Years 5-10 ARVSBP (n=2685) 0.118*** 0.169*** 1.00 0.141*** 
Year 10+ ARVSBP (n=1099) 0.113*** 0.103*** 0.141*** 1.00 
 
Year 1 ARVDBP   
(n=7136) 
Years 2-5 ARVDBP   
(n=5715) 
Years 5-10 ARVDBP   
(n=2685) 
Year 10+ ARVDBP   
(n=1292) 
Year 1 ARVDBP  (n=7136) 1.00 0.184*** 0.127*** 0.121*** 
Years 2-5 ARVDBP  (n=5715) 0.184*** 1.00 0.193*** 0.114*** 
Years 5-10 ARVDBP  (n=2685) 0.127*** 0.193*** 1.00 0.140*** 
Year 10+ ARVDBP  (n=1099) 0.121*** 0.114*** 0.140*** 1.00 
***p<0.001. SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, ARV=Average Real Variability.  
Table 3-6: Intra-class correlation coefficients (ICC) between average real blood pressure variability in quartiles.  
Variables 
Year 1 ARVSBP   
(n=7136) 
Years 2-5 ARVSBP  
(n=5715) 
Years 5-10 ARVSBP   
(n=2685) 
Year 10+ ARVSBP   
(n=1292) 
Year 1 ARVSBP (n=7136) 1.00 0.27 (0.25-0.30)*** 0.19 (0.15-0.23)*** 0.19 (0.13-0.25)*** 
Years 2-5 ARVSBP (n=5715) 0.27 (0.25-0.30)*** 1.00 0.28 (0.24-0.31)*** 0.17 (0.11-0.23)*** 
Years 5-10 ARVSBP (n=2685) 0.19 (0.15-0.23)*** 0.28 (0.24-0.31)*** 1.00 0.22 (0.16-0.28)*** 
Year 10+ ARVSBP (n=1099) 0.19 (0.13-0.25)*** 0.17 (0.11-0.23)*** 0.22 (0.16-0.28)*** 1.00 
 
Year 1 ARVDBP  
 (n=7136) 
Years 2-5 ARVDBP  
(n=5715) 
Years 5-10 ARVDBP   
(n=2685) 
Year 10+ ARVDBP   
(n=1292) 
Year 1 ARVDBP (n=7136) 1.00 0.31 (0.28-0.30)*** 0.20 (0.16-0.25)*** 0.14 (0.08-0.20)*** 
Years 2-5 ARVDBP (n=5715) 0.31 (0.28-0.33)*** 1.00 0.31 (0.27-0.34)*** 0.13 (0.07-0.19)*** 
Years 5-10 ARVDBP (n=2685) 0.20 (0.16-0.25)*** 0.31 (0.27-0.34)*** 1.00 0.22 (0.16-0.28)*** 
Year 10+ ARVDBP (n=1099) 0.14 (0.08-0.20)*** 0.13 (0.07-0.19)*** 0.22 (0.16-0.28)*** 1.00 
Numbers in parenthesis indicate 95% CI of intra-class correlation coefficient. ***p<0.001. SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, 
ARV=Average Real Variability.  
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Table 3-7: Spearman's correlation coefficient (r) between mean blood pressure variables and average real blood pressure variability.  
 
Year 1 ARVSBP Years 2-5 ARVSBP Years 5-10 ARVSBP Year 10+ ARVSBP 
Variables  (n=7136) (n=5715) (n=2685) (n=1292) 
Year 1 Mean SBP  
Year 1 Mean SBPtw   
0.35*** 
0.34*** 
   Years 2-5 Mean SBP  
Years 2-5 Mean SBPtw   
 
0.47*** 
0.47*** 
  Years 5-10 Mean SBP  
Years 5-10 Mean SBPtw   
  
0.41*** 
0.42*** 
 Year 10+ Mean SBP  
Year 10+ Mean SBPtw   
   
0.41*** 
0.40*** 
 
Year 1 ARVDBP Years 2-5 ARVDBP Years 5-10 ARVDBP Year 10+ ARVDBP 
 
(n=7136) (n=5715) (n=2685) (n=1292) 
Year 1 Mean DBP  
Year 1 Mean DBPtw 
0.24*** 
0.19*** 
   Years 2-5 Mean DBP  
Years 2-5 Mean DBPtw 
 
0.28*** 
0.27*** 
  Years 5-10 Mean DBP  
Years 5-10 Mean DBPtw 
  
0.19*** 
0.17*** 
 Year 10+ Mean DBP  
Year 10+ Mean DBPtw 
   
0.10*** 
0.07** 
SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, tw=time weighted, ARV=Average Real Variability,  AUC=area under the curve,  r=Spearman's 
correlation coefficient, **p<0.01, ***p<0.001 
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Table 3-8: Event rates per 1000 person years of follow-up (p-y) and their 95% confidence interval (95% CI) stratified by quartiles of average real systolic 
blood pressure variability.  
Variables  ACD CV IHD Stroke non-CV 
Year 1 ARVSBP  Quartile1 14.61 (13.15-16.23) 8.13 (7.06-9.36) 4.52 (3.50-5.17) 2.19 (1.67-2.87) 6.48 (5.54-7.59) 
Year 1 ARVSBP Quartile2 20.67 (19.03-22.46) 12.00 (10.76-13.38) 7.26 (6.31-8.35) 2.45 (1.92-3.11) 8.67 (7.63-9.85) 
Year 1 ARVSBP Quartile3 24.74 (22.91-26.71) 15.61 (14.17-17.19) 8.41 (7.37-9.59) 4.39 (3.66-5.27) 9.13 (8.05-10.36) 
Year 1 ARVSBP Quartile4 34.37 (32.13-36.76) 21.20 (19.46-23.10) 11.83 (10.55-13.27) 5.37 (4.53-6.37) 13.17 (11.81-14.68) 
      Year 2-5 ARVSBP Quartile1 13.01 (11.24-15.06) 6.47 (5.25-7.96) 3.27 (2.44-4.38) 1.53 (1.00-2.34) 6.54 (5.32-8.04) 
Year 2-5 ARVSBP Quartile2 21.21 (19.12-23.52) 12.23 (10.67-14.01) 7.38 (6.20-8.80) 2.66 (1.98-3.56) 8.98 (7.67-10.53) 
Year 2-5 ARVSBP Quartile3 28.58 (26.14-31.25) 16.22 (14.41-18.27) 9.21 (7.88-10.78) 3.45 (2.66-4.46) 12.36 (10.79-14.16) 
Year 2-5 ARVSBP Quartile4 38.29 (35.37-41.44) 23.77 (21.50-26.29) 13.39 (11.71-15.31) 6.07 (4.97-7.40) 14.51 (12.76-16.51) 
      Year 5-10 ARVSBP Quartile1 17.35 (14.11-21.33) 8.48 (6.31-11.40) 4.63 (3.10-6.90) 2.51 (1.46-4.32) 8.87 (6.64-11.84) 
Year 5-10 ARVSBP Quartile2 27.89 (24.07-32.31) 16.70 (13.81-20.20) 10.56 (8.31-13.41) 2.36 (1.42-3.92) 11.19 (8.86-14.12) 
Year 5-10 ARVSBP Quartile3 33.96 (29.84-38.64) 17.86 (14.95-21.35) 10.48 (8.31-13.23) 3.69 (2.49-5.46) 16.09 (14.34-19.42) 
Year 5-10 ARVSBP Quartile4 39.18 (34.36-44.67) 21.96 (18.43-26.17) 12.82 (10.20-16.13) 5.09 (3.54-7.33) 17.22 (14.12-20.99) 
      Year 10+ ARVSBP Quartile1 20.94 (15.78-27.79) 9.16 (5.97-14.05) 3.49 (1.75-6.98) 3.49 (1.75-6.98) 11.78 (8.08-17.18) 
Year 10+ ARVSBP Quartile2 22.29 (17.67-28.13) 11.62 (8.42-16.03) 6.91 (4.55-10.49) 2.51 (1.26-5.02) 10.67 (7.63-14.94) 
Year 10+ ARVSBP Quartile3 31.59 (26.02-38.36) 16.41 (12.54-21.49) 10.22 (7.27-14.38) 2.17 (1.03-4.55) 15.18 (11.47-20.08) 
Year 10+ ARVSBP Quartile4 39.88 (32.47-48.99) 22.35 (16.98-29.41) 14.02 (9.92-19.83) 4.82 (2.67-8.71) 17.53 (12.86-23.90) 
ACD=all-cause mortality, CV=cardiovascular mortality, IHD=ischemic heart disease mortality, Stroke=stroke mortality, non-CV=non-cardiovascular 
mortality, ARV=average real variability, SBP=systolic blood pressure.  
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Table 3-9: Event rates per 1000 person years of follow-up (p-y) and their 95% confidence interval (95% CI) stratified by quartiles of average real diastolic 
blood pressure variability.  
Variables  ACD CV IHD Stroke non-CV 
Year 1 ARVDBP  Quartile1 17.24 (15.53-19.14) 9.40 (8.16-10.83) 5.34 (4.43-6.44) 1.96 (1.44-2.67) 7.84 (6.71-9.15) 
Year 1 ARVDBP Quartile2 20.94 (19.31-22.72) 12.86 (11.59-14.26) 7.08 (6.15-8.14) 3.29 (2.68-4.04) 8.09 (7.10-9.22) 
Year 1 ARVDBP Quartile3 25.39 (23.51-27.41) 15.50 (14.06-17.10) 8.89 (7.80-10.10) 3.80 (3.12-4.63) 9.88 (8.74-11.17) 
Year 1 ARVDBP Quartile4 29.38 (27.43-31.44) 18.08 (16.57-19.72) 9.93 (8.83-11.17) 4.93 (4.17-5.83) 11.29 (10.11-12.61) 
      Year 2-5 ARVDBP Quartile1 16.07 (13.91-18.57) 8.30 (6.79-10.14) 4.63 (3.54-6.06) 1.75 (1.13-2.71) 7.77 (6.31-9.57) 
Year 2-5 ARVDBP Quartile2 23.76 (21.50-26.24) 13.18 (11.52-15.08) 7.55 (6.32-9.02) 3.16 (2.40-4.15) 10.58 (9.11-12.29) 
Year 2-5 ARVDBP Quartile3 25.84 (23.60-28.30) 14.89 (13.21-16.78) 8.19 (6.97-9.62) 3.65 (2.87-4.65) 10.96 (9.53-12.59) 
Year 2-5 ARVDBP Quartile4 33.44 (30.86-36.24) 20.87 (18.86-23.10) 12.12 (10.61-13.85) 4.71 (3.81-5.84) 12.57 (11.03-14.33) 
      Year 5-10 ARVDBP Quartile1 22.98 (18.91-27.92) 11.15 (8.42-14.75) 7.51 (5.34-10.56) 1.59 (0.76-3.34) 11.83 (9.01-15.52) 
Year 5-10 ARVDBP Quartile2 28.79 (24.82-33.38) 17.77 (14.71-21.45) 9.54 (7.38-12.34) 4.28 (2.91-6.28) 11.02 (8.67-14.00) 
Year 5-10 ARVDBP Quartile3 29.49 (25.73-33.81) 15.75 (13.06-18.99) 9.59 (7.55-12.19) 3.29 (2.19-4.96) 13.74 (11.25-16.79) 
Year 5-10 ARVDBP Quartile4 36.38 (32.04-41.31) 19.72 (16.59-23.43) 11.77 (9.41-14.72) 3.97 (2.71-5.84) 16.66 (13.81-20.10) 
      Year 10+ ARVDBP Quartile1 20.55 (15.44-27.35) 11.80 (8.09-17.21) 7.43 (4.62-11.96) 1.75 (0.66-4.66) 8.74 (5.64-13.55) 
Year 10+ ARVDBP Quartile2 26.00 (20.83-32.46) 14.00 (10.35-18.94) 8.00 (5.36-11.94) 3.00 (1.56-5.77) 12.00 (8.66-16.64) 
Year 10+ ARVDBP Quartile3 28.30 (22.99-34.83) 13.67 (10.14-18.43) 7.95 (5.37-11.76) 3.50 (1.94-6.32) 14.63 (10.95-19.53) 
Year 10+ ARVDBP Quartile4 38.35 (31.46-46.75) 19.57 (14.83-25.82) 11.35 (7.89-16.33) 3.91 (2.11-7.27) 18.79 (14.16-24.93) 
ACD=all-cause mortality, CV=cardiovascular mortality, IHD=ischemic heart disease mortality, Stroke=stroke mortality, non-CV=non-cardiovascular 
mortality, ARV=average real variability, DBP=diastolic blood pressure.  
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Figure 3-2: Log-log survival curves of average real systolic blood pressure (ARVSBP) 
variability in quartiles.  
 
Figure 3-3: Log-log survival curves of average real diastolic blood pressure (ARVDBP) 
variability in quartiles.  
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Figure 3-4: Forest plots showing the multivariate adjusted hazard ratios of quartiles of 
ARVSBP and all-cause, cardiovascular, and non-cardiovascular mortality.  
SBP=systolic blood pressure, ARV=average real variability, CV=cardiovascular, Non-
CVD=non-cardiovascular, CI=confidence interval.   
All-cause  (n=2170)
ARV Y1
All-cause  (n=1559)
ARV Y2-5
All-cause  (n=707)
ARV Y5-10
All-cause  (n=309)
ARV Y10+
CV (n=1287)
ARV Y1
CV (n=902)
ARV Y2-5
CV (n=388)
ARV Y5-10
CV (n=161)
ARV Y10+
Non-CVD  (n=883)
ARV Y1
Non-CVD  (n=657)
ARV Y2-5
Non-CVD  (n=319)
ARV Y5-10
Non-CVD  (n=148)
ARV Y10+
BPV
Deaths
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Group
1.00 (1.00, 1.00)
1.18 (1.02, 1.36)
1.13 (0.98, 1.30)
1.37 (1.20, 1.57)
1.00 (1.00, 1.00)
1.12 (0.93, 1.35)
1.35 (1.12, 1.61)
1.39 (1.16, 1.67)
1.00 (1.00, 1.00)
1.24 (0.95, 1.60)
1.48 (1.14, 1.91)
1.55 (1.19, 2.01)
1.00 (1.00, 1.00)
0.83 (0.57, 1.21)
1.06 (0.74, 1.51)
1.40 (0.96, 2.03)
1.00 (1.00, 1.00)
1.19 (0.99, 1.44)
1.19 (0.99, 1.43)
1.44 (1.20, 1.72)
1.00 (1.00, 1.00)
1.21 (0.94, 1.56)
1.38 (1.08, 1.77)
1.50 (1.16, 1.92)
1.00 (1.00, 1.00)
1.45 (1.00, 2.08)
1.47 (1.02, 2.10)
1.64 (1.14, 2.36)
1.00 (1.00, 1.00)
1.05 (0.61, 1.80)
1.30 (0.77, 2.19)
1.72 (1.00, 2.96)
1.00 (1.00, 1.00)
1.16 (0.94, 1.43)
1.05 (0.85, 1.30)
1.28 (1.04, 1.58)
1.00 (1.00, 1.00)
1.03 (0.79, 1.35)
1.33 (1.02, 1.72)
1.28 (0.98, 1.67)
1.00 (1.00, 1.00)
1.03 (0.70, 1.50)
1.51 (1.05, 2.16)
1.46 (1.00, 2.11)
1.00 (1.00, 1.00)
0.67 (0.40, 1.12)
0.87 (0.54, 1.42)
1.14 (0.68, 1.93)
Ratio (95% CI)
Hazard
  10 2 3
Hazard Ratio
Chapter 3 BPV and Mortality 104 
 
 
Figure 3-5: Forest plots showing the multivariate adjusted hazard ratios of quartiles of 
ARVSBP and ischemic heart disease and stroke mortality.   
SBP=systolic blood pressure, ARV=average real variability, IHD=ischemic heart disease, 
CI=confidence interval.   
  
IHD (n=721)
ARV Y1
IHD (n=513)
ARV Y2-5
IHD (n=231)
ARV Y5-10
IHD (n=95)
ARV Y10+
Stroke (n=318)
ARV Y1
Stroke (n=210)
ARV Y2-5
Stroke (n=80)
ARV Y5-10
Stroke (n=33)
ARV Y10+
BPV
Deaths
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Group
1.00 (1.00, 1.00)
1.43 (1.11, 1.85)
1.24 (0.96, 1.59)
1.63 (1.27, 2.09)
1.00 (1.00, 1.00)
1.55 (1.09, 2.21)
1.69 (1.19, 2.40)
1.85 (1.30, 2.63)
1.00 (1.00, 1.00)
1.66 (1.03, 2.69)
1.60 (0.99, 2.60)
1.83 (1.12, 2.98)
1.00 (1.00, 1.00)
1.64 (0.73, 3.69)
2.05 (0.93, 4.53)
2.66 (1.18, 5.99)
1.00 (1.00, 1.00)
0.87 (0.59, 1.29)
1.25 (0.88, 1.79)
1.18 (0.83, 1.69)
1.00 (1.00, 1.00)
1.01 (0.60, 1.72)
1.05 (0.63, 1.77)
1.34 (0.80, 2.23)
1.00 (1.00, 1.00)
0.68 (0.31, 1.47)
1.01 (0.50, 2.05)
1.26 (0.63, 2.55)
1.00 (1.00, 1.00)
0.56 (0.20, 1.56)
0.42 (0.14, 1.22)
0.93 (0.33, 2.63)
Ratio (95% CI)
Hazard
  10 2 3
Hazard Ratio
Chapter 3 BPV and Mortality 105 
 
Figure 3-6: Forest plots showing the multivariate adjusted hazard ratios of quartiles of 
ARVDBP and all-cause, cardiovascular, and non-cardiovascular mortality.  
DBP=diastolic blood pressure, ARV=average real variability, CV=cardiovascular, Non-
CVD=non-cardiovascular, CI=confidence interval.   
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Figure 3-7: Forest plots showing the multivariate adjusted hazard ratios of quartiles of 
ARVDBP and IHD and stroke mortality.  
DBP=diastolic blood pressure, ARV=average real variability, IHD=ischemic heart disease, 
CI=confidence interval.   
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Table 3-10: Cox proportional hazards model data for all-cause mortality, by quartiles of 
blood pressure variability during each period of follow-up. 
All cause 
mortality 
Year 1 Years 2-5 Years 5-10 Year 10+ 
2170 events 1559 events 707 events 309 events 
ARVSBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.18 (1.02-1.36)* 1.12 (0.93-1.35) 1.24 (0.95-1.60) 0.83 (0.57-1.21) 
Q3 1.13 (0.98-1.30) 1.35 (1.12-1.61)** 1.48 (1.15-1.91)** 1.06 (0.74-1.51) 
Q4 1.37 (1.20-1.57)*** 1.39 (1.16-1.67)** 1.55 (1.19-2.01)** 1.40 (0.96-2.03) 
ARVDBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.02 (0.89-1.18) 1.01 (0.84-1.22) 1.20 (0.94-1.54) 1.19 (0.83-1.72) 
Q3 1.12 (0.97-1.29) 1.06 (0.88-1.27) 1.17 (0.91-1.49) 1.25 (0.87-1.79) 
Q4 1.25 (1.09-.44)** 1.15 (0.96-1.38) 1.483(1.17-1.89)** 1.79 (1.25-2.57)** 
CoeffVSBP
% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.10 (0.96-1.26) 1.12 (0.95-1.32) 1.10 (0.87-1.38) 1.13 (0.80-1.60) 
Q3 1.08 (0.95-1.24) 1.13 (0.96-1.32) 1.28 (1.02-1.61)* 1.73 (1.23-2.44)** 
Q4 1.07 (0.94-1.23) 1.27 (1.08-1.50)** 1.3 (1.09-1.73)** 1.49 (1.04-2.13)* 
CoeffVDBP
% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.05 (0.91-1.22) 0.95 (0.79-1.13) 0.87 (0.68-1.12) 1.06 (0.74-1.51) 
Q3 0.92 (0.80-1.06) 0.98 (0.83-1.16) 1.12 (0.89-1.41) 1.27 (0.90-1.78) 
Q4 0.99 (0.8-1.14) 1.04 (0.89-1.24) 1.17 (0.92-1.49) 160 (1.11-2.30)* 
Numbers in parenthesis indicate 95% CI of hazard ratio.      *p<0.05,  **p<0.01, ***p<0.001, 
ARV=average real variability, SBP=systolic blood pressure, DBP = diastolic blood pressure, 
CoeffV = coefficient of variation. 
 
Table 3-11: Cox proportional hazards model data for cardiovascular mortality, by quartiles 
of blood pressure variability during each period of follow-up. 
Cardiovascular 
mortality 
Year 1 
1287 events 
Years 2-5 
902 events 
Years 5-10 
388 events 
Year 10+ 
161 events 
ARVSBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.19 (0.99-1.44) 1.21 (0.94-1.56) 1.45 (1.01-2.08)* 1.05 (0.61-1.80) 
Q3 1.19 (0.99-1.43) 1.38 (1.08-1.77)* 1.47 (1.02-2.10)* 1.30 (0.77-2.19) 
Q4 1.44 (1.20-1.72)*** 1.50 (1.16-1.92)** 1.64 (1.14-2.36)** 1.72 (1.00-2.96)* 
ARVDBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.14 (0.95-1.3) 0.99 (0.77-1.28) 1.52 (1.08-2.15)* 1.10 (0.67-1.80) 
Q3  1.21 (1.00-1.46) 1.04 (0.81-1.34) 1.25 (0.88-1.77) 1.04 (0.64-1.71) 
Q4 1.30 (1.09-1.57)** 1.19 (0.93-1.53) 1.57 (1.11-2.20)* 1.46 (0.89-2.37) 
CoeffVSBP
% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.13 (0.94-1.35) 1.07 (0.86-1.33) 1.04 (0.77-1.40) 1.27 (0.78-2.07) 
Q3 1.08 (0.91-1.29) 1.11 (0.89-1.36) 1.12 (0.83-1.52) 1.79 (1.11-2.90)* 
Q4 1.04 (0.87-1.25) 1.23 (1.00-1.53) 1.19 (0.87-1.63) 1.69 (1.02-2.77)* 
CoeffVDBP
% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 0.95 (0.79-1.15) 0.79 (0.63-0.99)* 0.78 (0.57-1.08) 1.03 (0.64-1.67) 
Q3 0.91 (0.75-1.09) 0.86 (0.69-1.07) 1.051 (0.78-1.42) 1.33 (0.84-2.09) 
Q4 0.86 (0.71-1.04) 0.91 (0.73-1.13) 0.91 (0.66-1.26) 1.46 (0.88-2.42) 
Numbers in parenthesis indicate 95% CI of hazard ratio.      *p<0.05,  **p<0.01, ***p<0.001, 
ARV=average real variability, SBP=systolic blood pressure, DBP = diastolic blood pressure, 
CoeffV = coefficient of variation. 
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Table 3-12: Cox proportional hazards model data for non-cardiovascular mortality, by 
quartiles of blood pressure variability during each period of follow-up. 
Non-CV mortality 
Year 1 
883 events 
Years 2-5 
657 events 
Years 5-10 
319 events 
Year 10+ 
148 events 
ARVSBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.16 (0.94-1.43) 1.03 (0.79-1.35) 1.03 (0.70-1.51) 0.67 (0.40-1.12) 
Q3 1.05 (0.85-1.30) 1.33 (1.02-1.72)* 1.51 (1.05-2.160)* 0.87 (0.54-1.42) 
Q4 1.28 (1.04-1.56)* 1.28 (0.98-1.67) 1.46 (1.00-2.11)* 1.14 (0.68-1.93) 
ARVDBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 0.88 (0.72-1.09) 1.04 (0.79-1.36) 0.91(0.63-1.31) 1.31 (0.75-2.27) 
Q3 1.01 (0.82-1.25) 1.09 (0.83-1.42) 1.10 (0.78-1.56) 1.54 (0.90-2.64) 
Q4 120 (0.97-1.47) 1.09 (0.83-1.44) 1.41 (1.00-1.98) 2.24 (1.31-3.81)** 
CoeffVSBP% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.05 (0.85-1.30) 1.19 (0.93-1.53) 1.18 (0.83-1.69) 1.00 (0.61-1.65) 
Q3 1.07 (0.87-1.32) 1.15 (0.90-1.47) 1.50 (1.06-2.12)* 1.67 (1.04-2.68)* 
Q4 1.11 (0.90-1.37) 1.32 (1.03-1.67)* 1.61 (1.13-2.29)** 1.27 (0.76-2.13) 
CoeffVDBP% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.21 (0.96-1.52) 1.20 (0.91-1.57) 1.01 (0.69-1.47) 1.08 (0.64-1.83) 
Q3 0.93 (0.74-1.17) 1.15 (0.88-1.51) 1.20 (0.83-1.73) 1.18 (0.71-1.98) 
Q4 1.18 (0.94-1.49) 1.24 (0.95-1.62) 1.54 (1.07-2.21)* 1.68 (0.99-2.86) 
Numbers in parenthesis indicate 95% CI of hazard ratio.      *p<0.05,  **p<0.01, ***p<0.001, 
ARV=average real variability, SBP=systolic blood pressure, DBP = diastolic blood pressure, 
CoeffV = coefficient of variation. 
 
Table 3-13: Cox proportional hazards model data for IHD mortality, by quartiles of blood 
pressure variability during each period of follow-up. 
IHD  mortality 
Year 1 
721 events 
Years 2-5 
513 events 
Years 5-10 
231 events 
Year 10 
95 events 
ARVSBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.43 (1.11-1.85)** 1.55 (1.09-2.21)* 1.66 (1.03-2.69)* 1.64 (0.73-3.69) 
Q3 1.24 (0.96-1.594) 1.69 (1.19-2.41)** 1.60 (0.99-2.60) 2.05 (0.93-4.53) 
Q4 1.63 (1.28-2.09)*** 1.85 (1.30-2.63)** 1.83 (1.12-2.98)* 2.66 (1.18-5.99)* 
ARVDBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.08 (0.84-1.39) 0.99 (0.70-1.38) 1.24 (0.80-1.93) 1.00 (0.53-1.89) 
Q3 1.18 (0.92-1.51) 0.99 (0.71-1.38) 1.21 (0.79-1.87) 0.98 (0.52-1.84) 
Q4 1.24 (0.97-1.59) 1.19 (0.86-1.66) 1.49 (0.97-2.28) 1.34 (0.72-2.50) 
CoeffVSBP% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.23 (0.97-1.57) 1.25 (0.93-1.68) 1.10 (0.73-1.64) 1.06 (0.56-2.02) 
Q3 1.18 (0.93-1.50) 1.28 (0.96-1.71) 1.25 (0.84-1.86) 1.73 (0.93-3.21) 
Q4 1.09 (0.85-1.40) 1.35 (1.01-1.82)* 1.23 (0.81-1.86) 1.58 (0.83-3.02) 
CoeffVDBP% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 0.97 (0.75-1.25) 0.81 (0.60-1.10) 0.84 (0.54-1.31) 0.70 (0.37-1.32) 
Q3 0.87 (0.68-1.11) 0.88 (0.66-1.18) 1.38 (0.92-2.07) 1.12 (0.64-1.95) 
Q4 0.84 (0.65-1.08) 0.89 (0.66-1.20) 1.06 (0.68-1.64) 1.17 (0.62-2.21) 
Numbers in parenthesis indicate 95% CI of hazard ratio.      *p<0.05,  **p<0.01, ***p<0.001, 
ARV=average real variability, SBP=systolic blood pressure, DBP = diastolic blood pressure, 
CoeffV = coefficient of variation, IHD=ischemic heart disease.  
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Table 3-14: Cox proportional hazards model data for stroke mortality, by quartiles of blood pressure variability during each period of follow-up. 
Stroke  mortality 
Year 1 
318 events 
Years 2-5 
210 events 
Years 5-10 
80 events 
Year 10+ 
33 events 
ARVSBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 0.870 (0.589-1.286) 1.014 (0.597-1.724) 0.679 (0.315-1.467) 0.556 (0.198-1.559) 
Q3 1.254 (0.878-1.791) 1.053 (0.627-1.767) 1.007 (0.495-2.048) 0.419 (0.143-1.224) 
Q4 1.180 (0.826-1.687) 1.338 (0.803-2.227) 1.264 (0.628-2.545) 0.931 (0.330-2.627) 
 
     
 
ARVDBP 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 1.482 (0.980-2.241) 1.195 (0.677-2.108)    2.421 (1.043-5.619)** 1.592 (0.479-5.295) 
Q3 1.530 (1.011-2.313)* 1.211 (0.692-2.122) 1.610 (0.676-3.836) 1.668 (0.508-5.474) 
Q4 1.672 (1.114-2.511)* 1.298 (0.739-2.279) 2.120 (0.908-4.951) 1.771 (0.509-6.159) 
 
     
 
CoeffVSBP% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 0.941 (0.655-1.353) 0.928 (0.577-1.491) 0.960 (0.483-1.910) 1.087 (0.339-3.483) 
Q3 0.989 (0.698-1.399) 1.115 (0.712-1.747) 1.214 (0.624-2.360) 1.649 (0.534-5.094) 
Q4 1.003 (0.706-1.423) 1.485 (0.952-2.314) 1.305 (0.664-2.562) 2.289 (0.780-6.717) 
 
     
CoeffVDBP% 
Q1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Q2 0.837 (0.578-1.210) 0.698 (0.443-1.100) 0.540 (0.289-1.012) 1.022 (0.351-2.979) 
Q3 0.806 (0.565-1.150) 0.747 (0.486-1.148) 0.514 (0.277-0.954)* 1.405 (0.515-3.836) 
Q4 0.771 (0.536-1.109) 0.787 (0.509-1.217) 0.521 (0.273-0.996)* 1.510 (0.493-4.625) 
Numbers in parenthesis indicate 95% CI of hazard ratio.      *p<0.05      **p<0.01      ***p<0.001 
ARV=average real variability, SBP=systolic blood pressure, DBP = diastolic blood pressure, CoeffV = coefficient of variation. 
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3.3.6 Sub-group analysis  
The sub-group analyses (stratified by baseline BP) for all-cause mortality and CV 
mortality are presented as forests plots in figures 3-8 and 3-9 on pages 111-112. 
All BP sub-groups showed consistently elevated all-cause mortality in ARVSBP 
quintiles 3 and 4 as compared to quintile 1. Similar results were observed for CV 
mortality.  
3.3.7 Four Groups Analysis 
When Y1 was compared with Y2-5, significant associations were observed 
between all-cause mortality and ARVSBP four groups (Log rank p < 0.001).  The 
lowest mortality risk was in the low-low variability group, and the highest risk in 
the high-high variability group.  When Y2-5 was compared with Y5-10 the pattern 
of results was the same.  Figures 3-10 to 3-15 presents (pages 113-115) the 
Kaplan Meier curves for the four groups’ analysis of ARVSBP for all-cause, CV, 
and non-CV mortality outcomes.   
For ARVDBP, membership in one of the four groups was associated with all-cause 
mortality when Y1 was compared with Y2-5 (Log rank p < 0.05).  However, when 
Y2-5 was compared with Y5-10 the picture was less clear.  Membership in one of 
the four groups was associated with all-cause, CV, and IHD mortality (Log rank p 
< 0.05), but neither non-CV nor stroke mortality. Figures 3-16 to 3-21 (pages 
116-118) presents the Kaplan Meier curves for the four groups analysis of ARVSBP 
for all-cause, CV, and non-CV death.   
The Cox-PH model data by four groups of ARVSBP and ARVDBP BPV comparing 
follow-up periods Y1 and Y2-5, for all mortality outcomes, are presented in table 
3-14 on page 109.   For all-cause and CV mortality the highest risk was in the 
high-high group (HR = 1.44, 95% CI = 1.21-1.71; and HR = 1.46, 95% CI 1.16-1.84, 
respectively), whereas non-CV mortality risk was highest in the low-high group 
(HR = 1.57, 95% CI = 1.17-2.12).  No association between group membership and 
mortality was observed for diastolic BP variability. 
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Figure 3-8: Forest plot for quartiles of average real systolic blood pressure variability and 
all-cause mortality stratified by baseline blood pressure categories.  
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Figure 3-9: Forest plot for quartiles of average real systolic blood pressure variability and 
cardiovascular mortality stratified by baseline blood pressure categories.  
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Figure 3-10: Kaplan-Meir survival curves of ARVSBP changes between Y1 and Y2-5 for all-
cause mortality. 
 
 
Figure 3-11: Kaplan-Meir survival curves of ARVSBP changes between Y2-5 and Y5-10 for all-
cause mortality. 
Comparison of ARVSBP between Y2-5 and Y5-10. Four groups of BPV: High-High (high 
ARVSBP at both time points of comparison), High-Low (high ARVSBP at initial assessment 
and low ARVSBP at later assessment), Low-High (low ARVSBP at initial assessment and 
high ARVSBP at later assessment), Low-Low (low ARVSBP at both time points). 
SBP=Systolic Blood Pressure. ARV=Average Real Variability. 
log-rank: P<0.001
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Figure 3-12: Kaplan-Meir survival curves of ARVSBP changes between Y1 and Y2-5 for 
cardiovascular mortality. 
Comparison of ARVSBP between Y1 and Y2-5.  
 
 
Figure 3-13: Kaplan-Meir survival curves of ARVSBP changes between Y2-5 and Y5-10 for 
cardiovascular mortality.  
Comparison of ARVSBP between Y2-5 and Y5-10. Four groups of BPV: High-High (high 
ARVSBP at both time points of comparison), High-Low (high ARVSBP at initial assessment 
and low ARVSBP at later assessment), Low-High (low ARVSBP at initial assessment and 
high ARVSBP at later assessment), Low-Low (low ARVSBP at both time points). 
SBP=Systolic Blood Pressure. ARV=Average Real Variability. 
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Figure 3-14: Kaplan-Meir survival curves of ARVSBP changes between Y1 and Y2-5 for non-
cardiovascular mortality.  
Comparison of ARVSBP between Y1 and Y2-5.  
 
Figure 3-15: Kaplan-Meir survival curves of ARVSBP changes between Y1 and Y2-5 for non-
cardiovascular mortality. 
Comparison of ARVSBP between Y2-5 and Y5-10. Four groups of BPV: High-High (high 
ARVSBP at both time points of comparison), High-Low (high ARVSBP at initial assessment 
and low ARVSBP at later assessment), Low-High (low ARVSBP at initial assessment and 
high ARVSBP at later assessment), Low-Low (low ARVSBP at both time points). 
SBP=Systolic Blood Pressure. ARV=Average Real Variability. 
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Figure 3-16: Kaplan-Meir survival curves of ARVDBP changes between Y1 and Y2-5 for all-
cause mortality. 
Comparison of ARVDBP between Y1 and Y2-5.  
 
Figure 3-17: Kaplan-Meir survival curves of ARVDBP changes between Y2-5 and Y5-10 for all-
cause mortality. 
Comparison of ARVDBP between Y2-5 and Y5-10. Four groups of BPV: High-High (high 
ARVDBP at both time points of comparison), High-Low (high ARVDBP at initial assessment 
and low ARVDBP at later assessment), Low-High (low ARVDBP at initial assessment and 
high ARVDBP at later assessment), Low-Low (low ARVDBP at both time points). 
DBP=Systolic Blood Pressure. ARV=Average Real Variability. 
log-rank: P<0.001
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Figure 3-18: Kaplan-Meir survival curves of ARVDBP changes between Y1 and Y2-5 for 
cardiovascular mortality. 
Comparison of ARVDBP between Y1 and Y2-5.  
 
 
Figure 3-19: Kaplan-Meir survival curves of ARVDBP changes between Y2-5 and Y5-10 for 
cardiovascular mortality. 
Comparison of ARVDBP between Y2-5 and Y5-10. Four groups of BPV: High-High (high 
ARVDBP at both time points of comparison), High-Low (high ARVDBP at initial assessment 
and low ARVDBP at later assessment), Low-High (low ARVDBP at initial assessment and 
high ARVDBP at later assessment), Low-Low (low ARVDBP at both time points). 
DBP=Systolic Blood Pressure. ARV=Average Real Variability. 
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Figure 3-20: Kaplan-Meir survival curves of ARVDBP changes between Y1 and Y2-5 for non-
cardiovascular mortality. 
Comparison of ARVDBP between Y1 and Y2-5.  
 
Figure 3-21: Kaplan-Meir survival curves of ARVDBP changes between Y2-5 and Y5-10 for 
non-cardiovascular mortality. 
Comparison of ARVDBP between Y2-5 and Y5-10. Four groups of BPV: High-High (high 
ARVDBP at both time points of comparison), High-Low (high ARVDBP at initial assessment 
and low ARVDBP at later assessment), Low-High (low ARVDBP at initial assessment and 
high ARVDBP at later assessment), Low-Low (low ARVDBP at both time points). 
DBP=Systolic Blood Pressure. ARV=Average Real Variability. 
log-rank: P=0.027
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Table 3-15: Cox proportional hazards model data for all cause mortality, cardiovascular 
mortality, non-cardiovascular mortality, IHD mortality, and stroke mortality, by four groups 
of blood pressure variability comparing follow-up periods Year 1 and Years 2-5. 
Mortality  
Y1 vs Y2-5 Y1 vs Y2-5 
ARVSBP ARVDBP 
All cause mortality 
1267 events 
low-low 1.00 (Ref) 1.00 (Ref) 
high-low 1.224 (1.021-1.468)* 1.079 (0.891-1.305) 
low-high 1.336 (1.089-1.640)** 1.218 (0.993-1.495) 
high-high 1.437 (1.208-1.710)*** 1.218 (1.017-1.458)* 
CV mortality 
739 events 
low-low 1.00 (Ref) 1.00 (Ref) 
high-low 1.290 (1.012-1.644)* 1.104 (0.853-1.428) 
low-high 1.168 (0.881-1.548) 1.176 (0.892-1.550) 
high-high 1.461 (1.159-1.842)** 1.230 (0.966-1.565) 
NonCV mortality 
528 events 
low-low 1.00 (Ref) 1.00 (Ref) 
high-low 1.137 (0.864-1.496) 1.054 (0.793-1.400) 
low-high 1.573 (1.167-2.121)** 1.288 (0.950-1.748) 
high-high 1.398 (1.074-1.819)* 1.200 (0.914-1.576) 
IHD mortality 
425 events 
low-low 1.00 (Ref) 1.00 (Ref) 
high-low 1.291 (0.944-1.764) 0.910 (0.651-1.273) 
low-high 1.128 (0.781-1.630) 1.008 (0.705-1.441) 
high-high 1.381 (1.023-1.864)* 1.105 (0.813-1.504) 
Stroke mortality 
170 events 
low-low 1.00 (Ref) 1.00 (Ref) 
high-low 1.497 (0.863-2.595) 1.535 (0.873-2.699) 
low-high 1.533 (0.833-2.822) 1.237 (0.657-2.329) 
high-high 1.747 (1.034-2.951)* 1.522 (0.886-2.615) 
ARV=average real variability, SBP=systolic blood pressure, DBP = diastolic blood pressure, 
CV = cardiovascular, IHD = ischaemic heart disease. *p<0.05      **p<0.01      ***p<0.001.  
 
3.4 Discussion 
In this study the relationship between BPV during different follow-up time points 
and mortality in a large cohort of hypertensive patients with treated 
hypertension was investigated. Blood pressure variability calculated over 
different sequential time-frames (of 1 to 5 years duration) are strong predictors 
of mortality independent of long-term average BP. The study also shows that 
even with well controlled mean SBP<140 mmHg there is a linear increase in 
mortality with increasing BPV.   
The linear relationship between BPV and mortality is maintained in all time-
frames including Y1 despite higher mean BPV in Y1. While the higher BPV during 
the first year of follow-up reflects variability primarily induced by a greater 
degree of physician related dose titration to get BP to target, BPV during 
successive time frames, Y2-5, Y5-10, Y10+ more likely reflect basal variability on 
an established treatment regime. Since these individuals were attending the BP 
clinic regularly, it is unlikely that the effect of BPV during later follow-up time 
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points on mortality after adjustment for mean BP is influenced by drug 
adherence.  
The relationship between BPV and mortality independent of mean BP suggests 
that the BPV captures a risk trait that is a marker of haemodynamic response 
rather than BP. The present study data contrasts with BPV from RCTs where 
drugs were titrated based on a fixed protocol thus minimising within-subject and 
between-subject variability. This can reflect the greater likelihood of 
compliance of patients who enrol in clinical trials. In a real-life hypertension 
clinic practice, the spectrum of patients is not selected and the treatment 
titration/escalation varies with each patient, though they tend to follow current 
guidelines.  
Despite low overall reproducibility of BPV over sequential time-frames, 60% of 
individuals show sustained high or low BPV over even longer time-frames of 6 to 
9 years and this sustained BPV status is also a strong predictor of mortality 
independent of long-term average BP. The results also suggest that the poor 
reproducibility of BPV is not a reflection of a trait that is completely random, 
but instead there is an underlying structure within subgroups of individuals who 
show consistent BPV in different time frames or do not. The consistent BPV 
sustained over long time-periods occurs irrespective of the length of time over 
which BPV was calculated - the study compared BPV calculated over 1 year and 4 
year periods and, in another analysis, over 4 year and 5 year periods. The low 
reproducibility of BPV in different time-frames may indicate a context-
dependency on BPV status; however despite this participants who maintained a 
low BPV over time had the lowest mortality and those who showed consistently 
high variability over time showed the highest mortality. All these indicate that 
BPV captures a risk trait that is unrelated to BP and could reflect specifically a 
response to external challenge. The present study findings also indicate that 
ARVSBP =17, calculated over any follow-up time frame greater than 1 year and 
using a minimum of 3 readings more that 30 days apart, can be used as a 
threshold to define treated hypertensive patients as low or high risk. A threshold 
of 17 was taken as it was the median of ARVSBP in the study population.  
The present study findings are consistent with the recent publications that have 
suggested a prognostic role for visit-to-visit BPV, independent of mean blood 
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pressure 362 544. One of the original studies in this area, carried out in 1997, 
identified an association with visit-to-visit BPV and an increased risk of coronary 
events 541. Post hoc analyses of large randomised control trials (RCTs) have found 
associations between high visit-to-visit BPV and increased stroke incidence in a 
population of subjects at increased risk of vascular events 359. Moreover, 
additional analyses of treated hypertensive populations in the Anglo-
Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT) 
found that increased systolic BPV between clinic visits was associated with 
stroke and coronary events 361. However, the present study did not find any 
association with stroke mortality which is not surprising as stroke incidence is a 
more specific outcome and different from stroke mortality. Additionally, there 
was no separate analysis for types of stroke events (ischemic or hemorrhagic) in 
the previous studies. More serious stroke events (hemorrhagic) may have 
contributed to a larger proportion of stroke mortality in the present study.  This 
would have partially explained the differences observed in the association 
between BPV and stroke mortality. The only study which evaluated mortality 
was the NHANES study, which demonstrated a 50% increased risk in subjects in 
the higher tertiles of BP standard deviation compared to the lowest tertile 542. 
However, this study was relatively small (n=958 and 240 deaths) and BP 
measurements were recorded during in-home visits and at mobile examination 
centres by different staff. In addition, variability was calculated over just 3 
clinic visits separated by days, suggesting intermediate variability may be the 
most appropriate classification of BP phenotype investigated here. In the 
present study, a large treated hypertensive population not randomised to 
intervention was examined, and found significant independent associations with 
increasing BPV and all cause mortality, and additionally discovered significant 
independent associations with CV and non-CV mortality. This study mimics real 
life practice unlike the previous studies. 
The BPV was calculated  and analysed in different time frames rather than the 
entire follow-up period for the following reasons - the determination of BPV 
depends on multiple BP measurements over a period of time, and in real-life 
practice it is impossible to maintain the same frequency of BP measurements 
over long time periods, in addition other factors that may affect BPV over time 
such as age, drug treatment, renal function etc vary over time, and hence BPV is 
more informative and accurate when calculated over shorter periods. The 
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observed poor reproducibility is due to the subgroup of individuals who swing 
between higher and lower BPV categories during follow-up. This can be 
explained parsimoniously if the visit-to-visit variation in BP is considered as a 
waveform. In individuals with BPV sustained over long time periods this would be 
a simple waveform where the frequency domain remains constant during any 
window of observation, and the risk is attributed to the amplitude of the 
waveform (magnitude of excursion of BP). In individuals who change BPV 
categories between time-frames, the frequency domain of the BP waveform 
would be more complex, and reflects BPV occurring over a longer time period 
than the time-frame over which it is calculated. Thus individuals whose BPV 
changes between time frames will behave as if their BPV is intermediate to 
those with sustained high BPV and sustained low BPV due to a mixture of 
waveforms of differing amplitude and frequency underlying their BPV. 
Interestingly, Mancia et al showed that Fourier analysis–derived residual 
component of 24 hour BP waveform was a strong predictor of cardiovascular 
events and all-cause death 344. The present study observations indicate that 
long-term variability may also be amenable to spectral analyses, which may 
make it possible to extract prognostic information of variability from a shorter 
window of observation.  
It may be argued that differences in risk seen in the sustained low BPV and high 
BPV groups may simply reflect the differences in the burden of co-morbidities, 
despite statistically adjusting for them in the models. While this is a plausible 
explanation, there are certain indicators that the relationship is real. For 
example, the proportion of women is significantly lower in the low-low group 
compared to the high-high group (women report longer survival time than men). 
While both BP and BPV increase with age, we show that BPV remains an 
independent predictor of risk at all strata of mean BP. More importantly, the 
survival analyses were conditional on the individual surviving for 5 years in the 
Y1-Y2-5 group and 9 years in the Y2-5-Y10 group, thus minimising reverse causation 
confounding the results in the four-groups analyses. 
Interestingly the present study found the relationship to mortality more 
consistent for ARV rather than coefficient of variation. However, both these 
measures reflect different methods of measuring variability and may represent 
different phenotypes. ARV measures variability by taking into account the order 
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of BP readings while coefficient of variation is an absolute measure of variation. 
However, the exact mechanisms at play which create this “variability” remain 
unconfirmed 545 549 550. 
Studies so far have not identified a prognostic role for diastolic BPV. In 
Rothwell’s analyses of ASCOT, an association with stroke risk was present only in 
the highest deciles of variability 359. The present study offers new insight into 
the prognostic role of DBP variability, presenting significant associations with 
all-cause, CV and non-CV mortality outcomes independent of mean DBP. Better 
understanding of the mechanisms of BPV induced survival risk may help enhance 
risk stratification and prediction strategies in hypertension management.  
3.5 Limitations  
The present study is however not without limitations; the observational nature 
lends itself to bias, and all subject data are derived from a predominantly White 
hypertensive cohort. The role of antihypertensive agents in determining BP 
variability was not studied due to incomplete prescribing data available for this 
analysis. However, previous publication on heart rate and mortality in these 
patients demonstrate that >90% of those who were prescribed beta-blockers had 
heart rate <70/min 551. This would suggest that non-adherence to treatment may 
not be a major factor among the patients who attend clinic regularly and these 
are patients included in the current analyses. Additionally, compliance was not a 
major issue in the ASCOT study. The role of specific antihypertensive agents was 
not studied - however, heart rate was looked at as a surrogate for beta blockers 
(presumed to increase BPV 360 547) during follow-up, to see if patients whose 
variability changed from low to high produced a similar change in heart rate, 
either due to commencing beta blocker therapy or discontinuing calcium channel 
blocker therapy (presumed to decrease BPV 360). There was no change in heart 
rate over Y2-5 and Y5-10 of follow-up, which supports the impression that BPV 
during later years of follow-up is largely dissociated from treatment induced 
BPV. There were no data on the physical activity levels in the GBPC cohort to 
facilitate its inclusion into the PH models. Data on patient compliance would 
have been insightful to include in the analyses. The nature of the present study 
analyses lead to exclusion of deaths which occurred during the time-frame over 
which BPV was calculated.  Furthermore, individuals who did not have the 
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requisite number of BP measurements within the time-frame were also 
excluded. This would have introduced some bias in our analyses. The present 
study mimics real life practice and given the high prevalence of hypertension, 
the results of our study can be considered generalisable. 
3.6 Summary  
The linear association of increasing BPV with higher mortality, independent of 
average BP and irrespective of the duration or context in which BPV was 
measured, indicates that BPV is likely a fundamental physiologic trait that is a 
marker of early mortality. Visit-to-visit BPV is an important prognostic indicator 
of long-term mortality, and physicians should be made aware that variability is 
measureable in clinical practice and should not be disregarded as random 
fluctuation between visits. The clinical implications of BPV depend on whether 
there are interventions that can change BPV and whether these interventions 
will result in improvement in outcomes. New diagnostic strategies should 
incorporate the known effect of BPV on mortality risk and antihypertensive drugs 
should be chosen to minimise variability as much as possible whilst also lowering 
usual office BP.  
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4 Haematocrit and mortality  
4.1 Introduction  
Haematocrit (Hct) is the proportion of blood volume occupied by red blood cells. 
It is a major determinant of blood viscosity, BP, venous return, cardiac output, 
and platelet adhesiveness 388-390 392. Although, plasma is mostly water it is about 
1.8 times more viscous than water at 37 degree Celsius. An increase in red cell 
count leads to increase in relative viscosity, resistance to blood flow, increase in 
work load of heart and impairment of organ perfusion 552. Blood viscosity is also 
dependent on the flow velocity, and a low-flow state permits increased 
molecular interaction between red cells and plasma proteins. This leads to red 
cells to stick together and form chains of several cells and further increases the 
blood viscosity and impairs blood flow 552. Experiments in healthy individuals 
suggest that an eleven percent increase in Hct is associated with 20% increase in 
relative viscosity, 17% reduction in flow rate and 20% increase in BP 553.  It is also 
estimated that the prevalence of hypertension is at least two times greater with 
10 units increase in Hct 554.  
Associations between Hct and risk of cardiovascular disease, including CHD and 
stroke have been demonstrated in several prospective studies 393-395. A sex 
specific effect of Hct on carotid atherosclerosis is reported in men but not in 
women 555-557. Multiple studies report independent association of plasma 
viscosity and carotid artery thickening in terms of intima-media thickness (IMT) 
558 559. Furthermore, higher Hct is independently associated with reduced 
reperfusion and greater infarct size in survivors of ischemic stroke 560. Diabetes 
risk is also elevated in individuals with high Hct levels. Compared to individuals 
in the lowest quartile of Hct, adults in the higher quartile were 63% more likely 
to develop diabetes in the Atherosclerosis Risk in Communities (ARIC) study 561.  
While the association between Hct and mortality has been described as “J” or 
“U” shaped in women, it is inverse-linear in men 393-395. In contrast, a 
population-based 17-year follow-up study reported a U-shaped relationship 
between Hct and CHD mortality (with the lowest CHD mortality rates being seen 
among those with Hct in the middle tertile) in men and a positive linear 
relationship in women (with linear increase in CHD mortality from the lowest to 
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highest tertile of Hct) 393. Coronary heart disease risk was 80% higher in 
individuals with borderline polycythemia (Hct >0.50) even after adjustment for 
established coronary risk factors in a 28-year follow-up study among men aged 
55 years 396. Elevated Hct is an independent predictor of mortality within the 
first 28 days of ischemic stroke in women 562.  
The observed association between Hct and BP 392 563  and the sex differences in 
blood viscosity and Hct levels 564 may be important factors to consider in the 
management of hypertensive patients. The independent association between Hct 
and long-term mortality was examined to dissect the sex-specific differences in 
risk associated with Hct in a large hypertensive cohort after the initiation of 
antihypertensive treatment. 
4.2 Methods  
4.2.1 Study setting and study population  
General details of the study setting and study population are described in 
section 2.1. Briefly, the study population comprised of attendees of the Glasgow 
Blood Pressure Clinic (GBPC). The GBPC provides secondary and tertiary level 
service to individuals with hypertension from the west of Scotland.  
4.2.2 Clinical Measurements 
Blood samples collected at the first visit and during follow-up at the BP clinic 
were analysed by the Western Infirmary central laboratory services using an 
auto-analyser, which calculates Hct as the product of red blood cell count and 
the erythrocyte mean cell volume. BP measurements at the clinic were taken 
manually 3 times using standardized sphygmomanometers at each visit by 
specialist hypertension nurses; the mean of the last 2 measurements was 
recorded at each visit. Estimated glomerular filtration rate was calculated from 
the baseline serum creatinine values using the MMRD Study Group equation 501. 
More details are provided in section 2.2-2.4.  
4.2.3 Outcome Assessment 
The details of outcome assessment are described in detail in the section 2.5.   
Chapter 4 Haematocrit and Mortality 127 
4.2.4 Subject Classification 
The study population was divided into 4 different groups based on Hct quartiles. 
Men and women have different reference ranges of Hct, hence 2 groups of 
quartiles separately for men and women were derived. These were <=0.420, 
0.421 to 0.440, 0.441 to 0.460, and >0.461 for men and <=0.380, 0.381 to 0.400, 
0.401 to 0.420, and >0.421 for women. The response to treatment for a subgroup 
of study population was examined to explore potential causal associations among 
BP, Hct, and mortality. Participants who had been followed for a minimum of 5 
years were selected and categorised into two groups, responders and non-
responders. Responders were people in whom BP was lowered to <=140/90 
mmHg measured >30 days after the first visit and remained below that level for 
at least a year, and non-responders were subjects who did not meet these 
criteria. 
4.2.5 Statistical Analysis 
The baseline characteristics of study subjects in different Hct quartiles were 
compared using ANOVA for continuous variables and Chi square test for 
categorical variables.  
The details of survival analysis are explained in section 2.6. Kaplan-Meir survival 
model was used to generate cumulative incidence of mortality over the follow-
up period (as explained in section 2.6.1) stratified by Hct quartiles in men and 
women. The PH assumption was tested by visually comparing the estimated log 
(-log) survival curves of Hct quartiles (as explained in section 2.6.3) in men and 
women. Cox proportional hazards models (section 2.6.2) were set up to analyse 
the influence of baseline Hct on all-cause, CV, ischemic heart disease (IHD), 
stroke, and non-CV mortality. The covariates included were baseline age, sex, 
body mass index, smoking status, systolic BP (SBP), diastolic BP, alcohol use, 
tobacco use, eGFR, and CVD co-morbidity. A variable on year of first visit strata 
(epochs) was used to adjust the secular trend in mortality and was divided into 5 
categories (first visit 1977 or before, between years 1978 and 1985, 1986 and 
1993, 1994 and 2001, or 2002 and after). Initially Hct was assessed as a 
continuous variable in the overall population (model 1). Because Hct range was 
different in men and women and since a non-linear trend in mortality was 
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observed, further analyses were performed using Hct as a categorical variable 
based on sex-specific quartiles (model 2 in men and model 3 in women). The 
final models included all of the covariates that were significant (P<0.10) in the 
multivariate analysis. A similar analysis protocol was followed for responder and 
non-responder subgroups. To model efficiently the nonlinear relationship 
observed for Hct and mortality, multivariable Cox regression models with 
restricted spline functions (section 2.6.4) were used 565.  
Generalized estimating equation (GEE) regression models were used to study the 
change in SBP and diastolic BP over the initial 5 years of follow-up across Hct 
quartiles. Details of GEE analysis are presented in section 2.7.1. The GEE model 
was adjusted for age, sex, smoking, alcohol use, body mass index, and estimated 
glomerular filtration rate.  
The association between Hct quartiles, the time to reach target BP, and the 
number of antihypertensive drugs prescribed were assessed using log-rank test in 
a bivariate model (as in section 2.6.1) and Cox proportional hazards regression in 
a multivariate model (as in section 2.6.2) after adjustment for all of the 
covariates that were significant (P<0.1). Data were censored after 5 years of 
follow-up and analyses performed in men and women separately. All of the 
analyses were performed using Stata, version 12 (Stata Corp). 
4.3 Results 
4.3.1 Baseline Characteristics  
A total of 10951 patients with baseline Hct values were included in the current 
analysis. The full demographic and clinical characteristics for men and women 
are given in table 4-1 on page 130. More than half of the study patients were 
women (51.3%; n=5722). Men were younger than women (49.6 versus 51.3 
years), and both were similarly overweight (body mass index, 27.5). Compared 
with women, men had significantly lower values for SBP (mean SBP: 164 Vs 169) 
and higher estimated glomerular filtration rate (mean eGFR: 76 Vs 72), and a 
significantly higher proportion of men reported alcohol (86% Vs 69%) and tobacco 
use (50% Vs 42%). A total of 192 and 503 people had missing data for tobacco use 
and alcohol use, respectively. 
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Hct was higher in men (median, 0.44; interquartile range, 0.42– 0.47) than in 
women (median, 0.41; interquartile range, 0.38–0.43). The distributions of Hct 
in men and women are shown as probability density plots in figure 4-1 on page 
130. The baseline characteristics of the study population stratified by sex and 
sex-specific Hct quartiles are shown in table 4-2 on page 131. The lowest Hct 
quartile in men was <=0.420 (range, 0.280–0.420), whereas for women it was 
<=0.380 (range, 0.220–0.380). The highest quartile was also different for men 
and women (>0.461 [range, 0.461 0.670] and 0.421 [range, 0.421– 0.550], 
respectively). 
4.3.2 Follow-Up Period and Event Rates 
Complete follow-up event data with information on all of the baseline risk 
variables were available for 10007 participants. During the 173246 person-years 
of follow-up, there were 3484 (34.8%) all-cause deaths; 52.6% of these deaths 
were in men. There were 1920 cardiovascular deaths (19.2%), 56.1% in men; 
1077 IHD deaths (10.8%), 60.4% in men; 458 stroke deaths (4.6%), 50.7% in men; 
and 1379 non-CVD deaths (13.8%), 48.1% in men. Unadjusted mortality rates in 
deaths per 1000 person-years are presented in table 4-3 on page 134. A J-shaped 
pattern in men for all-cause and CVD mortality and a U-shaped pattern in women 
for all-cause and non-CVD mortality were observed (Table 4-3 on page 134 and 
figure 4-2 on page 132). The lowest mortality rate in both men and women for 
all-cause mortality was in quartile 2, corresponding with a Hct range of 0.421 to 
0.440 and 0.381 to 0.400, respectively. The median survival rates for each 
quartile 1 to 4, in men and women, were 24.10/29.94/26.56/24.93 and 
34.08/34.76/32.79/28.38 years, respectively (log-rank P value for both men and 
women <0.001).  
Chapter 4 Haematocrit and Mortality 130 
Table 4-1: Baseline characteristics of the study population.  
Variables  Men (N=5229) Women (N=5722) P value  
Age at first visit (years), mean (SD) 49.58 (12.86) 51.28 (15.10) <0.001 
BMI (Kg/m2), mean (SD) 27.47 (4.83) 27.47 (7.02) 0.96 
SBP (mmHg), mean (SD) 164.35 (27.08) 168.49 (30.25) <0.001 
DBP (mmHg), mean (SD) 99.67 (14.91) 97.50 (15.04) <0.001 
eGFR (mL/min per 1.73 m2), mean (SD) 76.28 (27.12) 71.50 (33.26) <0.001 
Alcohol Use, n (%) 4297 (86) 3764 (69.0) <0.001 
Tobacco Use, n (%) 2555 (49.8) 2348 (41.7) <0.001 
Baseline CVD, n (%) 1145 (21.9) 975 (17.0) <0.001 
Hct (%), mean (SD)  0.443 (0.04) 0.406 (0.04) <0.001 
BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, 
eGFR=estimated glomerular filtration rate based on MDRD equation, Baseline 
CVD=prevalent cardiovascular disease at baseline, Hct=heamatocrit, SD=standard deviation 
 
 
Figure 4-1: Haematocrit distribution in men and women.   
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Table 4-2: Baseline characteristics stratified by haematocrit quartiles.  
Characteristics (Men) <=0.420 (N=1454) 0.421-0.440 (N=1179) 0.441-0.460 (N=1183) >=0.461 (N=1413) P Value  
Age at first visit (years), mean (SD) 52.95 (13.31) 48.84 (12.51) 48.26 (12.56) 47.85 (12.27) <0.001 
BMI (Kg/m2), mean (SD) 26.99 (4.55) 27.56 (4.54) 27.55 (4.91) 27.82 (5.23) <0.001 
SBP (mmHg), mean (SD) 165.78 (28.25) 162.14 (26.41) 163.41 (26.36) 165.51 (26.87) <0.001 
DBP (mmHg), mean (SD) 97.81 (15.93) 98.71 (14.52) 100.74 (14.35) 101.48 (14.33) 0.036 
eGFR (mL/min per 1.73 m2), mean (SD) 71.51 (31.86) 78.06 (26.40) 77.84 (19.95) 78.41 (27.05) <0.001 
Alcohol Use, n (%) 1173 (84.82) 968 (86.66) 987 (86.58) 1169 (86.34) 0.483 
Tobacco Use, n (%) 663 (46.72) 532 (45.86) 572 (48.85) 788 (56.90) <0.001 
CVD, n (%) 326 (22.42) 246 (20.87) 258 (21.81) 315 (22.29) 0.777 
First visit <= Year 1977, n (%) 217 (14.92) 226 (19.17) 248 (20.96) 435 (30.79) 
 First visit between years 1978 - 1985, n (%) 275 (18.91) 256 (21.71) 243 (20.54) 258 (18.26) 
 First visit between years 1986 - 1993, n (%) 382 (26.27) 252 (21.37) 226 (19.10) 170 (12.03) 
 First visit between years 1994 - 2001, n (%) 299 (20.56) 216 (18.32) 198 (16.74) 217 (15.36) 
 First visit >=  Year 2002, n (%) 281 (19.33) 229 (19.42) 268 (22.65) 333 (23.57) <0.001 
Characteristics (Women) <=0.380 (N=1422) 0.381-0.400 (N=1283) 0.401-0.420 (N=1341) >=0.421 (N=1676) P Value 
Age at first visit (years), mean (SD) 52.33 (17.01) 50.42 (15.77) 50.88 (14.25) 51.36 (13.37) <0.001 
BMI (Kg/m2), mean (SD) 27.23 (6.21) 26.92 (6.26) 27.81 (6.02) 27.80 (8.72) <0.001 
SBP (mmHg), mean (SD) 167.33 (30.05) 165.49 (29.15) 167.68 (29.50) 172.42 (31.78) 0.059 
DBP (mmHg), mean (SD) 94.87 (15.22) 96.32 (14.86) 97.83 (14.25) 100.34 (15.16) 0.004 
eGFR (mL/min per 1.73 m2), mean (SD) 69.23 (30.92) 73.40 (51.28) 72.07 (23.26) 71.53 (22.66) <0.001 
Alcohol Use, n (%) 883 (65.31) 857 (70.30) 889 (69.89) 1135 (70.45) 0.009 
Tobacco Use, n (%) 432 (31.01) 414 (32.91) 581 (44.15) 921 (55.58) <0.001 
CVD, n (%) 234 (16.46) 220 (17.15) 325 (19.39) 1145 (21.90) 0.006 
First visit <= Year 1977, n (%) 212 (14.91) 204 (15.90) 234 (17.45) 480 (28.64) 
 First visit between years 1978 - 1985, n (%) 294 (20.68) 282 (21.98) 269 (20.06) 325 (19.39) 
 First visit between years 1986 - 1993, n (%) 359 (25.25) 287 (22.37) 324 (24.16) 262 (15.63) 
 First visit between years 1994 - 2001, n (%) 286 (20.11) 244 (19.02) 237 (17.67) 250 (14.92) 
 First visit >=  Year 2002, n (%) 271 (19.06) 266 (20.73) 277 (20.66) 359 (21.42) <0.001 
BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; CVD, prevalent 
cardiovascular disease. 
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Figure 4-2: Haematocrit in quintiles and all-cause mortality in men and women.   
The top curves are deaths per 1000 person years and the bottom curves are adjusted hazard 
ratios. A J-shaped pattern is seen in men and a U-shaped pattern is seen in women both in 
unadjusted and multivariate adjusted measures of risk. HR=Hazard Ratio.  
 
 
 
 
Haematocrit 
Chapter 4 Haematocrit and Mortality 133 
4.3.3 Kaplan-Meir survival models   
The PH assumption was tested across Hct categories by plotting log-log survival 
curves (Figure 4-3 on page 136). The log-log survival curves for haematocrit 
categories were parallel to each other in both men and women. All-cause 
mortality rates for men and women by Hct quartiles are presented as Kaplan-
Meier plots (Figures 4-4 to 4-5 on page 137). While the survival time was shortest 
in quintile 4 of haematocrit in men, it was shortest in quintile 1 in women.  
4.3.4 Cox-proportional hazard models  
Using Hct as a continuous variable, a 1% increase in Hct augmented the overall 
adjusted event rates for all-cause mortality (hazard ratio [HR], 1.15 [95% CI, 
1.05–1.26]), CV mortality (HR, 1.21 [95% CI, 1.08 –1.37]), IHD (HR, 1.3 [95% CI, 
1.10 –1.53]), and borderline for stroke mortality (HR, 1.28 [95% CI, 1.00 –1.65]) 
but not non-CV mortality (HR, 1.05 [95% CI, 0.91–1.21]). Considering Hct as a 
categorical variable, the relationship between Hct quartiles and all-cause 
mortality showed a U-shaped pattern in women and a J-shaped pattern in men 
after adjusting for all baseline risk factors (P<0.02 and 0.001 in men and women, 
respectively; Table 4-4 and Figure 4-6 on pages 135 and 138). In men, compared 
with quartile 2, the lowest quartile was associated with a 25% (HR, 1.25 [95% CI, 
1.04 –1.50]) increased risk of CV mortality, and higher quartiles showed a linear 
increase in risk of CV mortality of 21% (HR, 1.21 [95% CI, 1.01–1.46]) and 28% 
(HR, 1.28 [95% CI, 1.08 –1.53]) higher risk for quartiles 3 and 4, respectively. 
This reflected the nonlinear pattern for all-cause mortality (J-shaped) in men 
but not for non-CV mortality (Figures 4-6 to 4-10 on pages 138-140). In women, 
quartiles 2 and 3 showed no difference in risk for any of the causes of mortality 
(U-shaped). However, the highest and the lowest quartiles showed, respectively, 
17% (HR, 1.17 [95% CI, 1.01–1.36]) and 19% (HR, 1.19 [95% CI, 1.04 –1.37]) 
increased risk of all-cause mortality (P<0.001) and 47% (HR, 1.47 [95% CI, 1.18 –
1.84]) and 25% (HR, 1.25 [95% CI, 1.00 –1.55]) higher risk of non-CV mortality 
(P<0.001). The hazard ratios in men and women are plotted as forests plots for 
all-cause (Figure 4-6 on page 138), CV (Figure 4-7 on page 138), IHD (Figure 4-8 
on page 139), stroke (Figure 4-9 on page 139) and non-cardiovascular (Figure 4-
10 on page 140) mortality outcomes.  
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Table 4-3: Person years of follow-up and mortality event rates in men and women.  
Men Data 
Haematocrit quartile (N) <=0.420 (N=1454) 0.421-0.440 (N=1179) 0.441-0.460 (N=1183) >=0.461 (N=1413) Total (N=5229) 
Person years of follow-up (p-y) 19350.34 18361.72 18220.12 23083.96 79016.14 
IHD mortality, n/1000 p-y (95% CI) 8.94 (7.70-10.38) 6.97 (5.86-8.29) 8.89 (7.62-10.37) 9.62 (8.43-10.97) 8.67 (7.98-9.34) 
Stroke mortality, n/1000 p-y (95% CI) 3.98 (3.18-4.98) 2.12 (1.55-2.91) 3.07 (2.37-3.99) 3.21 (2.55-4.03) 3.11 (2.89-3.44) 
CVD mortality, n/1000 p-y (95% CI) 16.54 (14.82-18.45) 11.16 (9.74-12.80) 13.89 (12.28-15.71) 15.60 (14.06-17.29) 14.40 (13.94-14.97) 
Non-CVD mortality, n/1000 p-y (95% CI) 9.25 (7.99-10.71) 7.84 (6.66-9.23) 9.17 (7.88-10.67) 9.10 (7.95-10.41) 8.86 (8.21-9.50) 
All-cause mortality, n/1000 p-y (95% CI) 27.49 (25.25-29.93) 20.04 (18.10-22.20) 23.98 (21.84-26.34) 25.99 (23.99-28.16) 24.51 (23.42-25.63) 
Women  Data  
Haematocrit quartile (N) <=0.380 (N=1422) 0.381-0.400 (N=1283) 0.401-0.420 (N=1341) >=0.421 (N=1676) Total (N=5722) 
Person years of follow-up (p-y) 22293.95 21324.47 22058.07 28553.19 94229.67 
IHD mortality, n/1000 p-y (95% CI) 3.72 (3.00-4.62) 4.46 (3.64-5.45) 5.44 (4.55-6.51) 5.85 (5.03-6.81) 4.93 (4.32-5.41) 
Stroke mortality, n/1000 p-y (95% CI) 2.29 (1.74-3.01) 2.39 (1.82-3.15) 2.40 (1.84-3.15) 3.29 (2.69-4.03) 2.64 (1.44-2.83) 
CVD mortality, n/1000 p-y (95% CI) 7.89 (6.81-9.15) 8.82 (7.64-10.17) 9.38 (8.19-10.75) 12.08 (10.87-13.43) 9.72 (9.19-10.25) 
Non-CVD mortality, n/1000 p-y (95% CI) 9.29 (8.10-10.64) 6.71 (5.69-7.90) 6.48 (5.50-7.64) 9.14 (8.10-10.32) 8.01 (7.48-8.61) 
All-cause mortality, n/1000 p-y (95% CI) 18.17 (16.48-20.03) 16.37 (14.74-18.18) 16.87 (15.24-18.67) 22.38 (20.71-24.18) 18.73 (17.54-19.89) 
CVD=Cardiovascular disease and IHD=ischemic heart disease 
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Table 4-4: Cox regression analysis for the association between haematocrit and mortality.  
 All-cause mortality CV mortality IHD mortality Stroke Mortality Non-CV mortality 
Cox-PH Models  
 
N=3484/10007 N=1920/10007 N=1077/10007 N=458/10007 N=1379/10007 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Baseline Haematocrit (Model 1),  
(All, 162398.62 p-y) 
1.15* 1.05-1.26 1.21* 1.08-1.37 1.30* 1.10-1.53 1.28 1.00-1.65 1.05 0.91-1.21 
Baseline Haematocrit (Model 2), (Men) N=1875/4931 N=1105/4931 N=665/4931 N=239/4931 N=675/4931 
<=0.420 1.11 0.97-1.28 1.25* 1.04-1.50 1.09 0.87-1.38 1.46 0.98-2.18 0.89 0.70-1.12 
0.421-0.440 1  1  1  1  1  
0.441-0.460 1.19* 1.04-1.37 1.21* 1.01-1.46 1.21 0.96-1.54 1.47 0.97-2.24 1.20 0.96-1.50 
>=0.461 1.22* 1.06-1.39 1.28* 1.08-1.53 1.22 0.98-1.53 1.50* 1.01-2.24 1.12 0.90-1.40 
Baseline Haematocrit (Model 3), (Women) N=1650/5226 N=842/5226 N=426/5226 N=226/5226 N=716/5226 
<=0.380 1.17* 1.01-1.36 0.95 0.76-1.18 0.91 0.66-1.24 0.94 0.63-1.41 1.47* 1.18-1.84 
0.381-0.400 1  1  1  1  1  
0.401-0.420 0.97 0.83-1.13 0.97 0.79-1.20 1.16 0.87-1.54 0.84 0.56-1.26 0.95 0.75-1.21 
>=0.421 1.19* 1.04-1.37 1.14 0.94-1.38 1.12 0.86-1.48 1.10 0.77-1.58 1.25* 1.00-1.55 
*p value <0.05, Model 1 is adjusted for age at first visit, gender, BMI=body mass index, baseline cardiovascular disease, CKD=Chronic kidney disease, 
tobacco smoking, alcohol use, year of first visit (epochs), SBP=systolic blood pressure, and DBP=diastolic blood pressure. Model 2 is adjusted for age at 
first visit, BMI=body mass index, baseline cardiovascular disease, CKD=Chronic kidney disease, tobacco smoking, year of first visit (epochs), 
SBP=systolic blood pressure, and DBP=diastolic blood pressure. Model 3 is adjusted for age at first visit, BMI=body mass index, baseline cardiovascular 
disease, CKD=Chronic kidney disease, tobacco smoking, alcohol use, year of first visit (epochs), SBP=systolic blood pressure, and DBP=diastolic blood 
pressure. CV=Cardiovascular disease and IHD=ischemic heart disease, HR=hazard Ratio, CI=confidence interval, p-y=person years. 
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Figure 4-3: Log-log survival curves of haematocrit in quartiles  
Proportionality hazard assumption is met when the curves are parallel to each other.  
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Figure 4-4: Kaplan-Meir survival curves for Hct quartiles and all-cause mortality (Men).     
 
 
Figure 4-5: Kaplan-Meir survival curves for Hct quartiles and all-cause mortality (Women).     
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Figure 4-6: Cox-proportional hazard model for haematocrit and all-cause mortality in men 
and women.  
 
Figure 4-7: Cox-proportional hazard model for haematocrit and cardiovascular mortality in 
men and women.  
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Figure 4-8: Cox-proportional hazard model for haematocrit and ischemic heart disease 
mortality in men and women. 
 
Figure 4-9: Cox-proportional hazard model for haematocrit and stroke mortality in men and 
women. 
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Figure 4-10: Cox-proportional hazard model for haematocrit and non-cardiovascular (Non-
CV) mortality in men and women. 
4.3.5    Regression spline Cox-proportional hazard model  
To fully examine the nonlinear relationship between Hct and mortality, the 
association of Hct was examined, represented as a cubic spline, with CV and 
non-CV mortality in men and women and the results were consistent with the 
primary analyses (Figures 4-11 to 4-14 on pages 141-142).  
4.3.6 Cox-proportional hazard models in sub-groups  
To address reverse causality and to also demonstrate that the baseline Hct of 
our study population was stable, the analysis was repeated in a subset of the 
population who had >=3 Hct readings in the first 5 years of follow-up (n=4477). 
The coefficient of variation of Hct in 94% (n=4122) of this subgroup was <=0.1. 
The same pattern of results was seen in the subgroup overall and in those with 
coefficient of variation <=0.1 (Tables 4-5 and 4-6 on page 143). 
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Figure 4-11: Haematocrit in men and cardiovascular disease mortality.  
 
 
Figure 4-12: Haematocrit in women and cardiovascular disease mortality.  
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Figure 4-13: Haematocrit in men and non-cardiovascular disease mortality.   
 
Figure 4-14: Haematocrit in women and non-cardiovascular disease mortality.  
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Table 4-5: Haematocrit and all-cause mortality in a subset of population who had repeat 
haematocrit measurements and with a coefficient of variation of <=0.1.   
Hematocrit All-cause mortality (Men: N=755/1978) 
 
HR 95% CI 
<=0.420  1.16 0.92-1.43 
0.421-0.440  1.00 (Ref) 
0.441-0.460  1.13 0.90-1.42 
>=0.461  1.21* 1.02-1.51 
 
All-cause mortality (Women: N=692/2093) 
HR 95% CI 
<=0.380  1.26* 1.03-1.62 
0.381-0.400  1.00 (Ref)  
 0.401-0.420  1.12 0.87-1.39 
>=0.421  1.36* 1.01-1.50 
HR=Hazard Ratio, CI=Confidence Interval, *p<0.05. 4122/4477 individuals with >=3 repeat 
haematocrit measurements in the first five years of follow-up is included in this analysis. 
HRs are adjusted for age at first visit, gender, BMI=body mass index, baseline 
cardiovascular disease, CKD=Chronic kidney disease, tobacco smoking, alcohol use, year 
of first visit (epochs), SBP=systolic blood pressure, and DBP=diastolic blood pressure. 406 
individuals did not have one of the above mentioned variables.  
 
 
Table 4-6: Haematocrit and all-cause mortality in all individuals who had repeat haematocrit 
measurements available.   
Hematocrit All-cause mortality (Men: N=766/2010) 
HR 95% CI 
<=0.420  1.11 0.89-1.38 
0.421-0.440  1.00 (Ref) 
 0.441-0.460  1.14 0.91-1.43 
>=0.461  1.24* 1.01-1.54 
All-cause mortality (Women: N=704/2130) 
HR 95% CI 
<=0.380  1.28* 1.02-1.61 
0.381-0.400  1.00 (Ref)  
 0.401-0.420  1.09 0.86-1.39 
>=0.421  1.36* 1.10-1.70 
HR=Hazard Ratio, CI=Confidence Interval, *p<0.05. 4477 individuals with >=3 repeat 
haematocrit measurements in the first five years of follow-up is included in this analysis. 
HRs are adjusted for age at first visit, gender, BMI=body mass index, baseline 
cardiovascular disease, CKD=Chronic kidney disease, tobacco smoking, alcohol use, year 
of first visit (epochs), SBP=systolic blood pressure, and DBP=diastolic blood pressure. 334 
individuals did not have one of the above mentioned variables.  
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4.3.7 Longitudinal change in blood pressure  
The population averaged effect of change in BP across Hct quartiles in men and 
women over the first 5-year follow-up period are presented in Figures 4-15 to 4-
16 on pages 145-146. Compared with Hct quartile 2, the mean SBP during the 
five year follow-up in men was relatively higher in Hct quartiles 3 and 4 by 1.29 
mmHg (95% CI, 0.35–2.23) and 3.22 mmHg (95% CI, 2.30–4.14), respectively. In 
women, the mean SBP was relatively higher by 3.79 mmHg (95% CI, 2.85– 4.74) in 
the Hct quartile 4 in comparison with quartile 2.  
4.3.8 Responders and Non-responders 
In the study population, 2297 and 2218 subjects were classified as non-
responders and responders, respectively. Among male responders and non-
responders, quartile 2 was associated with the lowest mortality and quartile 4 
associated with the highest mortality risk. In women, the relationship was more 
linear, with the quartiles 1 and 4 associated with the lowest and the highest 
risks, respectively. The Kaplan-Meier plots illustrating this for all-cause mortality 
are presented in Figures 4-17 to 4-20 (on pages 147-148), and the multivariate-
adjusted survival analyses are presented in table 4-7 on page 149. The time to 
reach target BP among responders was similar across Hct quartiles on bivariate 
analysis (log rank test P=0.072 and P=0.654 for men and women, respectively) 
and multivariate analysis adjusting for covariates significant at P<0.1 (P=0.204 
and P=0.280 for men and women, respectively). 
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Figure 4-15: Longitudinal change in systolic blood pressure by haematocrit (Hct) quartile 
during the first 5 years of follow-up. 
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Figure 4-16: Longitudinal change in diastolic blood pressure (DBP) by haematocrit (Hct) 
quartile during the first 5 years of follow-up. 
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Figure 4-17: Kaplan-Meier all-cause mortality curves of haematocrit (Hct) categories in 
quartiles among responders (Men).  
 
Figure 4-18: Kaplan-Meier all-cause mortality curves of haematocrit (Hct) categories in 
quartiles among non-responders (Men).  
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Figure 4-19: Kaplan-Meier all-cause mortality curves of haematocrit (Hct) categories in 
quartiles among responders (Women).   
 
Figure 4-20: Kaplan-Meier all-cause mortality curves of haematocrit (Hct) categories in 
quartiles among non-responders (Women).  
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Table 4-7: Haematocrit and all-cause mortality in hypertensive individuals classified by achievement of target blood pressure at final clinic visit.  
Cox-PH Models  All-cause mortality  
  
CV Mortality  
  
 
Non-responders  
 
Responders  
 
Non-responders Responders  
 
 
HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Baseline Haematocrit, (Men) N=1103/3449 
 
N=332/1025 
 
N=635/3449 
 
N=182/1025 
 <=0.420 0.87 0.73-1.04 1.17 0.83-1.69 1.06 0.84-1.34 1.53 0.94-2.51 
0.421-0.440 1.00 
 
1.00 
 
1.00 
 
1.00 
 0.441-0.460 1.22* 1.02-1.46 1.10 0.78-1.57 1.20 0.95-1.53 1.50 0.91-2.48 
>=0.461 1.31* 1.10-1.55 1.28 0.91-1.78 1.24 0.99-1.56 1.53 0.94-2.51 
Baseline Haematocrit, (Women) N=1080/3909 
 
N=332/1004 
 
N=549/3909 
 
N=125/1004 
 <=0.380 1.15 0.95-1.38 1.17 0.83-1.64 0.96 0.73-1.26 0.69 0.38-1.27 
0.381-0.400 1.00 
 
1.00 
 
1.00 
 
1.00 
 0.401-0.420 1.04 0.87-1.25 1.10 0.78-1.57 1.12 0.87-1.43 0.99 0.57-1.71 
>=0.421 1.20* 1.01-1.42 1.28 0.91-1.78 1.13 0.89-1.43 1.33 0.81-2.21 
Adjusted for age, epochs, smoking, alcohol use, baseline CVD, BMI, achieved SBP, and eGFR. CVD=Cardiovascular Disease, BMI=Body Mass Index, 
SBP=Systolic Blood Pressure, eGFR=estimated Glomerular Filtration Rate.   
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4.4 Discussion 
Haematocrit is an independent predictor of all-cause, CV, IHD, and non-CV 
mortality in hypertensive patients. However, the strength and magnitude of 
relationship vary widely according to the Hct levels and outcome of interests. 
The Hct ranges with the lowest mortality risk in men and women are 0.421 to 
0.44 (quartile 2; J-shaped) and 0.381 to 0.420 (quartiles 2,3; U-shaped), 
respectively. While in men risk of death increases at Hct<0.42, it increases in 
women only at a lower threshold of Hct <0.38. The association between Hct and 
mortality observed in the present study is independent of the effect of Hct on 
BP.  
The present study shows a non-linear relationship between Hct and mortality in 
a hypertensive cohort, and this is consistent with several other reports of non-
linear relationships between Hct and mortality outcomes in more general 
populations 393 395. Haematocrit, a major determinant of whole blood viscosity, is 
associated with an increased risk of IHD, stroke, and all-cause mortality in 
subjects with and without pre-existing CVD 394 566-569. However, in some studies, 
after adjustment for multiple risk factors, Hct failed to significantly predict all-
cause or CVD mortality events 566 568. The non-linear association between Hct and 
mortality may explain the lack of association of Hct and mortality observed in 
some studies. The general Cox-PH models assume that the association between a 
predictor variable and survival is linear. However, the present study modelled 
the non-linear relationship efficiently by using cubic-regression spline models.  
Gender differences in blood viscosity and normal Hct are known to exist 564. The 
Hct distribution was shifted to the right side of the distribution curve in men 
with higher mean Hct levels than in women in the present study.  Tobacco use 
was less common in women than in men in the present study. Tobacco use 
increases Hct 390 570 and it is independently associated with mortality. In the 
present study, the proportion of tobacco users in the last quartile of Hct was 
significantly higher than that in the first quartile in both men and women. 
Haematocrit is also associated with eGFR and the filtration fraction decreases 
with fall in Hct 571. Women had significantly lower eGFR and Hct in the present 
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study than men. These clinical characteristics may explain the differences in 
association between heamatocrit and mortality in men and women.  
The strength and magnitude of association of Hct and mortality appears to differ 
depending upon Hct levels and sex. Men and women also show differences in 
causes of Hct-related mortality in the present study. While quartiles of Hct 
predict CV mortality in men, it was associated with non-CV mortality in women. 
The reason for this apparent dichotomy is unclear. However, the differences in 
clinical characteristics in men and women as explained in the previous paragraph 
may partially explain this dichotomy. The evidence linking Hct with 
cardiovascular events are plenty in the literature 390 394 396 568 569. The relatively 
high effect sizes in the association between CV mortality and Hct observed in 
the present study are also consistent with previous reports 390 396. The relatively 
lower risk for IHD observed in women may be due to low Hct and reduced plasma 
viscosity. The hormone estrogen has been linked with platelet aggregation 572 
and smooth muscle cell proliferation 573 574 and in combination with a high Hct 
may predispose to increased morbidity in women. A dose dependent relationship 
between oestrogen containing oral contraceptives and platelet activation in 
women is also reported 575. Hct is therefore a more potent risk factor in younger 
women 393 395. A lower fibrinogen and plasma viscosity were observed in older 
women (aged 52–65 years) taking hormone replacement therapy, which would 
suggest that estrogen is only partly responsible for mediating the effects of Hct 
576. The present study shows that the different reference ranges of Hct in men 
and women influence mortality in a complex manner and can explain the 
variable results in previous studies. Further studies in larger cohorts are required 
to explain the biological reasons for the differences in association between Hct 
and mortality outcomes in men and women. 
The lack of significant association between stroke death and Hct in women may 
be attributable to a relatively low number of events in this group. There were 
only 226 stroke deaths in the Cox model for women. Stroke mortality risk was 
however 50% higher in the last quartile of Hct in comparison to the first quartile 
in men. Inconsistent findings have been reported previously. High mean Hct 
predicted lacunar stroke in an analysis of 2077 people who had experienced a 
stroke event 577. A non-linear U-shaped relationship between Hct quartiles and 
stroke mortality was reported in the Framingham Heart Study women 
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participants in the age group of 65 to 94 years 393. In another prospective study 
of 7735 men aged 40 to 59 years at baseline, an Hct of >0.51 was found to be 
associated with fatal and nonfatal stroke 397. However, these studies failed to 
include diastolic BP, a strong independent predictor of stroke, as a covariate in 
their analysis models in comparison to the present study. 
A positive linear association between Hct and BP in both normotensive and 
hypertensive subjects have been demonstrated in several epidemiological 
studies 554 563 578. Hct was positively correlated with both SBP (r=0.085, P<0.01 
and r=0.264, P<0.001 for men and women, respectively) and DBP (=0.214, 
P<0.001 and r=0.266, P<0.001) in a mixed hypertensive and normotensive cohort 
554. Among British men free of IHD, Hct was associated with both DBP and SBP 
397. Since Hct increases blood viscosity and vascular resistance and thus affect 
total peripheral resistance to blood flow, which is abnormally high in essential 
hypertension, these results are not unexpected 563 579-581. The present study 
shows that higher baseline Hct is associated with higher on-treatment BP during 
follow-up, and this may partly explain the higher risk associated with higher Hct. 
Despite this relationship, baseline Hct did not affect the time to reach target 
SBP or DBP in this cohort. The increased risk of death because of higher Hct was 
seen in men and women irrespective of their achievement of target BP, 
indicating that the risk is independent of the effect of Hct on BP. However, the 
present study did not have the data to determine whether more aggressive 
management of BP in the higher Hct groups with earlier time-to-target BP would 
have reduced the risk. 
4.5 Strengths and limitations 
The main strengths of this study are the prospective design, long-term follow-
up, high event rates, almost equal numbers of men and women, the outcomes 
based on fatal end points, and the effect sizes adjusted for multiple confounding 
factors, including baseline pre-existing disease conditions. In the final Cox 
models, there were 1875 and 1650 mortality events in men and women, 
respectively. This is probably highest among similar epidemiological studies. For 
example in the Framingham Heart study with 34 years of follow-up, the number 
of mortality events were 1234 and 1097 in men and women, respectively. The 
participants in the present study were however taken from a hypertensive, 
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overwhelmingly white population, and, therefore, the findings cannot be 
generalised to other populations. The changes in management of hypertension 
during the course of follow-up would have influenced the outcomes. Although 
there was an attempt to adjust for changes in management of hypertensive 
individuals by including a variable on year of attendance in the models, bias may 
still be present. We could not adjust for treatment adherence due to 
unavailability of validated adherence data. Inference about mortality relating to 
Hct measures taken many years before mortality occurred may be subject to 
bias. However, the variation in Hct observed in a subgroup of the study 
population with repeat Hct measurements was relatively small. Additionally, the 
Cox proportional hazard model results were consistent even in a subgroup of 
individuals with coefficients of variation of Hct <=0.1. Residual confounding due 
to unmeasured risk exposures cannot be ruled out completely.  
4.6 Summary  
Haematocrit is associated with follow-up BP and is an independent predictor of 
mortality in the hypertensive population. There are distinct differences both in 
terms of the strength and magnitude of the association of Hct and mortality 
between men and women that have not previously been shown. While Hct is 
associated with CV mortality in men, it is more closely associated with non-CV 
mortality in women. Nevertheless in the assessment and management of newly 
diagnosed hypertensive patients, Hct levels should be taken into consideration 
as an important risk predictor, and further research is needed to elucidate the 
mechanism of this risk and to define management strategies. Haematocrit is an 
inexpensive marker that is routinely measured in clinical practice and patients 
with Hct levels outside of the sex-specific low-risk reference ranges as identified 
in this study should be targeted for more aggressive BP and CV risk reduction 
treatment. 
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5 Serum phosphate and mortality  
5.1 Introduction  
Inorganic phosphate is an important mineral that is directly linked to energy 
metabolism, bone mineralisation, signal transduction, storage and translation of 
genetic information and maintenance of lipid membrane structure. It is 
regulated within a narrow range in human body by a complex interplay of 
multiple mechanisms that involve factors associated with intestinal absorption, 
exchange between intracellular and bone storage pools, renal filtration and 
renal tubular re-absorption of phosphate 582.   
Serum phosphate has a putative adverse role in arterial stiffness and 
atherosclerosis. Higher levels of phosphate have been shown in vitro and in vivo 
to be associated with vascular calcification, arterial stiffness and atherosclerosis 
583-585.  In animal studies, a high phosphate diet accelerates atherosclerosis 
independent of cholesterol levels 583.  
Several studies report association between elevated serum phosphate and 
mortality in CKD patients. In a systematic review and meta-analyses of the 
association between serum phosphate and mortality in individuals with CKD, 
each 1 mg/dl increase in serum phosphorous increased the risk of all-cause 
mortality by 18% (RR=1.18, 95% CI: 1.12-1.25) 441. Overall, one mg/dl increase in 
serum phosphorous increased the risk of CV mortality by 10% 441. However there 
were serious limitations in the quality across studies included in the meta-
analyses and many of them were not fully adjusted for all potential confounding 
factors. Serum phosphate is also associated with decline in renal function 586. In 
non-diabetic CKD patients, higher serum phosphate is independently associated 
with left ventricular mass 587. 
The association between serum phosphate and mortality in individuals with 
normal renal function has not been investigated in detail in longitudinal 
epidemiological studies. In a middle aged general population cohort of more 
than 15000 individuals, all cause-mortality increased linearly with phosphate 
levels 450. However, the results were not adjusted for many important variables 
including BP. In the post hoc analyses of the Cholesterol and Recurrent Events 
(CARE) study, higher serum phosphate was independently associated with 
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adverse cardiovascular outcomes in patients with coronary artery disease and 
after myocardial infarction but normal renal function 444. In the Framingham 
Offspring study cohort, in individuals with no prior CV events and normal renal 
function, serum phosphate within the normal range linearly increased the 
incidence of heart failure 588. Similarly, higher phosphate was associated with 
incident CVD in the same cohort 449.  
The association of serum phosphate with vascular calcification and arterial 
stiffness indicates that serum phosphate may positively influence BP levels. By 
contrast multiple small studies report an inverse association between serum 
phosphate and BP 589-591. Higher serum phosphate is associated with a non-
dipping pattern of nocturnal BP in hypertensive patients 592, while low serum 
phosphate is associated with a non-dipping pattern of BP in individuals with 
white coat hypertension 593.  It is however unclear whether serum phosphate 
influences follow-up clinic BP and of outcomes in hypertensive patients. 
Factors that determine serum phosphate level remain unclear. In the NHANES III, 
a week relationship was observed between dietary phosphorous intake and 
serum phosphorous concentration 594. However, inorganic phosphate in food 
addictives is quickly absorbed from the intestine unlike the natural phosphate in 
food items and can increase the serum phosphate levels 595. In general, there is a 
socio-economic gradient in eating patterns with individuals in the lower socio-
economic status consuming more processed food. Consequent to that, a low 
socio-economic status or greater social deprivation is often associated with 
higher serum phosphate levels 596 597. A low deprivation score (indicates greater 
social deprivation) is independently associated with increased mortality 598 599. 
Therefore, the deprivation index as an indicator of socio-economic status may 
confound the association between serum phosphate and mortality.  
The aim of the present study was to elucidate the association between serum 
phosphate with BP control and long-term mortality in a large treated 
hypertensive cohort independent of other known risk factors and deprivation 
status.  
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5.2 Materials and methods  
5.2.1 Study Setting and Study Population 
Subjects used in this analysis were identified from the Glasgow Blood Pressure 
Clinic (GBPC). The study setting is described in detail in section 2.1. Use of the 
anonymised database for analyses is approved by the West of Scotland research 
ethics service (WoSRES) of the National Health Service (11/WS/0083). 
5.2.2 Clinical Measurements 
The Glasgow Blood Pressure Clinic (GBPC) uses specialist hypertension nurses for 
initial assessment.  Details of study measurements are described in detail in 
section 2.2-2.4.  
5.2.3 Laboratory measurements 
As part of their clinical care, patients underwent venepuncture during initial and 
regular follow-up visits to the GBPC for biochemical and haematological 
assessment.  All laboratory assays were performed at the central laboratory 
services of the Western Infirmary. More details of laboratory measurements are 
explained in section 2.4.  
5.2.4 Outcome assessment  
Details of outcomes assessment are described in detail in section 2.5 
5.2.5 Study definitions  
Systolic and diastolic BP control were defined as at least 3 consecutive clinic 
measurements of BP (usually 3 months apart) less than 140 mmHg or 90 mmHg 
respectively. Scottish Index of Multiple Deprivation (SIMD) data based on the 
postcode was used to stratify individuals into five different groups (Quintile 1-
Quintile 5 of SIMD). Quintile 1 represents the most deprived group whereas 
quintile 5 represents the least deprived group.  
5.2.6 Statistical Analysis 
Summary statistics of baseline participant characteristics were calculated in men 
and women separately. Continuous variables were summarised as means (±SDs). 
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They were compared between groups using independent 't' tests. Categorical 
variables are shown as counts and percentages and were compared between 
groups using Chi square tests for association. The summary statistics estimation 
process repeated after stratification by deprivation status. Histograms were 
plotted for phosphate levels in men and women to check the distribution.  
The Cox proportional hazards (Cox-PH) model as explained in section 2.6.2 was 
used to determine the risk of all-cause death for each increment of 0.1 mmol/L 
increase in baseline phosphate. The model was adjusted for major CV risk 
factors: age, gender, BMI, smoking, alcohol use, SBP, DBP, total cholesterol, 
eGFR, calcium, and alkaline phosphatase. A variable on year of first visit strata 
(epochs) was included to adjust the secular trend in mortality and was divided 
into five categories (first visit 1976 or before, between years 1977-1987, 1988-
1997, 1998-2004, 2005 and after). The final model included all of the covariates 
that were significant (p<0.10) in the multivariate analysis. The same model is 
repeated in gender groups and for all other mortality outcomes. Another model 
after adjustment for the deprivation index in quintiles was also generated in 
men and women separately.  Separate models for all-cause mortality were 
generated in diuretic users at baseline and non-diuretic users. Furthermore, a 
sub-group analysis was also conducted for all-cause, CV and non-CV mortality 
outcomes stratified by the baseline characteristics.  The PH assumption was 
tested in the multivariate models (details are explained in section 2.6.3) by the 
goodness-of-fit tests.  The association of serum phosphate on a continuous scale 
with all-cause mortality was tested using multivariate Cox-PH models with 
restricted spline functions (details are explained in section 2.6.4) in men and 
women separately. The regression spline models were repeated after adjustment 
for deprivation status. Finally, serum phosphate in quartiles based on sex 
specific cut-off points was used to generate multivariate Cox-PH models in men 
and women separately.  
Generalized estimating equations (GEE) regression models as explained in 
section 2.7.1 were employed to study the change in SBP and DBP over the initial 
five years of follow-up with each increment increase in 0.1 mmol/L of baseline 
phosphate in men and women separately. Individuals with at least four annual 
BP assessments in the first five years of follow-up and survival up to a minimum 
of five years period  were included in the GEE analyses. The GEE model was 
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adjusted for age, sex, smoking, alcohol use, BMI and eGFR. The analysis was 
repeated after adjustment for deprivation index.  All of the analyses were 
carried out using Stata version 12 (Stata Corp, LP). 
5.3 Results  
5.3.1 Baseline characteristics  
A total of 9260 patients with baseline phosphate were included in the current 
analysis. Of these, 47% (n=4318) were men. The population was middle aged 
with mean age of 51.7+14.6 years. The baseline characteristics of the study 
population in men and women are described in table 5-1 on page 159.The 
baseline mean BMI was in the overweight region and different in men (28.4+5.6) 
and women (28.0 +6.4). While the mean SBP was 161.6+26.2 in men, it was 
165.0+29.3 in women. Smokers and alcohol users were more common in men.  
Compared with men, women had significantly higher levels of serum calcium.   
The distributions of phosphate in men and women are presented as probability 
density plots in figure 5-1 on page 159. The mean phosphate was higher in 
women (1.10+0.20) than in men (1.02+0.21). The baseline characteristics of the 
study population in men and women stratified by phosphate quartiles are 
presented in table 5-2 and 5-3 on pages 167-168. Age and SBP show an inverse 
linear relationship with phosphate in men whereas they show positive linear 
relationships in women. Chronic kidney disease status and tobacco use gradually 
increased with phosphate quartiles in both men and women. Serum ALP level 
was significantly elevated in quartile 1 of phosphate in comparison to other 
quartiles in men and women. The prevalence of CVD and mean total cholesterol 
level at baseline increased with phosphate quartiles in women but not in men.  
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Table 5-1: Baseline characteristics of the study population stratified by gender  
Variables  Men (n=4318)  (n=4942)  P value  
Age at first visit (years), mean (SD) 50.36 (13.33) 52.84 (15.57) <0.001 
BMI (Kg/m2), mean (SD) 28.39 (5.63) 27.98 (6.42) 0.001 
SBP (mmHg), mean (SD) 161.59 (26.20) 164.99 (29.33) <0.001 
DBP (mmHg), mean (SD) 98.01 (14.29) 95.40 (14.13) <0.001 
Total Cholesterol (mmol/l), mean (SD) 5.79 (1.18) 6.00 (1.35) <0.001 
Calcium (mg/dl), mean (SD) 2.33 (0.12) 2.35 (0.12)  <0.001 
Alkaline Phosphatase (IU/L), median 
(IQR) 124 (78-178) 124 (78-185) 0.342 
Phosphate (mmol/L), mean (SD) 1.02 (0.21) 1.10 (0.20) <0.001 
eGFR<60 mL/min, n (%) 803 (18.60) 1447 (29.28) <0.001 
Alcohol >6 units, n (%)  2985 (73.09) 2044 (43.73) <0.001 
Tobacco smoking, n (%) 2042 (48.24) 1953 (40.22) <0.001 
CVD, n (%) 955 (22.12) 880 (17.81) <0.001 
SIMD Quintiles, n(%)   - - 0.003 
Quintile 1 1016 (25.63)  1313 (28.82)   
Quintile 2 719 (18.14) 869 (19.07)  
Quintile 3 604 (15.24) 659 (14.46)  
Quintile 4 639 (16.12) 689 (15.12)  
Quintile 5 986 (24.87) 1026 (22.52)  
BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, 
eGFR=estimated glomerular filtration rate based on MDRD equation, Baseline 
CVD=prevalent cardiovascular disease at baseline, SD=standard deviation, SIMD=Scottish 
Index of Multiple Deprivation. 
 
Figure 5-1: Distribution of serum phosphate in men and women  
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Table 5-2: Characteristics of study population stratified by quintiles of phosphate in men.  
Variables 
PO4≤0.9 
(N=1272) 
PO4=0.91-1.0 
(N=960) 
PO4=1.01-1.14 
(N=1050) 
PO4>1.14 
(1036) 
P 
value 
Age (years), mean 
(SD) 51.12 (12.56) 50.86 (12.95) 49.63 (13.40) 49.69 (14.43) <0.001 
BMI (Kg/m
2)
, mean 
(SD) 28.61 (5.91) 28.61 (5.80) 28.44 (5.61) 27.85 (5.06) 0.358 
SBP (mmHg), mean 
(SD) 163.33 (26.66) 162.07 (25.47) 159.60 (25.57) 161.01 (26.78) 0.01 
DBP (mmHg), mean 
(SD) 98.73 (14.20) 98.28 (13.56) 98.47 (14.18) 97.43 (15.14) 0.233 
TC (mmol/l), mean 
(SD) 5.76 (1.16) 5.80 (1.11) 5.80 (1.22) 5.81 (1.22) 0.385 
eGFR≤60, n (%) 209 (16.43) 164 (17.08) 186 (17.71) 244 (23.55) <0.001 
Ca (mg/dl), mean 
(SD) 2.34 (0.12) 2.33 (0.11) 2.32 (0.11) 2.34 (0.12) 0.105 
ALP, Median (IQR) 136 (85-185) 119 (78-176) 130 (78-181) 106 (72-164) <0.001 
Alcohol >6 units, n 
(%) 1033 (86.59) 794 (87.93) 870 (87.09) 848 (85.74) 0.554 
Tobacco smoking, n 
(%) 539 (43.05) 460 (48.88) 488 (47.56) 555 (54.73) <0.001 
CVD, n (%) 272 (21.28) 222 (23.13) 229 (21.81) 232 (22.39) 0.785 
 
Table 5-3: Characteristics of study population stratified by quintiles of phosphate in women.  
Variables  
PO4≤0.98 
(N=1256) 
PO4=0.99-1.1 
(N=1469) 
PO4=1.11-1.2 
(N=1010) 
PO4>1.2  
(1207) 
P 
value  
Age (years), mean 
(SD) 49.49 (14.21) 52.16 (15.57) 54.42 (15.77) 55.83 (16.02) <0.001 
BMI (Kg/m2), mean 
(SD) 28.31 (4.74) 28.31 (4.81) 28.24 (4.94) 27.77 (4.84) 0.002 
SBP (mmHg), mean 
(SD) 160.94 (27.85) 165.76 (29.16) 165.81 (29.06) 167.60 (30.83) 0.016 
DBP (mmHg), mean 
(SD) 95.82 (13.18) 95.95 (14.14) 94.88 (14.35) 94.73 (14.85) 0.004 
TC (mmol/l), mean 
(SD) 5.80 (1.20) 6.06 (1.35) 6.04 (1.38) 6.13 (1.43) 0.027 
eGFR≤60, n (%) 282 (22.45) 390 (26.55) 308 (30.50) 467 (38.69) <0.001 
Ca (mg/dl), mean 
(SD) 2.33 (0.13) 2.35 (0.13)  2.35 (0.12) 2.35 (0.13) <0.001 
ALP, Median (IQR) 139 (85-193) 111 (73-176) 118 (78-185) 124 (79-187) <0.001 
Alcohol >6 units, n 
(%) 855 (71.61) 1006 (71.96) 665 (69.56) 777 (69.01) 0.296 
Tobacco smoking, n 
(%) 420 (33.95) 576 (39.81) 417 (41.99) 540 (45.80) <0.001 
CVD, n (%) 176 (14.01) 271 (18.45) 183 (18.12) 250 (20.71) <0.001 
PO4=Serum Phosphate in mmol/L, BMI=Body Mass Index, SBP=Systolic Blood Pressure, 
DBP=Diastolic Blood Pressure, TC=Total Cholesterol, eGFR=estimated Glomerular Filtration 
Rate, Ca=Serum Calcium, ALP=Serum Alkaline Phosphatase, CVD=Prevalent 
Cardiovascular Diseases, SD=Standard Deviation, IQR=Inter Quartile Range, , Kg=Kilogram, 
mmHg=millimeter of mercury, mg/dl=milligram per decilitre 
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5.3.2 Deprivation status and baseline variables  
Despite lower mean age, men from the most deprived regions had significantly 
higher mean levels of BMI, SBP, DBP and serum alkaline phosphatase in 
comparison to men from least deprived regions (Table 5-4 on page 163). Similar 
trends were seen in women (Table 5-5 on page 164). Serum calcium was 
elevated in men from the most deprived regions in comparison to their 
counterparts from the least deprived regions. Smoking rates were significantly 
higher in individuals from the most deprived regions in both men and women. 
However, alcohol use was less frequently observed in women from the most 
deprived regions in comparison to women from least deprived regions. Baseline 
mean serum phosphate was higher in men from the most deprived regions in 
comparison to men from least deprived regions. However, phosphate levels were 
similar in women from all groups based on SIMD quintiles (Table 5-5 on page 
164).  
5.3.3  Follow-up period and event rates  
The total duration of follow-up was 129272.64 person years (p-y) with median 
survival time of 33.3 years. The time at risk in men and women were 59286.13 p-
y and 69986.51 p-y, respectively. The overall event rates per 1000 p-y of follow-
up were 16.50 (95% CI: 15.82-17.22), 8.95 (8.44-9.48), 4.70 (4.34-5.09), 2.31 
(2.06-2.59), and 7.56 (7.10-8.05) for all-cause, cardiovascular, IHD, Stroke and 
non-CVD mortality, respectively. The event rates per 1000 p-y of follow-up 
stratified by quartiles of phosphate in men and women are presented in table 5-
6 on page 165. All-cause mortality increased linearly with phosphate quartiles.  
5.3.4 Survival analysis  
In the Kaplan-Meir survival curves of serum phosphate in quartiles and all-cause 
mortality (Figure 5-2 on page 162), the shortest survival time was observed in 
the quartile 4. Using phosphate as a continuous variable, each increment of 0.1 
mmol/L phosphate augmented the all-cause mortality by 6% (HR=1.06, 95% CI: 
1.04-1.08) after adjustment for all other relevant variables. In men the increase 
in mortality was 7% (HR=1.07, 95% CI: 1.03-1.10), while in women it was 6% 
(HR=1.06, 95% CI: 1.02-1.10). Adjustment for deprivation did not change the risk 
estimates in the Cox-PH models (Table 5-7 on page 166). The cubic spline 
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regression analyses of phosphate and all-cause mortality showed a linear 
increase in mortality with serum phosphate >1 mmol/L in men, while in women 
mortality increased linearly with serum phosphate >0.4 mmol/L (Fig 5-3 on page 
168). Despite social deprivation influencing serum phosphate levels in men, it 
did not have an influence on the association between phosphate and all-cause 
mortality in both men and women in the regression spline Cox models.   
Cardiovascular mortality increased with each increment of 0.1 mmol/L 
phosphate by 8% (HR=1.08, 95% CI: 1.03-1.12) in men. The association did not 
change significantly after adjustment for deprivation in men. However, the 
moderate effect seen in women disappeared after adjustment for deprivation 
(Table 5-7 on page 167) and indicates residual confounding in the unadjusted 
analyses (Table 5-6 on page 165). Similarly, the IHD mortality was also increased 
with unit increase in phosphate in men. Phosphate had no effect on stroke 
mortality in men and women.  
Although 0.1 mmol/L increase in phosphate was associated with 5% (HR=1.05, 
95% CI: 1.00-1.11) increase in nonCV mortality in men with borderline 
significance level, the association almost disappeared after adjustment for 
deprivation. However, in women 0.1 mmol/L increase in phosphate increased 
the non-CV mortality by 8% (HR=1.08, 95% CI: 1.03-1.14) and 9% (HR=1.09, 95% 
CI: 1.02-1.15) respectively before and after adjustment for deprivation (Table 5-
7 on page 167).  
 
Figure 5-2: Kaplan-Meir survival curves of serum phosphate in quartiles  
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Serum phosphate in quartiles and mortality are presented in men (Figure 5-4 on 
page 169) and women (Figure 5-5 on page 169) separately after adjustment for 
all variables. While CV mortality was associated with higher serum phosphate in 
men, the relationship was stronger in women for non-CV mortality.  
In the sub-group analysis, 0.1 mmol/L increase in phosphate increased all-cause 
mortality consistently in all sub-groups (Figure 5-6 on page 170). Stratification 
by baseline SBP, follow-up BP control status, serum calcium and alkaline 
phosphatase levels and smoking status did not have a significant influence on the 
association between phosphate and mortality. However, the association was very 
strong in individuals with poor kidney function in comparison to individuals with 
better kidney function.  However, this could be a chance finding as I had tested 
the differences in more than 20 subgroups. All-cause mortality hazard ratios 
were similar in users (HR=1.07, 95% CI: 1.00-1.14) and non-users (HR=1.07, 95% 
CI: 1.03-1.120) of diuretics in men. Consistent results were reported in women in 
non-users of diuretics (HR=1.07, 95% CI: 1.02-1.12) and users of diuretics 
(HR=1.04, 95% CI: 0.98-1.10).  
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Table 5-4: Baseline characteristics of the study population stratified by deprivation status in men  
  Men      
Variables  
 
SIMD Quintile 1 
(N=1016) 
SIMD Quintile 2 
(N=719) 
SIMD Quintile 3 
(N=604) 
SIMD Quintile 4 
(N=639) 
SIMD Quintile 5 
(N=986) 
P 
value  
Age at first visit (years), mean (SD) 49.67 (13.57) 50.21 (13.87) 49.95 (13.63) 50.10 (13.36) 51.97 (12.94) 0.003 
BMI (Kg/m2), mean (SD) 29.19 (6.54) 28.51 (5.68) 28.55 (5.52) 28.40 (5.73) 27.91 (4.86) <0.001 
SBP (mmHg), mean (SD) 163.78 (28.08) 162.30 (26.86) 160.83 (25.37) 159.67 (24.80) 158.59 (24.17) <0.001 
DBP (mmHg), mean (SD) 99.03 (15.27) 97.91 (14.17) 98.09 (14.49) 96.48 (13.51) 96.48 (13.01) <0.001 
Total Cholesterol (mmol/l), mean (SD) 5.81 (1.20) 5.80 (1.19) 5.66 (1.16) 5.79 (1.17) 5.71 (1.12) 0.061 
Calcium (mg/dl), mean (SD) 2.34 (0.12) 2.33 (0.12) 2.32 (0.11) 2.32 (0.12) 2.32 (0.11) <0.001 
Alkaline Phosphatase (IU/L), median 
(IQR) 129 (82-181) 132 (83-187) 131 (78-187) 120 (73-170) 
86 (63-140) 
0.004 
Phosphate (mmol/L), mean (SD) 1.03 (0.20) 1.03 (0.19) 1.04 (0.24) 1.01 (0.20) 1.00 (0.19) 0.003 
eGFR<60 mL/min, n (%) 188 (18.50) 127 (17.66) 103 (17.05) 117 (18.31) 188 (19.07) 0.873 
Alcohol >6 units, n (%)  690 (71.73) 485 (70.09) 414 (73.14) 435 (72.50) 677 (73.27) 0.655 
Tobacco smoking, n (%) 539 (53.95) 369 (52.12) 288 (48.81) 257 (41.19) 422 (43.91) <0.001 
CVD, n (%) 245 (24.11) 174 (24.20) 130 (21.52) 132 (20.66) 191 (19.37) 0.052 
       
ALP=Serum alkaline phosphatase, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, eGFR=estimated glomerular 
filtration rate based on MDRD equation, Baseline CVD=prevalent cardiovascular disease at baseline, SD=standard deviation, SIMD=Scottish Index of 
Multiple Deprivation 
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Table 5-5: Baseline characteristics of the study population stratified by deprivation status in women    
  Women     
Variables  
SIMD Quintile 1 
(N=1313) 
SIMD Quintile 2 
(N=869) 
SIMD Quintile 3 
(N=659) 
SIMD Quintile 4 
(N=689) 
SIMD Quintile 5 
(N=1026) 
P 
value  
Age at first visit (years), mean (SD) 52.26 (15.46) 54.47 (16.33) 52.12 (14.45) 51.83 (15.63) 55.03 (15.46) <0.001 
BMI (Kg/m2), mean (SD) 28.72 (6.71) 28.61 (6.79) 28.15 (6.43) 27.83 (6.41) 27.03 (5.73) <0.001 
SBP (mmHg), mean (SD) 166.62 (30.92) 165.50 (29.80) 163.69 (28.77) 161.30 (27.53) 162.31 (27.48) <0.001 
DBP (mmHg), mean (SD) 96.12 (14.84) 94.87 (14.27) 95.30 (13.49) 94.20 (13.42) 93.70 (12.91) <0.001 
Total Cholesterol (mmol/l), mean (SD) 6.01 (1.35) 5.91 (1.37) 5.97 (1.31) 5.93 (1.32) 5.99 (1.29) 0.503 
Calcium (mg/dl), mean (SD) 2.35 (0.13) 2.34 (0.12) 2.34 (0.12) 2.35 (0.13) 2.34 (0.12) 0.172 
Alkaline Phosphatase (IU/L), median 
(IQR) 128 (80-192) 129 (83-195) 127 (77-185) 118 (77-174) 
90 (63-147) 
0.084 
Phosphate (mmol/L), mean (SD) 1.10 (0.20) 1.11 (0.20) 1.08 (0.19) 1.09 (0.20) 1.10 (0.20) 0.199 
eGFR<60 mL/min, n (%) 394 (30.01) 305 (35.10) 178 (27.01) 179 (25.98) 305 (29.73) 0.001 
Alcohol >6 units, n (%)  519 (41.85) 317 (38.75) 240 (38.46) 293 (45.15) 439 (45.59) 0.006 
Tobacco smoking, n (%) 643 (49.73) 356 (41.78) 223 (34.63) 227 (33.24) 339 (33.90) <0.001 
CVD, n (%) 284 (21.63) 171 (19.68) 105 (15.93) 102 (14.80) 147 (14.33) <0.001 
ALP=Serum alkaline phosphatase, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, eGFR=estimated glomerular 
filtration rate based on MDRD equation, Baseline CVD=prevalent cardiovascular disease at baseline, SD=standard deviation, SIMD=Scottish Index of 
Multiple Deprivation 
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Table 5-6: Person years of follow-up and event rates stratified by groups based on quintiles of phosphate in men and women.  
  
Men  
  
Follow-up and event rates  
PO4≤0.9 mmol/L 
(N=1272) 
PO4=0.91-1.0 mmol/L 
(N=960) 
PO4=1.01-1.14 mmol/L 
(N=1050) 
PO4>1.14 mmol/L 
(1036) 
Person years of follow-up (p-y) 17283.24 13301.58 14327.82 14373.49 
IHD mortality, n/1000 p-y (95% CI) 5.09 (4.13-6.27) 5.71 (4.56-7.15) 5.10 (4.05-6.41) 7.51 (6.22-9.07) 
Stroke mortality, n/1000 p-y (95% CI) 2.03 (1.45-2.82) 3.01 (2.21-4.10) 1.88 (1.29-2.48) 2.85 (2.10-3.87) 
CV mortality, n/1000 p-y (95% CI) 8.98 (7.66-10.48) 11.13 (9.47-13.07) 9.77 (8.28-11.53) 12.52 (10.82-14.49) 
Non-CV mortality, n/1000 p-y (95% CI) 7.58 (6.39-9.00) 7.44 (6.11-9.06) 7.05 (5.80-8.57) 8.00 (6.66-9.61) 
All-cause mortality, n/1000 p-y (95% CI) 16.55 (14.74-18.58) 18.57 (16.39-21.04) 16.82 (14.83-19.08) 20.52 (18.31-23.01) 
  
Women  
  
Follow-up and event rates  
PO4≤0.98 mmol/L 
(N=1256) 
PO4=0.99-1.1 mmol/L 
(N=1469) 
PO4=1.11-1.2 mmol/L 
(N=1010) 
PO4>1.2 mmol/L 
(1207) 
Person years of follow-up (p-y) 16685.93 22954.54 14072.01 16274.02 
IHD mortality, n/1000 p-y (95% CI) 2.16 (1.56-2.99) 3.88 (3.15-4.77) 4.05 (3.12-5.25) 4.92 (3.95-6.12) 
Stroke mortality, n/1000 p-y (95% CI) 1.74 (1.21-2.50) 2.13 (1.61-2.82) 2.56 (1.85-3.55) 2.64 (1.96-3.56) 
CV mortality, n/1000 p-y (95% CI) 4.91 (3.96-6.10) 7.67 (6.61-8.89) 7.96 (6.61-9.58) 10.14 (8.70-11.81) 
Non-CV mortality, n/1000 p-y (95% CI) 4.91 (3.96-6.10) 6.80 (5.81-7.95) 9.38 (7.91-11.13) 9.83 (8.42-11.48) 
All-cause mortality, n/1000 p-y (95% CI) 9.83 (8.43-11.45) 14.46 (12.99-16.11) 17.34 (15.29-19.666) 19.97 (17.91-22.26) 
p-y=Person Years of Follow-up, PO4=Serum Phosphate, mmol/L=millimol/Litre, IHD=Ischeamic Heart Disease, CV=Cardiovascular, Non-CV=Non 
Cardiovascular, CI=Confidence Interval.  
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Table 5-7: Cox-Proportional Hazard models of phosphate and mortality outcomes.  
Cox-Proportional Hazard 
Models  
All-cause mortality 
  
CVD mortality 
  
IHD mortality 
  
Stroke Mortality 
  
Non-CVD mortality 
  
  HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
 
N=1026/4042 N=591/4042 N=327/4042 N=136/4042 N=435/4042 
Baseline Phosphate, Men 
(Model 1) 
1.07* 1.03-1.10 1.08* 1.03-1.12 1.08* 1.02-1.14 1.04 0.95-1.14 1.05 1.00-1.11 
 
N=847/3704 N=482/3704 N=260/3704 N=114/3704 N=365/3704 
Baseline Phosphate, Men 
(Model 2) 
1.05* 1.01-1.09 1.07* 1.02-1.13 1.09* 1.01-1.16 1.03 0.93-1.14 1.03 0.97-1.09 
 
N=1010/4606 N=507/4606 N=247/4606 N=146/4606 N=503/4606 
Baseline Phosphate, 
Women (Model 1) 
1.06* 1.02-1.10 1.04 0.99-1.09 1.03 0.96-1.11 1.01 0.92-1.11 1.08* 1.03-1.14 
 
N=858/4230 N=427/4230 N=208/4230 N=126/4230 N=431/4230 
Baseline Phosphate, 
Women (Model 2) 
1.05* 1.01-1.10 1.02 0.96-1.08 1.02 0.94-1.11 0.98 0.88-1.09 1.09* 1.02-1.15 
Model 1: adjusted for age, epochs, smoking, alcohol use, baseline systolic blood pressure, diastolic blood pressure, serum calcium, and serum alkaline 
phosphatase. Model 2: adjusted for all variables as in model 1 and deprivation index in quintiles. The hazard ratios are for each increment of 0.1 mmol/L of 
phosphate.  
 
 
 
 
Chapter 5 Phosphate and Mortality 168 
 
 
Figure 5-3: Regression spline Cox hazard model for serum phosphate and all-cause 
mortality.  
Panel 1: Before adjustment for deprivation in men. Panel 2: Adjusted for deprivation in men. 
Panel 3: Before adjustment for deprivation in women. Panel 4: Adjusted for deprivation in 
women. All models also include age, epochs, smoking, alcohol use, baseline systolic blood 
pressure, diastolic blood pressure, serum calcium, and serum alkaline phosphatase.  
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Figure 5-4: Serum phosphate in quartiles and mortality in men.  
 
Figure 5-5: Serum phosphate in quartiles and mortality in women.  
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Figure 5-6: Sub-group analyses of serum phosphate and all-cause mortality.  
The hazard ratios are for each increment of 0.1 mmol/L of phosphate.  
5.3.5 Association of phosphate with follow-up blood pressure  
The annual reduction in SBP and DBP were 3.64(95% CI: 3.48-3.86) and 1.92 (95% 
CI: 1.80-2.10) mmHg, respectively. During the initial five years of follow-up, 
longitudinal change in mean SBP was not influenced by serum phosphate in men 
and women after adjustment for age, BMI, smoking status, alcohol use, serum 
calcium, epochs and eGFR (Table 5-8 on page 171).  While mean DBP did not 
change with serum phosphate in men, it decreased moderately in women by 0.13 
mmHg (95% CI: 0.25 to 0.04) with each increment of  0.1 mmol/L increase in 
serum phosphate.  
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Table 5-8: Longitudinal increase in blood pressure across baseline phosphate levels in men 
and women  
 SBP mmHg  DBP mmHg  
GEE Models 
Men 
GEE β [95% CI] 
Women 
GEE β [95% CI] 
Men 
GEE β [95% CI] 
Women 
GEE β [95% CI] 
Phosphate 
(Model 1)  
-0.09   
[-0.33; 0.16] 
0.16  
[-0.09; 0.41] 
-0.05  
[-0.18; 0.09] 
0.13  
[-0.25; 0.04] 
 
Model 1: Adjusted for age, body mass index, smoking, alcohol use, serum calcium, epochs, 
and eGFR CKD status. The regression coefficients (βs) are for each increment of 0.1 mmol/L 
of phosphate.  
 
5.4 Discussion  
The present study demonstrates that in a large cohort of hypertensive 
individuals followed-up for over 30 years, elevated initial serum phosphate is an 
independent predictor of all-cause mortality. While serum phosphate is 
associated with CV mortality in men, it is more closely associated with non-CV 
mortality in women.  
Although there are consistent reports on the association between serum 
phosphate and mortality in patients with CKD and end stage renal disease 441, 
the relationship is not clear in individuals with normal kidney function.  Post- 
hoc analyses of the post myocardial infarction CARE cohort have demonstrated a 
significant association between elevated serum phosphate and adverse CV 
outcomes in individuals with normal renal function 444. Even though a large study 
in the general population reported a positive association of high phosphate with 
mortality, the results were partially adjusted for confounding factors 450. By 
contrast in a recent 8 year follow-up study of 1206 patients with acute 
cardiovascular events, serum phosphate was not independently associated with 
all-cause mortality or CV events 600. However, the total number of events 
reported was relatively small in this cohort and all-cause mortality showed a 
non-significant increase with increase in serum phosphate.  The present study in 
a large hypertensive cohort supports the evidence that serum phosphate is 
independently associated with mortality. The findings are important as they are 
adjusted for all the conventional risk factors, serum calcium and alkaline 
phosphatase.  
 
Vascular calcification, vascular stiffness and associated peripheral arterial 
resistance are hypothesised as potential mechanisms mediating the association 
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of serum phosphate with incident CVD and mortality. Higher serum phosphorous 
is associated with coronary artery calcification and obstruction in individuals 
with suspected coronary artery disease 601. Higher phosphate levels even within 
the normal range is associated with coronary artery calcium deposits as 
estimated by computed tomography measurements in young adults in the CARDIA 
study 584. Similar findings are reported in Koreans with normal renal function 602. 
In vitro experiments suggest that exogenous serum phosphorous induces 
phenotypic transformation of aortic vascular smooth muscle cells to osteoblast 
like cells, production of calcium binding proteins and secretion of matrix vesicles 
603 604. These changes invariably facilitate calcium deposition on smooth muscle 
cell walls of the vasculature. Interestingly, the sodium-phosphate co-
transporter, PT1-I is present in vascular smooth muscles which is essential for 
calcification 585 605. A low phosphate diet in animal models decreased 
hyperphosphatemia and ameliorated endothelial dysfunction associated with 
increased serum phosphate 606.  
Mechanisms that link hyperphosphataemia and CVD also allude to dysregulation 
of vitamin D (Vit. D) synthesis and elevated parathyroid hormone (PTH) levels. 
However, animal studies provide evidence on independent association of serum 
phosphate with vascular calcification and mortality. Fibroblast growth factor 
FGF-23 regulates phosphate re-absorption from the renal tubules and therefore 
the phosphate levels in serum 607. Despite higher serum phosphate levels in FGF-
23 gene knocked-out mice, a phosphate deficient diet decreased serum 
phosphate and prevented vascular calcification and mortality independent of 
Vit.D and calcium levels 608. Over expression of FGF-23 and Klotho (the gene 
regulating the synthesis of FGF-23) is associated with hypophosphatemia and 
increased longevity 609.  
Type of mortality associated with phosphate differs in men and women. While 
phosphate is associated with CV mortality in men, the association is stronger in 
women for non-CV mortality. Consistent findings for CV mortality are reported in 
the literature 610. Despite women having significantly higher serum phosphate in 
comparison to men 611, the association of phosphate with CV mortality is weaker 
in women in comparison to men. The reasons for these apparent differences are 
not clear.  The hormonal status has a role in phosphate metabolism and 
oestrogens in general have a phosphaturic effect 612. Menopausal status and 
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hormone replacement therapy therefore may have an independent effect on 
phosphate levels 611. However, in the post hoc analyses of MORE study 
participants (7259 postmenopausal women with osteoporosis), serum phosphate 
was not associated with all-cause mortality 454. There are no clear explanations 
on the influence of hormonal status on association between serum phosphate 
and mortality. It is impossible to tease out the potential causes of this 
difference in the present study, but may merit further investigation in future 
studies. 
The present study also demonstrates a gender specific effect of phosphate and 
degree of deprivation.  It is unclear why phosphate level remained significantly 
higher only in men from more deprived background compared to their less 
deprived counterparts.  The lack of association of phosphate with deprivation 
status in women could possibly be explained by the phosphaturic effect of 
oestrogens which may act as an additional homeostatic mechanism of 
maintaining tight control of serum phosphate in pre-menopausal women 613.  
Inappropriate adjustment for confounding factors is often cited as a major 
criticism in the association between phosphate and mortality in previous studies 
440 441. In the present study we adjust for all conventional risk factors, serum 
calcium, alkaline phosphatase and deprivation status. Serum phosphate is 
associated with intake of processed food items which contain significant amount 
of inorganic phosphate. There is evidence to suggest that poor socio-economic 
status and greater deprivation are associated with intake of more processed food 
and high serum phosphate levels 596. The models adjusting for Scottish 
deprivation index provide reasonable evidence to suggest that the association 
between phosphate and mortality observed in the present study is not 
confounded by deprivation. Thiazides like diuretics are associated with 
phosphaturia614 and may have a confounding effect on the association between 
serum phosphate and mortality. However, the results were consistent in users 
and non-users of diuretics at baseline. The longitudinal change in SBP in this 
hypertensive cohort is not influenced by baseline serum phosphate levels. 
Therefore, the association of phosphate and mortality observed in this study is 
not subjective to the effect of phosphate on BP.  
The factors associated with higher serum phosphate remain unclear.  
Environmental factors include increased dietary intake of protein rich and 
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processed foods and liquids 594.  However there are no dietary intervention 
studies in the literature that evaluates the role of a low phosphate diet on serum 
phosphate, BP and other cardiovascular outcomes. Such studies are required to 
establish the causal role of phosphate on BP and mortality outcomes.  
5.5 Strengths and limitations  
The strengths of the current study include; a large cohort of nearly 10,000 
hypertensive adults, 35 years of follow-up with median survival time of 33 years, 
the ability to link serum phosphate with differing causes of mortality outcomes, 
inclusion of the entire distribution of serum phosphate in the analyses, and 
adjustment for all potential confounding factors including the deprivation status. 
Since serum phosphate distribution was different in men and women, all 
analyses were conducted in men and women separately. The exclusion of 
individuals without serum phosphate assessed at baseline from our analysis and 
the bias introduced by the missing covariates in the adjusted Cox-PH models 
especially the deprivation status are the major limitations of this study. 
However, the results were consistent across multiple models with and without 
such variables.  
5.6 Summary  
Serum phosphate is an independent predictor of mortality in a treated 
hypertensive population. While CV mortality is more closely associated with 
higher serum phosphate in men, women show prominent association with non-CV 
mortality. Deprivation status, serum calcium and serum alkaline phosphatase 
levels do not attenuate the mortality risk associated with serum phosphate in 
men and women. Further study is required to address the effect of dietary 
intervention to reduce intake of phosphate rich foods on long term achieved BP, 
CV and all-cause mortality outcomes. Clinical trials of alternative strategies for 
lowering serum phophate (e.g. phosphate binding drugs) may represent a further 
strategy for improving outcomes in hypertensive subjects. 
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6 Serum electrolytes and mortality 
6.1 Introduction  
Electrolytes, especially sodium, chloride, potassium and bicarbonates, play a 
vital role in maintaining homeostasis within the human body. Serum sodium is an 
essential electrolyte that regulates blood volume, BP, osmotic equilibrium and 
the acid-base balance 615 616. The volume of extracellular fluid (ECF) is directly 
proportional to the content of sodium in plasma. The normal plasma 
concentration of sodium is 135-145 mEq/L. An increase in dietary sodium intake 
from very low to moderately high level results in an 18% increase in the ECF 
volume 617. Moreover, an increase in daily sodium excretion of 200 mmol 
(equivalent to the effect of a 5g increase in sodium intake), increases mean 
arterial BP by 1 mmHg 618. The association between dietary sodium intake and 
mortality shows a non-linear "j" shaped pattern with significantly higher 
mortality at intakes above and below the range of 2.5-6.0 g/day 619.  
Chloride is the major extracellular anion and is principally responsible for 
maintaining proper hydration, osmotic pressure, and normal cation-anion 
balance in the vascular and intestinal fluid compartments 620. Furthermore, 
chloride is the main determinant of metabolic acid-base state in critical illnesses 
621. The normal plasma concentration of chloride is 95-105 mEq/L. Most of the 
chloride in the body comes from table salt (sodium chloride) or other salt 
contained in the diet. While chloride is almost completely absorbed from the 
intestinal tract, it is removed from the blood by glomerular filtration and then 
reabsorbed by the kidney tubules 620. Contrasting findings are reported in the 
literature on the association between dietary chloride intake and BP in animal 
models. While earlier studies did not find any association of dietary chloride 
with BP independent of dietary sodium content 622 623, some of the new animal 
studies suggest an independent positive association 624-626. Data on association of 
serum chloride level and mortality are scarce in the general population.  In a 
general population cohort study conducted in Belgium, serum chloride level 
below the range of 100 mEq/L was independently associated with mortality 467. 
Consistent findings are reported in the post hoc analyses of North American 
CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and 
Morbidity) study cohort 627. 
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Similar to serum chloride, bicarbonates are also important electrolytes that 
determine the acid base balance in the body and are routinely measured in 
hypertensive patients as part of renal function evaluation tests. Low serum 
bicarbonate levels (acidosis) precede the development of high BP in animal 
models 628. Those who were in the highest quintile of serum bicarbonate had SBP 
2.73 mmHg lower (95% CI: 1.26 to 4.20 mmHg) than participants in the lowest 
quintile in the 1999-2000 and 2001-2002 NHANES 629. A non-linear relationship 
between serum bicarbonate and progression of kidney disease (with significant 
elevation of mortality at the lower end of distribution and a moderate elevation 
at the higher end of the distribution) was evident in a retrospective cohort study 
of 5422 participants. Similarly, a 'j' shaped relationship between serum 
bicarbonate and mortality is reported in patients with stage 3 and 4 CKD 470.  
Potassium is the most abundant cation in the body. Normal serum potassium is in 
the range of 3.5 to 5.5 mEq/L, and long-term potassium homeostasis is 
maintained by the kidneys. Although potassium is freely filtered, 90% is 
reabsorbed in the tubular segments proximal to the distal convoluted tubule. 
Minor departure of serum potassium from its tightly controlled range is 
associated with significant mortality and morbidity.  
Hypertension is a significant global public health problem that affects 
approximately one in four adults 305. It is an important risk factor for CVD 293 and 
has a bi-directional relationship with renal function 382. While the associations 
between dietary salt (sodium chloride) and BP have been assumed to be related 
primarily to the sodium content of salt 630 631, the hypertensive effect of sodium 
chloride is also dependent on the concomitant presence of both sodium and 
chloride ions 632 633. Furthermore, increased production of organic acids, increase 
in unmeasured anions, and metabolic acidosis are linked to the development and 
progression of hypertension 634-636. Despite the involvement of serum electrolytes 
in a variety of physiological functions in the human body such as regulation of 
blood volume, BP, osmotic equilibrium and the acid-base balance, the 
epidemiological significance of serum electrolytes especially serum chloride in 
relation to long term mortality outcomes have not been studied in detail. In this 
study associations of serum chloride and other electrolytes with mortality 
outcomes are explored by employing survival analysis in a high risk hypertensive 
cohort followed-up for more than 35 years.  
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6.2 Materials and Methods  
6.2.1 Study setting and study population  
Detailed description of study settings and population are described in section 2.1  
6.2.2 Clinical measurements  
Clinical, anthropometric and demographic data are collected as described in 
section 2.2.-2.4. Blood samples were collected at baseline and at regular 
intervals for estimation of routine haematological and biochemical indices. The 
serum electrolytes, especially, sodium, potassium, chloride and bicarbonate 
were part of the routine blood assay and available in almost all clinic attendees 
at baseline and at specific intervals. All biochemical assays were performed at 
the central laboratory services of the Western Infirmary.  
6.2.3 Outcome assessment  
The details are explained in section 2.5.  
6.2.4 Statistical Methods 
All analyses were restricted to the hypertensive individuals in the database with 
serum chloride assessed at the registration visit (N=12,968). In the presence of 
free water disturbances, which are common in treated hypertensive patients, 
serum sodium, chloride, and bicarbonate concentrations is expected to move 
concordantly, except when a competing acid-base disorder is present. Adjusted 
serum chloride (adjusted for serum sodium levels) and bicarbonate (adjusted for 
serum sodium and anion-gap) were estimated based on the following conversion 
equations.  
Adjusted serum chloride (Cladjusted) = measured chloride + 0.76*(140-measured 
sodium).  Adjusted serum bicarbonate (HCO3adjusted ) = measured bicarbonate + 
∆Anion Gap + 0.19*(140-measured sodium)637where '∆Anion Gap' is the difference 
between the patient’s anion gap and the normal anion gap.  
The study population was divided into five groups based on quintiles of serum 
chloride. The characteristics of the study population across these five groups 
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were compared using one way ANOVA for continuous variables and Chi square 
test for categorical variables. Spearman correlation coefficients were generated 
to study the overall association between serum electrolytes in the whole cohort, 
and among individuals who were on treatment with diuretics. Participants were 
also categorized into four groups based on serum chloride and bicarbonate 
measured at baseline, to examine the effects of both variables on mortality.  
The groups were; chloride ≤100 mEq/L and bicarbonate ≤25 mEq/L, chloride 
≤100 mEq/L and bicarbonate >25 mEq/L, chloride >100 mEq/L and bicarbonate 
≤25 mEq/L, and chloride >100 and bicarbonate >25 mEq/L.  Finally, they were 
categorized into four groups based on serum chloride and sodium measured at 
baseline.  The groups were; chloride ≤100 mEq/L and sodium ≤135 mEq/L, 
chloride ≤100 mEq/L and sodium >135 mEq/L, chloride >100 mEq/L and sodium 
≤135 mEq/L, and chloride >100 and sodium >135 mEq/L.   
A generalized estimating equation (GEE) model as explained in section 2.7.1 was 
used to study the association between baseline serum chloride in quintiles and 
change in mean BP during the follow-up period after adjusting for age, sex, year 
of first visit, BMI, and eGFR.  
The survival probabilities of serum chloride groups in quintiles and groups 
stratified based on serum sodium and bicarbonate levels were compared using a 
Kaplan-Meier plot and log-rank test (details are explained in section 2.6.2). Cox 
proportional hazards (Cox-PH) models as explained in section 2.6.3 were set up 
to analyze the influence of baseline serum chloride on all-cause, CV, IHD, stroke 
and non-CV mortality. The covariates included were baseline age, gender, BMI, 
smoking status (never versus ever), SBP, DBP, alcohol use, tobacco use, eGFR, 
and last SBP. A variable on year of first visit strata (epochs) was used to adjust 
for the secular trend in mortality and was divided into three categories (first 
visit 1987 or before, between years 1988-1997, 1998 and after). Hazard ratios 
were then generated. The PH assumption was evaluated by plotting the –ln(-
ln(survival)) curves for each category of the ordinal covariate versus ln(analysis 
time) 548. Initially, serum chloride was assessed as a quantitative trait (Model 1). 
A second model was generated after adding anion-gap as a predictor variable to 
Model 1 (Model 2). The anion-gap variable in model 2 was replaced with 
individual serum electrolytes values (Model 3). Model 4 contained the same 
covariates as 3, with the exception of chloride which was coded as quintiles. 
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Finally, model 4 was extended by stratification by concomitant diuretic use 
(Model 5). The KM and Cox-PH models were repeated by replacing the measured 
serum chloride in quintiles with adjusted serum chloride and serum bicarbonate 
in quintiles. Given the potential for a non-linear relationship of serum chloride 
with time to mortality, regression spline Cox-PH models (details are provided in 
section 2.6.5) were also set up to smoothen the hazard functions of each of the 
predictor variables.  
6.3 Results  
6.3.1 Demographic and clinical characteristics of the study 
population  
Baseline characteristics of the sample are presented in table 6-1 (page 181).  
The study population was middle aged (50.55+14.17) and predominantly women 
(52.2%). It was also overweight (mean BMI=27.49+5.66), and hypertensive (SBP 
166.23+29.23 and DBP 98.38+16.97). While 45% were smokers, >6 units of alcohol 
use per week was reported in 61.3% of the population.  Less than one fifth of the 
population (18.2%) reported co-existing CVD morbidity at the time of 
registration. More than one fifth (22.0%) of the population were on diuretics. 
The achieved SBP and DBP were significantly lower than the baseline BP.   The 
distribution of serum sodium, chloride, potassium and bi-carbonate are 
presented as density plots in figure 6-1 (page 180). Serum sodium, chloride, 
potassium and bicarbonate were normally distributed in the study population 
with mean and standard deviation of 140.06±2.76 mEq/L, 102.74±3.51 mEq/L, 
4.10±0.45 mEq/L and 26.01±3.06 mEq/L, respectively.    
The highest positive Spearman correlation coefficient was observed for 
association between serum chloride and sodium (0.39, p<0.001), while the 
lowest negative correlation coefficient was observed for association between 
serum chloride and bicarbonate (-0.37, p<0.001). Consistent results were 
observed in users of diuretics (Table 6-2 on page 181). However, adjusting serum 
chloride and bicarbonate for free water changes resulted in a near perfect 
correlation (-0.99, p<0.001) between them.  
While serum sodium and potassium showed a positive linear association with 
increase in serum chloride quintiles (P<0.001), mean serum bicarbonate 
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confirmed an inverse linear association across groups based on serum chloride 
(P<0.001) (Table 6-3 on page 182).  Consequently, mean anion gap was higher in 
the first quintile of serum chloride in comparison to other quintiles (P<0.001). 
The proportion of men in the first quintile (51.4%) of serum chloride was 
significantly higher than other groups (P<0.001) (Table 6-3 on page 182). Age, 
BMI, SBP, DBP, TC, eGFR, alcohol use, and prevalence of CVD at baseline were 
significantly different across groups based on quintiles of serum chloride 
(P<0.001). The proportions of individuals with eGFR<60 mL/min, and alcohol 
users, were lowest in the fifth quintile of serum chloride (Table 6-3 on page 
182). Participants with lower serum chloride (≤100 mEq/L) were older and had 
higher BP, cholesterol, and CVD prevalence, regardless of bicarbonate and 
sodium levels (Table 6-4 and Table 6-5 on pages 183-184). The achieved SBP and 
DBP were also higher at lower levels of serum chloride (p<0.001).  
 
 
Figure 6-1: Distribution of serum sodium, chloride, potassium and bicarbonate in the study 
population.  
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Table 6-1: Correlation matrix of serum electrolytes (Spearman correlation coefficient)  
Serum 
electrolytes  
Sodium  Potassium Bicarbonate  Chloride Anion 
Gap 
Sodium  1.00     
Potassium 0.02 (0.041) 
-0.01 (0.479)* 
1.00    
Bicarbonate  0.10 (<0.001) 
0.07 (<0.001)* 
-0.12 (<0.001) 
-0.15 (<0.001)* 
1.00   
Chloride 0.39 (<0.001) 
0.39 (<0.001)* 
0.22 (<0.001) 
0.20 (<0.001)* 
-0.37 (<0.001) 
-0.39 (<0.001)* 
1.00  
Anion Gap 0.25  (<0.001) 
0.28 (<0.001)* 
0.03 (0.008) 
0.04 (<0.333)* 
-0.46 (<0..001) 
-0.46 (<0.001)* 
-0.30 (<0.001) 
-0.27 (<0.001)* 
1.00 
*Pearson Correlation coefficient and corresponding p values in diuretic users.    
 
Table 6-2: Characteristics of the study population  
 Total  
N=12968 
Men  
(N=6193) 
Women 
(N=6775) 
Age at first visit (years), mean (SD) 50.55 (14.16) 49.68 (12.94) 51.34 (13.90) 
BMI (Kg/m2), mean (SD) 27.48 (5.66) 27.49 (5.06) 27.48 (6.16) 
SBP (mmHg), mean (SD) 166.22 (29.25) 164.07 (27.41) 168.18 (30.71)  
DBP (mmHg), mean (SD) 98.38 (16.97) 99.35 (15.19) 97.50 (18.41) 
Total cholesterol (mmol/l), mean (SD) 5.95 (1.46) 5.84 (1.58) 6.05 (1.35) 
eGFR <60 mL/min per 1.73 m2, n(%) 2922 (23.70) 1099 (18.70)  1823 (28.26)  
Alcohol use, n (%) 7549 (61.31) 4450 (75.73)  3099 (48.15) 
Tobacco use, n (%) 5691 (44.80) 2972 (49.08)  2719 (40.91) 
CVD, n (%) 2354 (18.15) 1266 (20.45) 1088 (16.06) 
Serum sodium, mean (SD)   140.04 (3.47) 140.25 (3.16) 139.84 (3.72)  
Serum potassium, mean (SD) 4.11 (0.73) 4.12 (0.62)  4.10 (0.82)  
Serum bicarbonate, mean (SD)   25.92 (3.28) 26.31 (3.21)  25.56 (3.30)  
Anion gap, mean (SD)  15.81 (3.28) 15.91 (3.20)  15.72 (3.35) 
Diuretic use, n (%)  2857 (22.03) 1306 (21.09) 1551 (22.89) 
Achieved SBP (mmHg), mean (SD) 151.20 (24.41) 149.68 (22.25) 152.59 (25.34) 
Achieved DBP (mmHg), mean (SD) 86.87 (13.03) 90.60 (12.98)  89.20 (13.04)  
SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic 
blood pressure, eGFR=estimated glomerular filtration rate, CVD=prevalent cardiovascular 
disease at baseline.  
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Table 6-3: Characteristics of study population stratified by serum chloride in quintiles.   
 Cl<=100 
(N=3085) 
Cl=101-102 
(N=2670) 
Cl=103-104 
(N=3228) 
Cl=105-106 
(N=2508) 
Cl>=107  
(N=1477) 
P 
Value  
Age at first visit (years), mean (SD) 52.58 (13.04) 50.35 (13.90) 49.44 (14.44) 50.93 (15.19) 50.01 (16.40) <0.001 
Men,n(%)  1587 (51.44)  1364 (51.09)  1511 (46.81)  1118 (44.58)  613 (41.50)  <0.001  
BMI (Kg/m2), mean (SD) 26.78 (5.05) 27.45 (5.61) 27.80 (6.00) 27.77 (6.01) 28.30 (6.28) <0.001 
SBP (mmHg), mean (SD) 172.14 (30.14) 167.79 (28.71)  164.92 (28.76) 161.46 (29.42) 161.46 (29.42) <0.001 
DBP (mmHg), mean (SD) 100.88 (16.32) 99.63 (22.19) 97.51 (14.76) 96.86 (14.24) 95.39 (15.22) <0.001 
Total cholesterol (mmol/l), mean (SD) 6.24 (1.35) 6.08 (1.46) 5.93 (1.21) 5.84 (1.22) 5.62 (1.19) <0.001  
eGFR <60 mL/min per 1.73 m2, n(%) 539 (18.82)  481 (19.13)  532 (17.43)  403 (16.81)  194 (13.72)  <0.001 
Alcohol use, n (%) 1952 (65.61)  1642 (64.22) 1876 (60.99) 1362 (58.16) 717 (52.64) <0.001 
Tobacco use, n (%) 1419 (46.88)  1165 (44.23) 1351 (42.63) 1114 (45.60) 642 (44.93) 0.015 
CVD, n (%) 656 (21.26) 476 (17.83) 527 (16.33) 438 (16.47) 257 (17.40) <0.001 
Serum sodium, mean (SD)   138.47 (3.20) 139.78 (2.49)  140.38 (2.28) 140.92 (2.23) 141.78 (2.44)  <0.001 
Serum potassium, mean (SD) 3.95 (0.51)  4.08 (0.42)  4.14 (0.43) 4.19 (0.42) 4.24 (0.44) <0.001 
Serum bicarbonate, mean (SD)   27.48 (3.08)  26.37 (2.75)  25.52 (2.78)  24.91 (2.76) 23.91 (3.01)  <0.001 
Anion gap, mean (SD)  17.15 (3.38)  15.98 (3.14) 15.48 (2.95)  14.83 (2.40)  14.25 (3.08)  <0.001  
Diuretic use, n(%)  811 (25.95) 647 (23.79) 657 (19.82) 475 (18.01) 267 (16.50) <0.001 
Achieved SBP (mmHg), mean (SD) 156.22 (25.63) 151.69 (23.81) 150.30 (24.07)  147.53 (22.56)  147.99 (24.80) <0.001 
Achieved DBP (mmHg), mean (SD) 91.62 (13.77)  89.92 (12.74)  89.71 (12.99)  88.14 (13.19)  88.23 (12.84)  <0.001 
Cl=serum chloride, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, eGFR=estimated glomerular filtration rate based 
on MDRD equation, Baseline CVD=prevalent cardiovascular disease at baseline, SD=standard deviation 
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Table 6-4: Characteristics of the study population stratified by serum chloride and bicarbonate levels.  
Variables  
Cl<=100 & 
HCO3<=25 
(N=692) 
Cl>100 & 
HCO3<=25 
(N=3693) 
Cl<=100 & 
HCO3>25 
(N=2003) 
Cl>100 & 
 HCO3>25  
(N=3681) P Value  
Age at first visit (years), mean (SD) 51.01 (13.26) 48.31 (14.19) 51.82 (12.18) 49.70 (13.64) <0.001 
Men, n (%)  329 (47.54)  1534 (41.54)  1091 (54.47)  1894 (51.45) <0.001  
BMI (Kg/m2), mean (SD) 26.49 (4.71) 27.35 (5.55) 26.64 (4.78) 27.35 (5.26) <0.001 
SBP (mmHg), mean (SD) 175.32 (31.26) 168.06 (29.30)  172.76 (29.79) 167.31 (28.30) <0.001 
DBP (mmHg), mean (SD) 102.57 (16.83) 99.37 (15.25) 101.99 (15.85) 99.19 (14.57) <0.001 
Total cholesterol (mmol/l), mean (SD) 6.40 (1.41) 6.03 (1.28) 6.33 (1.29) 5.99 (1.36) <0.001  
eGFR <60 mL/min per 1.73 m2, n(%) 174 (27.62)  845 (24.27)  471 (24.45)  762 (21.36)  <0.001 
Alcohol use, n (%) 464 (68.64)  2720 (63.04) 1316 (67.42) 2248 (62.93) <0.001 
Tobacco use, n (%) 334 (48.76)  1736 (47.21) 932 (47.17) 1618 (44.24) 0.02 
CVD, n (%) 152 (21.97) 628 (17.01) 443 (22.12) 695 (18.88) <0.001 
Serum sodium, mean (SD)   137.73 (3.13) 140.18 (2.32)  138.90 (2.85) 140.92 (2.40) <0.001 
Serum potassium, mean (SD) 4.02 (0.49)  4.14 (0.41)  3.90 (0.49) 4.11 (0.42) 0.655 
Anion gap, mean (SD)  19.82 (3.05)  16.74 (2.79) 16.23 (2.96)  13.91 (2.71)  <0.001  
Diuretic use, n (%)  153 (22.01) 801 (21.58) 597 (29.78) 921 (24.95) <0.001 
Achieved SBP (mmHg), mean (SD) 157.57 (26.09) 152.42 (24.65) 157.01 (24.45)  150.73 (23.12)  <0.001 
Achieved DBP (mmHg), mean (SD) 92.36 (13.09)  90.83 (13.07)  92.58 (13.69)  89.95 (12.21)  <0.001 
Cl=serum chloride, HCO3=bicarbonate, SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, 
eGFR=estimated glomerular filtration rate based on MDRD equation, CVD=prevalent cardiovascular disease at baseline. 
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Table 6-5: Characteristics of the study population stratified by serum chloride and sodium levels. 
Variables  
Cl<=100 & 
Na<=135 
(N=430) 
Cl>100 & 
Na<=135  
(N=170) 
Cl<=100 & 
Na>135 
(N=2653) 
Cl>100 & 
Na>135 
 (N=9703) P Value  
Age at first visit (years), mean (SD) 58.49 (14.60) 52.91 (16.93) 51.61 (12.51) 49.86 (14.39) <0.001 
Men, n (%)  260 (60.47)  116 (68.24)  1236 (46.59)  5154 (53.12) <0.001  
BMI (Kg/m2), mean (SD) 26.51 (5.11) 27.45 (5.08) 26.83 (5.04) 27.72 (5.84) 0.02 
SBP (mmHg), mean (SD) 172.26 (27.75) 163.73 (30.45)  172.12 (30.52) 164.38 (2868) <0.001 
DBP (mmHg), mean (SD) 97.07 (16.33) 93.79 (15.07) 101.51 (15.24) 97.67 (17.13) <0.001 
Total cholesterol (mmol/l), mean (SD) 6.18 (1.45) 5.77 (1.50) 6.25 (1.33) 5.87 (1.49) <0.001  
eGFR <60 mL/min per 1.73 m2, n(%) 116 (28.02)  48 (29.63)  628 (25.35)  2128 (22.97)  0.003 
Alcohol use, n (%) 221 (54.70)  81 (50.94) 1731 (67.35) 5512 (60.12) <0.001 
Tobacco use, n (%) 209 (50.12)  71 (44.38) 1210 (46.40) 4194 (44.12) 0.026 
CVD, n (%) 87 (20.23) 33 (19.41) 569 (21.45) 1664 (17.15) <0.001 
Serum bicarbonate, mean (SD)   26.35 (3.11) 24.38 (3.27)  27.64 (3.04) 25.44 (2.89) <0.001 
Serum potassium, mean (SD) 4.04 (0.57)  4.24 (0.54)  3.94 (0.50) 4.15 (0.43) <0.001 
Anion gap, mean (SD)  14.75 (3.61)  11.47 (3.61) 17.49 (3.21)  15.39 (3.01)  <0.001  
Diuretic use, n (%)  102 (23.08) 27 (15.00) 709 (26.46) 2019 (19.99) <0.001 
Achieved SBP (mmHg), mean (SD) 155.62 (26.49) 152.24 (24.69) 156.34 (25.49)  149.59 (23.78)  <0.001 
Achieved DBP (mmHg), mean (SD) 88.54 (14.13)  87.44 (13.64)  92.13 (13.65)  89.35 (12.73)  0.018 
Cl=serum chloride, Na=sodium, SD=standard deviation, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, 
eGFR=estimated glomerular filtration rate based on MDRD equation, CVD=prevalent cardiovascular disease at baseline. 
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6.3.2 Association of serum chloride and blood pressure  
The population averaged effects of unit increase in adjusted serum chloride and 
other electrolytes, on both longitudinal SBP and DBP, are described in table 6-6 
on page 186. Serum chloride showed no effect on SBP change over time. Among 
the electrolytes, only serum bicarbonate showed a significant independent 
effect on longitudinal SBP, with each unit rise in serum bicarbonate associated 
with a 0.34 mmHg reduction in SBP over 5 years. For DBP, serum chloride 
showed no effect while serum sodium, potassium and bicarbonate showed small 
effects on DBP over time.  
6.3.3 Survival characteristics  
The total time at risk was 197102 person years (p-y) with median survival time of 
30.32 years. While the median survival time was lowest in the first quintile 
(22.46 years), it was highest in the fourth quintile of serum chloride (33.89 
years). The incidence rates were 20.84 (95% CI: 20.21-21.49), 12.48 (95% CI: 
12.00-12.98), 6.82 (95% CI: 6.47-7.20), 3.18 (2.94-3.44), and 8.36 (7.97-8.77) per 
1000 p-y of follow-up for all-cause, CV, IHD, stroke and non-CV mortality 
outcomes, respectively (Table 6-7 on page 186).  
6.3.4 Association of serum chloride and mortality outcomes  
The shortest survival time was observed in the first quintile of serum chloride in 
the unadjusted K-M analysis (log rank P<0.001) (Figure 6-2 on page 188). 
Consistent relationship was seen in K-M analysis with adjusted serum chloride 
quintiles (Figure 6-3 on page 188).  Mortality risk was greater in the groups with 
chloride ≤100 mEq/L, regardless of sodium or bicarbonate levels (log-rank 
p<0.001; Figures 6-4 and 6-5 on page 189). The log-log survival curves of serum 
chloride categories were parallel to each other and confirmed the agreement 
with the PH assumption (Figure 6-6 on page 190). 
In the Cox-PH models, there was an inverse linear association between serum 
chloride and all-cause mortality. For example, each 1 mEq/L increase in serum 
chloride was associated with decrease in all-cause mortality by 3% (HR=0.97, 95% 
CI: 0.96-0.98) after adjustment for baseline confounding variables, achieved BP 
and other serum electrolytes levels as in model 3. In the Cox-PH models with 
serum chloride in quintiles, the HRs were significantly lower in all other quintiles 
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in comparison to quintile 1 (model 4). In the final model (model 5), even after 
accounting for the influence of diuretic use, the HRs for all-cause mortality were 
0.82 (95% CI: 0.74-0.90), 0.79 (95% CI: 0.71-0.87), 0.79 (95% CI: 0.70-0.89) and 
0.80 (0.68-0.93) in quintiles 2, 3 , 4 and 5 respectively in comparison to quintile 
1 of serum chloride. Similar results were observed for CV mortality as well as 
non-CV mortality (Table 6-8). In the RS Cox-PH model, the risk for all-cause 
mortality increased linearly below serum chloride level 100 mEq/L (Figure 6-7 on 
page 190).  
Table 6-6: Longitudinal association between serum electrolytes and blood pressure.  
Serum electrolytes  GEE β (SBP)*  95% CI β P value  
Adjusted serum chloride  0.01 -0.19; 0.21 0.893 
Serum sodium  0.16 -0.03; 0.35 0.105 
Serum potassium  -0.65 -1.82; 0.53 0.281 
Serum bicarbonate  -0.34 -0.53; -0.15 0.001 
 GEE β (DBP)*  95% CI β P value  
Adjusted serum chloride  -0.01 -0.11; 0.10 0.876 
Serum sodium  0.15 0.05; 0.25 0.003 
Serum potassium  -1.23 -1.85; -0.61 <0.001 
Serum bicarbonate  -0.19 -0.29; -0.09 <0.001 
*per one unit (1 mEq/L) increase in serum electrolytes. Number of groups in the 
analyses=3599 and average number of blood pressure observations in each groups=5.2.  
 
Table 6-7: Person years of follow-up and mortality event rates stratified by chloride categories 
in quintiles. 
Follow-up and 
event rates  
Cl<=100 
(N=3085) 
Cl=101-
102 
(N=2670) 
Cl=103-
104 
(N=3228) 
Cl=105-
106 
(N=2508) 
Cl>=107  
(N=1477) 
Total 
(N=12968) 
Person years of 
follow-up (p-y) 
 
50700.86 43858.01 48665.01 35664.03 18170.12 197101.81 
IHD mortality, 
(95% CI) 
 
9.96  
(9.13-
10.87) 
6.34  
(5.64-
7.13) 
5.96  
(5.31-
6.69) 
4.88  
(4.21-
5.66) 
5.34  
(4.38-
6.51) 
6.82  
(6.47-7.20) 
Stroke mortality, 
(95% CI) 
 
4.46  
(3.91-
5.08) 
2.90  
(2.43-
3.45) 
2.65  
(2.23-
3.15) 
2.66  
(2.18-
3.26) 
2.75  
(2.09-
3.63) 
3.18  
(2.94-3.44) 
CV mortality, (95% 
CI) 
 
18.19  
(17.05-
19.40) 
11.86  
(10.88-
12.92) 
10.46  
(9.59-
11.41) 
9.11  
(8.17-
10.16) 
10.07  
(8.71-
11.64) 
12.48  
(12.00-
12.98) 
Non-CV mortality, 
(95% CI) 
 
11.16  
(10.28-
12.12) 
7.80  
(7.01-
8.67) 
7.38  
(6.65-
8.18) 
6.65  
(5.85-
7.55) 
7.93  
(6.73-
9.33) 
8.36  
(7.97-8.77) 
All-cause 
mortality, (95% CI) 
29.35  
(27.90-
30.88) 
19.65  
(18.39-
21.01) 
17.84  
(16.69-
19.06) 
15.76  
(14.51-
17.12) 
17.80  
(16.15-
20.06) 
20.84  
(20.21-
21.49) 
Mortality rates are given as deaths/1000 person years (p-y). Cl=Serum chloride, 
CVD=Cardiovascular disease and IHD=ischemic heart disease 
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Table 6-8: Cox regression analysis for the association between serum chloride and mortality.  
 All-cause mortality CV mortality IHD mortality Stroke Mortality Non-CV mortality 
 N=3434/11043 N=2019/11043 N=1132/11043 N=485/11043 N=1415/11043 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Baseline Serum Chloride (Model 1) 0.97* 0.96-98 0.97* 0.96-0.99 0.97* 0.96-0.99 0.99 0.97-1.02 0.97* 0.96-0.99 
 N=3373/9035 N=1993/9035 N=1119/9035 N=477/9035 N=1380/9035 
Baseline Serum Chloride (Model 2) 0.98* 0.97-0.99 0.98* 0.97-0.99 0.97* 0.96-0.99 0.99 0.97-1.02 0.98* 0.96-0.99 
 N=3373/9035 N=1993/9035 N=1119/9035 N=477/9035 N=1380/9035 
Baseline Serum Chloride (Model 3) 0.97* 0.96-0.98 0.97* 0.96-0.99 0.97* 0.95-0.99 0.99 0.97-1.03 0.97* 0.95-0.99 
Baseline Serum Chloride (Model 4) N=3373/9035 N=1993/9035 N=1119/9035 N=477/9035 N=1380/9035 
Serum Chloride <=100 1   1   1   1   1   
Serum Chloride =101-102 0.82* 0.73-0.90 0.83* 0.73-0.94 0.81* 0.68-0.96 0.84 0.64-1.09 0.81* 0.69-0.94 
Serum Chloride =103-104 0.79* 0.71-0.87 0.79* 0.69-0.90 0.88 0.74-1.05 0.80 0.61-1.06 0.78* 0.67-0.92 
Serum Chloride =105-106 0.79* 0.70-0.89 0.79* 0.67-0.92 0.76* 0.62-0.95 1.03 0.75-1.40 0.80* 0.66-0.96 
Serum Chloride >=107 0.80* 0.68-0.93 0.79* 0.64-0.97 0.77 0.58-1.01 1.07 0.73-1.58 0.81 0.64-1.03 
Baseline Serum Chloride (Model 5) N=3373/9035 N=1993/9035 N=1119/9035 N=477/9035 N=1380/9035 
Serum Chloride <=100 1   1   1   1   1   
Serum Chloride =101-102 0.82* 0.74-0.90 0.83* 0.73-0.94 0.81* 0.68-0.96 0.84 0.64-1.09 0.81* 0.69-0.94 
Serum Chloride =103-104 0.79* 0.71-0.87 0.79* 0.69-0.91 0.88 0.74-1.05 0.80 0.61-1.06 0.78* 0.66-0.91 
Serum Chloride =105-106 0.79* 0.70-0.89 0.79* 0.67-0.93 0.77* 0.62-0.95 1.03 0.76-1.41 0.79* 0.65-0.95 
Serum Chloride >=107 0.80* 0.68-0.93 0.79* 0.65-0.97 0.77 0.58-1.02 1.08 0.73-1.59 0.81 0.64-1.03 
*p value <0.05, Model 1 is adjusted for age at first visit, gender, BMI=body mass index, baseline cardiovascular disease, CKD=Chronic kidney disease, 
tobacco smoking, alcohol use, year of first visit (epochs), SBP=systolic blood pressure, DBP=diastolic blood pressure, and achieved SBP. Model 2 is 
adjusted for all variables in model 1 and anion gap. Model 3 is adjusted for all variables in model 1 and serum sodium, serum potassium and serum bi-
carbonate. Model 4 is same as model 3 but the serum chloride was considered as a categorical variable in quintiles. Model 5 is adjusted for all variables in 
model 5 and consistent diuretic use in the first five years of follow-up (Cox model stratified for diuretics use).  CVD=Cardiovascular disease and 
IHD=ischemic heart disease, HR=hazard Ratio, CI=confidence interval.    
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Figure 6-2: Kaplan Meir survival curves of serum chloride in quintiles.  
 
 
Figure 6-3: Kaplan Meir survival curves of adjusted serum chloride in quintiles. 
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Figure 6-4: Serum chloride stratified by sodium and cumulative mortality.   
 
Figure 6-5: Serum chloride stratified by bicarbonate levels and cumulative mortality.  
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Figure 6-6: Log-Log survival curves of serum chloride in quintiles  
 
 
Figure 6-7: Regression spline Cox-PH model for all-cause mortality and serum chloride.  
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6.3.5 Serum sodium and mortality outcomes  
The shortest survival time was observed in the fifth quintile of serum chloride in 
the unadjusted Kaplan-Meir analysis (log rank P<0.001) (Figure 6-8 on page 191). 
There was no deviation from the proportional hazard assumption (Figure 6-9 on 
page 192). However, there was no significant relationship with serum sodium 
and all-cause mortality in the multivariate adjusted regression spline Cox-PH 
model (Figure 6-10 on page 192).  
 
Figure 6-8: Serum sodium in quintiles and cumulative mortality  
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Figure 6-9: Log-log survival curves of serum sodium in quintiles  
 
Figure 6-10: Regression spline Cox-PH model for serum sodium and all-cause mortality.  
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6.3.6 Serum potassium and mortality outcomes  
The shortest survival time was observed in the fifth quintile of serum potassium 
in the unadjusted Kaplan-Meir analysis (log rank P<0.001) (Figure 6-11 on page 
193). There was no deviation from the proportional hazard assumption (Figure 6-
12 on page 194). In the multivariate adjusted regression spline Cox-PH model, 
there was a non-linear 'U' shaped relationship between serum potassium and 
mortality  (Figure 6-13 on page 194). 
 
Figure 6-11: Serum potassium in quintiles and cumulative mortality. 
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Figure 6-12: Log--log survival curves of serum potassium in quintiles.  
 
Figure 6-13: Regression spline Cox-PH model for serum potassium and all-cause mortality.  
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6.3.7 Serum bicarbonate and mortality outcomes  
The shortest survival time was observed in the fifth quintile of serum 
bicarbonate in the unadjusted Kaplan-Meir analysis (log rank P<0.001) (Figure 6-
14 on page 195). A positive linear relationship was evident in the KM survival 
analysis of adjusted serum bicarbonate in quintiles (Figure 6-15 on page 196). 
There was no deviation from the PH assumption (Figure 6-16 on page 196). In the 
multivariate adjusted regression spline Cox-PH model, there was positive linear 
increase in mortality with adjusted serum bicarbonate (Figure 6-17 on page 197).  
 
Figure 6-14: Serum bicarbonate in quintiles and cumulative mortality.  
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Figure 6-15: Adjusted serum bicarbonate in quintiles and mortality.  
 
Figure 6-16: Log-log survival curves for serum bicarbonate in quintiles.  
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Figure 6-17: Regression spline Cox-PH model for adjusted serum bicarbonate and all-cause 
mortality.  
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in the BIRNH study. Furthermore, even in multivariate models after 
incorporating all confounding variables serum chloride remained a significant 
predictor of all-cause, CV and non-CV mortality outcomes. Consistent findings 
are reported in individuals with heart failure 627. The present study, involving a 
larger sample with longer follow-up (35 year of follow-up and median survival 
time of 30 years), confirms this relationship in a hypertensive cohort 
independent of other risk factors.  
In order to maintain electro-neutrality, chloride deficiency often leads to 
increased absorption of bicarbonate 621 638.  Sodium and potassium levels also 
influence chloride absorption so as to maintain the cation-anion balance. 
Therefore, other electrolytes can act as confounders in the relationship between 
serum chloride and mortality outcomes. Furthermore, most acid-base disorders 
cause opposite and equal changes in serum chloride and bicarbonate 
concentrations, and this inverse relationship is influenced by changes in the 
anion gap and/or water balance 637. The findings of the present study are 
consistent in different models even after adjustment for other electrolytes and 
anion gap. They are also supported by the recent report that higher anion gap 
(which can be associated with low chloride) in early CKD is a marker of early 
mortality 639. Moreover, the risk posed by low chloride in the present study is 
independent of concomitant sodium or bicarbonate levels, suggesting that this is 
a chloride specific finding and does not reflect risks associated with 
hyponatremia or acid-base disturbances.  
Diuretics such as frusemide and thiazides interfere with re-absorption of chloride 
in the renal tubules 640. During diuretic use, urinary loss of chloride exceeds that 
of bicarbonate. As our study population were treated hypertensive patients, 
confounding due to diuretic use is a likely possibility. However, only 22% of 
patients in the present study were on diuretics at the first visit when serum 
chloride was measured, and the relationship between low chloride and mortality 
persisted even when the analyses were stratified for diuretic use.  Moreover, we 
attempted to adjust the chloride levels for free water changes that are 
commonly induced by diuretic use and found that the relationship persisted with 
adjusted chloride. The observed association of low serum chloride with mortality 
is therefore independent of all known potential confounders including diuretic 
use.  
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All-cause, CV, IHD and non-CV mortality outcomes were significantly higher 
among individuals with low serum chloride in comparison with individuals with 
higher serum chloride in our study. However, the mechanisms by which chloride 
influences mortality outcomes are not clear. High anion-gap and the 
corresponding low levels of serum chloride are associated with inflammatory 
markers such as higher leukocyte count and higher C-reactive protein level in 
healthy individuals 641. Higher levels of inflammatory biomarkers are associated 
with increased mortality and the development of CVD 642 643. However further 
studies are required to understand the role of inflammatory markers in 
mediating the relationship between low serum chloride and mortality.  
Contrasting findings are reported in the literature on the association between 
dietary chloride intake and BP in animal models. While earlier studies did not 
find any association of dietary chloride with BP independent of dietary sodium 
content 622, some of the new animal studies suggest an independent positive 
association 624-626. It is also relevant to note that normal BP is a characteristic 
feature of Bartter syndrome despite its association with selective chloride 
deprivation and salt wasting. It is however not clear whether dietary chloride 
increases BP by some mechanisms other than by influencing the renal tubular re-
absorption of chloride. By contrast, high anion gap and the corresponding low 
serum chloride levels are associated with higher BP 629. In the present study 
serum chloride showed no independent effect on BP change over time. Hence we 
believe the findings on association of chloride and mortality are not confounded 
by BP control. 
There is a near perfect negative correlation between serum chloride (adjusted) 
and bicarbonate (adjusted) after corrections for serum sodium and anion gap. 
Serum bicarbonate also shows a positive linear increase in mortality with 
increasing bicarbonate levels in the present study. Consistent to these 
observations, high serum bicarbonate level are associated with mortality in both 
stage 3 and stage 4 chronic kidney disease patients 470. By contrast, each unit 
increase in serum bicarbonate within the normal range was associated with 
reduced risk of death and progression to CKD among African Americans 644. 
However, in both of the above mentioned studies the serum bicarbonate level 
was not corrected for serum sodium and anion gap.  
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Serum potassium independently predicts mortality and the relationship is non-
linear in the present study with elevated mortality risk at both ends of the 
distribution.  Higher levels of potassium increase mortality despite achieving 
greater BP reduction during follow-up. Similar findings on BP are reported in 
other studies in hypertensive population 645. Consistent results on mortality are 
seen in individuals with myocardial infarction 646, heart failure 647 648, abnormal 
renal function 649and individuals selected from the general population 461 462.   
6.5 Strengths and limitations  
A large cohort of nearly 13,000 hypertensive adults, 35 years of follow-up with 
median survival time of 30 years, ability to link serum electrolytes with differing 
causes of mortality outcomes and most importantly the competence to model 
the potential non-linear association of serum chloride on mortality outcomes are 
the strengths of our study.  
The exclusion of individuals without serum chloride assessed at baseline from 
the analyses, and the bias introduced by the missing covariates in the adjusted 
Cox-PH models are the major limitations. The present study was conducted in a 
treated hypertensive cohort and hence the results may not be generalisable 
even though the prevalence of hypertension in the adult population is high. Long 
term estimates of mortality based on a single measurement of serum 
electrolytes at baseline would have introduced some bias. A time-dependent 
analysis on serum electrolytes on mortality is required to establish the 
association of serum electrolytes and mortality outcomes.  
6.6 Summary  
In summary, serum chloride is an independent predictor of mortality outcomes in 
hypertensive population. Although the relationship with mortality outcomes are 
non-linear across the entire range of serum chloride, an inverse linear 
relationship of serum chloride levels below 100 mEq/L with mortality outcomes 
is evident. Similar studies in other population are required to confirm this 
independent association. Further studies are also necessary to elucidate the 
underlying mechanisms involved in the association of low serum chloride levels 
with mortality outcomes.  
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7 Indices of liver dysfunction or injury and 
mortality  
7.1 Introduction  
Serum albumin, alanine transaminase (ALT), aspartate transaminase (AST), 
gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and bilirubin are 
widely used markers of liver function or injury to liver cells 650.  While serum 
albumin levels indicate liver function, the enzymes transaminases are associated 
with the integrity of liver cells. Serum GGT and alkaline phosphatase (ALP) are 
markers of biliary tract diseases. Serum bilirubin is a marker of hepatic 
processing of haemoglobin breakdown products. All of them are components of 
the panel of laboratory assays performed to assess liver function, but except for 
albumin and bilirubin these are not specific markers of liver function. Clearly an 
elevation of any of these liver tests notionally above twice the upper limit of 
normal (ULN) is an indicator of liver disease that may have an adverse impact on 
survival. Infection, non-alcoholic fatty liver disease (NAFLD) and alcoholic liver 
disease are the commonest causes of deranged liver tests that are consequently 
associated with early mortality.   
Abnormal liver enzymes not only indicate liver injury or dysfunction, but also 
significant predictors of mortality outcomes in the general population.  The 
enzyme ALT is a more specific marker of hepatocyte damage and is involved in 
catalyzing the transfer of amino groups to generate products in gluconeogenesis 
and amino acid metabolism. Limited evidence suggests that ALT is the liver 
enzyme most closely associated with liver fat content and NAFLD 651. High ALT 
levels have been associated with increased risk of diabetes 652, metabolic 
syndrome 653 and mortality in the general population 654. In the NHANES-III 
cohort, the HR for all-cause mortality among participants with unexplained 
elevation of ALT (attributed to NAFLD) was 1.37 [95% confidence interval (CI) 
0.98, 1.91] compared with other participants 485. ALT is also found to be 
associated with mortality among participants with a BMI below the median (22.7 
kg/m2) in a Japanese cohort, but not among participants with a BMI at or 
greater than the median 655. By contrast, Ford et al recently demonstrated an 
inverse relationship with ALT within the normal range and total mortality, in 
middle-to-older aged subjects, independent of traditional cardiovascular risk 
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factors in three independent populations 656. Furthermore, a non-linear 
relationship with ALT and mortality is emerging 654 656-659 and further studies are 
warranted to model this potential complex relationship.  
While abnormal AST levels well above the upper limit of normal range are 
associated with increased mortality, AST in the normal range was associated 
with lower than expected mortality 654. This association has not been studied in 
detail across the entire range of AST using appropriate survival analysis methods.  
Although GGT has long been considered a marker of excessive alcohol intake, 
recently it has been suggested to reflect oxidative stress 660.  It is linked to 
NAFLD 659 661, metabolic syndrome 659 662 and coronary heart disease 659 663. The 
independent associations of GGT with mortality 489-491 664 665 is well established. 
Alkaline phosphatase (ALP) is an enzyme in the cells lining the biliary duct of the 
liver 650.   Although, ALP is part of the routine liver function test assay, it is 
elevated in both obstructive liver conditions and bone disorders.  Serum ALP is 
associated with coronary artery calcification 666 and cardiovascular mortality 478. 
Multiple studies confirm the independent association of serum ALP with 
mortality 476 667.   
Serum bilirubin is also routinely measured as it is traditionally part of the panel 
of markers in the regular liver function test 650. Serum bilirubin levels are 
determined by enzymes involved in bilirubin production, namely heme 
oxygenase and uridine diphosphate–glucuronosyltransferase 1 (UGT1A1). The 
former is involved in production of bilirubin from haemoglobin, and the latter 
convert insoluble bilirubin to a form suitable for renal and biliary excretion 668 
669. Bilirubin has been shown to be an effective antioxidant both in vitro 670 and 
in vivo 671.  As an antioxidant, it has been shown to suppress the oxidation of 
lipids and lipoproteins, especially LDL cholesterol 672, and to be directly related 
to the total serum antioxidant capacity in humans 673.  Serum bilirubin is 
inversely associated with both cardiovascular diseases 493-495 674 675 and cancer 496 
in cross-sectional epidemiological studies. In the Korean Longitudinal study of 
Health and Aging (KLoSHA), the group with high serum bilirubin and low ALP had 
better survival rates in comparison to the group with low bilirubin and high ALP 
676. It is not clear whether this relationship is independent of potential 
confounding factors associated with mortality in this population. Consistent 
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findings of association between serum bilirubin levels and mortality have been 
reported in other studies 497 677. 
Hypertension is a global public health problem that affects one in four 
individuals worldwide and contributes to 7.6 million deaths annually 293. Liver 
function tests are frequently conducted in outpatient settings in the 
management of hypertension. However, the usefulness of these markers in 
predicting long-term mortality outcomes in hypertensive population has not 
been studied in detail. The aim of this study was to describe the long-term 
mortality outcomes and their association with liver enzymes and serum bilirubin 
in a large treated hypertensive cohort.  
7.2 Methods  
7.2.1 Study setting and study population  
The Glasgow blood pressure clinic (GBPC) database has information on more 
than 15,000 hypertensive patients. More details of the study settings, population 
and study measurements are described in section 2.1-2.3.  
7.2.2 Laboratory measurements  
Venous blood samples were collected at baseline and at regular intervals for 
estimation of routine hematological and biochemical indices, including liver 
function and renal function tests. Liver function tests were part of the initial 
assessment of patients and were measured centrally by the Western Infirmary 
central clinical laboratory services.  All biochemical analyses were performed in 
auto-analysers using standardised estimation methods. More details are provided 
in section 2.4.  
7.2.3 Outcome assessment  
Outcome assessment is described in section 2.5.  
7.2.4 Statistical analysis 
All analyses were restricted to individuals in the database with at least one of 
the liver enzymes assessed at the registration visit (N=12,000).  Analyses were 
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performed in the overall population and in the subset after excluding individuals 
with high liver test values - defined as  AST > 100mg/dl (n=665, 5.7%) and/or ALT 
> 100mg/dl (n=115, 1.2%) and /or GGT > 100mg/dl (n=665, 6.4%) and/or ALP > 
240mg/dl (n=977, 8.6%) and/or bilirubin>30mg/dl (n=145, 1.3%). The 
distributions of liver enzymes were observed in the remaining dataset (AST, 
N=11059; ALT, N=9832; ALP, N=11362; GGT, N=10454; bilirubin, N=10890) using 
histograms.  All except serum albumin showed non-normal distributions and 
were logarithmically transformed for analysis. The detailed study flow chart is 
presented in figure 7-1 on page 207.  
The characteristics of the study population in men and women were compared 
using independent 't' tests and analysis of variance, where appropriate, for 
continuous variables and Chi-Square tests for categorical variables. The study 
population was divided into groups based on quartiles of serum liver enzymes. 
Kaplan-Meier (KM) time to event curves were generated for each liver enzyme 
variable in quartiles as explained in section 2.6.1.  Cox proportional hazard (Cox-
PH) models were used to analyse the influence of baseline liver enzymes on all-
cause, CV, IHD, stroke and non-CV mortality (details are provided in section 
2.6.2). The covariates included were baseline age, sex, BMI, smoking status 
(never versus ever), SBP, DBP, alcohol use, eGFR and final achieved SBP. A 
variable on year of first visit strata (epochs) was used to adjust the secular trend 
in mortality and was divided into five categories (first visit 1977 or before, 
between years 1978-1985, 1986-1993, 1994-2001, 2002 and thereafter). The PH 
assumption was assessed (as explained in section 2.6.3) through examination of 
log-minus-log plots (23). Initially, the liver enzymes were assessed as categorical 
variables in quartiles (Models 1-5) adjusted for the described covariates. Next 
the analysis was repeated with inclusion of all other liver function variables as 
covariates (Models 6 and 7).  
Given the non-linear relationship of the liver function variables and time to 
mortality, a regression spline model was also employed to further smoothen the 
hazard functions. The relative log hazard functions with associated 95% 
confidence intervals were plotted in a graph. Details of regression spline models 
are provided in section 2.6.4. In order to elucidate the independent effects of 
ALT, bilirubin and GGT on mortality, the regression spline models were 
performed in sub-groups stratified by age, smoking, BMI and alcohol status.  
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Regression modelling with generalised estimating equations (GEE) was used to 
study the association of markers of liver dysfunction or injury with follow-up BP. 
Initially, individuals with at least four annual BP assessments in the first five 
years of follow-up and survival up to a minimum of five years period were 
selected. Particulars of the GEE model are explained in detail in section 2.7.1. 
Separate GEE models were used to study the relationship between liver 
biochemistry variables and follow-up SBP and DBP. The association was adjusted 
for baseline age, sex, epochs, alcohol and tobacco use, and eGFR based renal 
function in all models. All non-missing pairs of data were used in estimating the 
working correlation parameters. The models were repeated after stratifying the 
population based on different baseline variables such as age, body mass index, 
alcohol use status and smoking status. Stata Version 12.0 (Statacorp) was used 
for all statistical analysis.  
7.3 Results  
7.3.1 Baseline characteristics of the study population  
The study population was middle aged (mean age=50.8 years), overweight (mean 
BMI=27.6 kg/m2), and hypertensive (mean SBP=164 and DBP=97 mmHg).  It 
comprised a relatively lower proportion of men (47%) than women (53%). While 
44% were smokers, nearly two thirds (60%) drank more than 6 units of alcohol 
per week.  The achieved BP after five years of follow-up was significantly lower 
than the baseline BP (achieved SBP=148 and DBP=88 mmHg). The full 
demographic and clinical characteristics are given in table 7-1 on page 206.  
Tables 7-2 to 7-6 (pages 208-211) provide demographic and clinical 
characteristics stratified by quartiles of liver function/injury markers.  ALT 
levels decreased with age in contrast to GGT and ALP which increased. Bilirubin 
showed no age relationship and AST showed a non-linear association.  ALT, GGT 
and ALP showed a linear increase with BMI while bilirubin and AST did not. All 
the liver tests were higher in men compared to women. A greater proportion of 
individuals who consume alcohol >6units/week were present in the higher 
quartiles of ALT, AST, GGT and Bilirubin but not ALP which showed a reverse 
association with alcohol use. ALT, ALP and Bilirubin showed an inverse linear 
association with SBP but a direct association with DBP. GGT showed no 
association with SBP, but showed a direct association with DBP. AST showed no 
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association with BP. CKD (eGFR<60) prevalence was significantly lower in the 
higher quartiles of all liver tests. GGT and ALP levels were higher and bilirubin 
lower among smokers. There was no association between transaminases and 
smoking. 
7.3.2 Survival characteristics  
The total time at risk was 173805.67 person years (p-y) with median survival 
time of 32.19 years. The incidence rates were 17.59 (95% CI: 16.98-18.22), 10.08 
(95% CI: 9.62-10.56), 5.40 (95% CI: 5.07-5.76), 2.50 (2.27-2.74), and 7.51 (7.11-
7.93) per 1000 p-y of follow-up for all-cause, CV, IHD, stroke and non-CV 
mortality outcomes, respectively.  
Table 7-1: Baseline characteristics of the study population  
Variables  Total (N=12,000) Men (N=5680)  Women (N=6320) P Value  
Age yrs,  (SD) 50.88 (14.51)  49.87 (13.28) 51.79 (15.48) <0.001  
BMI kg/m2,  (SD) 27.79 (5.82)  27.86 (5.26)  27.73 (6.27)  0.23 
Smoking, n (%) 5254 (44.63)  2719 (48.89)  2535 (40.81)  <0.001 
Alcohol >6, n (%) 6676 (58.62)  3967 (73.56)  2709 (45.19)  <0.001  
SBP mmHg,  (SD) 163.53 (28.45)  161.78 (26.69)  165.10 (29.86)  <0.001  
DBP mmHg,  (SD) 96.91 (17.89)  98.00 (14.62)  95.93 (20.33)  <0.001  
TC mmol/l,  (SD) 5.94 (1.47)  5.83 (1.58)  6.03 (1.35)  <0.001 
eGFR, M (IQR) 72.59 (60.92-84.60) 75.54 (64.07-87.42) 69.68 (58.33-82.05) <0.001  
ALP IU/L, M (IQR) 125.0 (78.1-183.0) 125.0 (78.1-181.0) 125 (78.1-185.0) 0.91 
ALT IU/L, M (IQR) 24.0 (17.0-34.0) 29.0 (21.0-41.0)  20.0 (15.0-28.0)  <0.001  
AST IU/L, M (IQR) 23.0 (18.0-28.0)  25.0 (20.0-31.0) 21.0 (17.0-26.0)  <0.001 
GGT IU/L, M (IQR) 27.0 (17.0-45.0)  34.0 (22.0-57.0)  21.0 (15.0-34.0)  <0.001  
Bilirubin µmol/l, M (IQR) 10.0 (7.0-13.0) 11.0 (8.0-14.0) 9.0 (7.0-12.0) <0.001 
Albumin g/L,  (SD) 43.82 (3.79) 44.35 (3.87) 43.34 (3.65) <0.001 
Last SBP mmHg,  (SD) 147.97 (22.46)  146.67 (21.30) 149.14 (23.39) <0.001 
Last DBP mmHg,  (SD) 87.93 (11.85)  88.78 (11.77) 87.17 (11.88) <0.001 
:;=mean, M=median, n=number of individuals, SD=standard deviation, SBP=systolic blood 
pressure, DBP=diastolic blood pressure, TC=total cholesterol, IQR=interquartile range, 
ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate transaminase, 
GGT=gamma gultamyl transferase.   
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Figure 7-1: Study flow chart  
*Numbers included in the cubic regression spline models. 
Excluded (n=408): 
ALT>100 mg/dl.  
N=12000 
Glasgow Blood Pressure Clinic (GPBC) 
Database: N=16011 
Excluded (n=4011): Missing data on any of 
the five liver enzymes  
ALP*: 
N=11426 N=10385 
Q1: 2751 
Q2: 2957 
Q3: 2828 
Q4: 1849 
 
Excluded (n=10341): 
ALP>240 mg/dl.  
ALT*: 
N=10125 N=9717 
Q1: 2168 
Q2: 3034 
Q3: 2184 
Q4: 2331 
 
AST*: 
N=11257 N=11059 
Q1: 2794 
Q2: 2582 
Q3: 2945 
Q4: 2738 
 
Excluded (n=198): 
AST>100 mg/dl.  
GGT*: 
N=10551 N=9789 
Q1: 2385 
Q2: 3040 
Q3: 2384 
Q4: 1980 
 
Excluded (n=762): 
GGT>100 mg/dl.  
Bilirubin*: 
N=10890 N=10890 
Q1: 2845 
Q2: 3348 
Q3: 2381 
Q4: 2316 
 
Excluded (n=145): 
Bili>130 mg/dl.  
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Table 7-2: Baseline characteristics of the study population, stratified by ALT quartiles.  
 
ALT<=16 U/L  
(n=2168) 
ALT 17-24 U/L  
(n=3034) 
ALT 25-34 U/L  
(n=2184) 
ALT>=35 U/L  
(n=2331) 
p value  
Age yrs, mean (SD) 53.24 (16.38) 52.80 (14.45) 50.83 (12.50) 47.89 (12.11) <0.001 
Men, n(%) 578 (26.7) 1212 (40.0) 1232 (56.4) 1618 (69.4) <0.001 
BMI kg/m2, mean (SD) 26.21 (5.44) 27.41 (6.09) 28.25 (5.48) 29.22 (5.57) <0.001 
Smoking, n(%) 950 (45.1) 1316 (44.0) 962 (44.7) 1022 (44.9) 0.881 
Alcohol >6 units, n(%) 1064 (51.9) 1582 (54.6) 1325 (63.7) 1591 (71.8) <0.001 
SBP mmHg, mean (SD) 167.45 (29.72) 166.60 (28.68) 164.20 (27.77) 161.08 (25.93) <0.001 
DBP mmHGg, mean (SD) 96.07 (15.29) 96.73 (14.92) 98.19 (23.23) 98.36 (13.94) <0.001 
TC mmol/l, mean (SD) 5.84 (1.33) 5.92 (1.27) 6.01 (1.92) 6.08 (1.51) 0.011 
eGFR<60, n(%) 667 (31.0) 834 (27.7) 444 (20.5) 355 (15.4)  <0.001 
ALP IU/L, M (IQR) 113 (71-174) 123 (78-182) 122 (78-180) 121 (78-184) <0.001 
AST IU/L, M (IQR) 18 (16-22) 21 (18-25) 25 (21-29) 31 (26-40) <0.001 
GGT IU/L, M (IQR) 18 (13-26) 23 (16-35) 31 (21-48) 46 (28-80) <0.001 
Bilirubin µmol/l, M (IQR) 9 (7-11) 9 (7-12) 10 (8-13) 11 (8-14) <0.001 
Albumin g/L, mean (SD) 42.81 (3.66) 43.40 (3.95) 44.10 (3.51) 44.61 (3.64) <0.001 
SD=standard deviation, M=Median, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, 
eGFR=estimated glomerular filtration rate, IQR=interquartile range, ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate transaminase, 
GGT=gamma gultamyl transpeptidase.   
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Table 7-3: Baseline characteristics of the study population, stratified by AST quartiles. 
 
AST<=18 U/L 
(n=2794) 
AST 19-22 U/L  
(n=2582) 
ALT 23-28 U/L  
(n=2945) 
AST>=29 U/L  
(n=2738) 
p value  
Age yrs, mean (SD) 49.99 (14.98) 52.41 (15.07) 52.11 (14.16) 49.69 (13.25) <0.001 
Men, n(%) 916 (32.8) 1084 (42.0) 1535 (52.1) 1715 (62.3) <0.001 
BMI kg/m2, mean (SD) 27.39 (6.07) 27.38 (5.54) 27.87 (5.54) 28.49 (5.79) <0.001 
Smoking, n(%) 1277 (46.5) 1152 (45.4) 1250 (43.5) 1188 (44.3) 0.105 
Alcohol >6 units, n(%) 1458 (54.8) 1351 (55.1) 1609 (58.0) 1769 (68.5) <0.001 
SBP mmHg, mean (SD) 165.28 (29.68) 164.29 (28.18) 164.03 (27.47) 163.07 (27.60) 0.406 
DBP mmHGg, mean (SD) 96.97 (15.37) 96.03 (14.15) 96.86 (14.39) 98.57 (21.62) 0.112 
TC mmol/l, mean (SD) 5.87 (1.31) 5.90 (1.26) 5.91 (1.28) 6.06 (1.80) 0.325 
eGFR<60, n(%) 704 (25.5) 670 (26.2) 723 (24.8) 515 (19.0)  <0.001 
ALP IU/L, M(IQR) 114 (71-173) 126 (79-180) 131 (82-187) 135 (83-193) <0.001 
ALT IU/L, M(IQR) 16 (13-21) 20 (16-25) 26 (20-34) 40 (28-55) <0.001 
GGT IU/L, M(IQR) 20 (14-30) 23 (16-35) 27 (18-42) 45 (26-79) <0.001 
Bilirubin µmol/l, M (IQR) 9 (6-11) 10 (7-12) 10 (8-13) 11 (8-14) <0.001 
Albumin g/L, mean (SD) 43.13 (3.84) 43.60 (3.40) 44.09 (3.67) 44.59 (3.65) <0.001 
SD=standard deviation, M=median, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, 
eGFR=estimated glomerular filtration rate, IQR=interquartile range, ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate transaminase, 
GGT=gamma gultamyl transpeptidase.   
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Table 7-4: Baseline characteristics of the study population, stratified by GGT quartiles.  
 
GGT<=18 U/L 
(n=2385) 
GGT 19-22 U/L  
(n=3040) 
ALT 23-28 U/L  
(n=2384) 
GGT>=29 U/L  
(n=1980) 
p value  
Age yrs, mean (SD) 48.75 (16.68) 52.51 (15.03) 52.42 (13.80) 51.07 (12.78) <0.001 
Men, n(%) 562 (23.6) 1266 (41.6) 1366 (57.3) 1273 (64.3) <0.001 
BMI kg/m2, mean (SD) 26.25 (5.32) 27.82 (5.84) 28.50 (5.93) 29.44 (6.09) <0.001 
Smoking, n(%) 830 (35.2) 1249 (41.8) 1138 (48.5) 997 (51.6) <0.001 
Alcohol >6 units, n(%) 1064 (46.8) 1468 (51.0) 1313 (58.3) 1258 (67.8) <0.001 
SBP mmHg, mean (SD) 159.94 (28.31) 162.31 (27.82) 162.72 (27.18) 161.94 (26.53) 0.164 
DBP mmHGg, mean (SD) 94.59 (14.37) 95.12 (19.23) 96.05 (13.58) 97.79 (23.69) <0.001 
TC mmol/l, mean (SD) 5.68 (1.25) 5.83 (1.26) 5.90 (1.50) 6.14 (1.28) <0.001 
eGFR<60, n(%) 565 (24.1) 777 (26.0) 545 (23.2) 382 (19.6)  <0.001 
ALP IU/L, M (IQR) 108 (70-159) 133 (84-184) 141 (87-194) 146 (92-200) <0.001 
ALT IU/L, M (IQR) 18 (14-23) 21 (16-28) 26 (19-35) 32 (23-46) <0.001 
AST IU/L, M (IQR) 20 (17-24) 21 (18-26) 23 (19-28) 27 (21-34) <0.001 
Bilirubin µmol/l, M (IQR) 9 (7-12) 10 (7-13) 10 (8-13) 10 (8-13) <0.001 
Albumin g/L, mean (SD) 43.36 (3.86) 43.65 (3.65) 44.17 (3.48) 44.32 (3.62) <0.001 
SD=standard deviation, M=median, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, 
eGFR=estimated glomerular filtration rate, IQR=interquartile range, ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate transaminase, 
GGT=gamma gultamyl transpeptidase.   
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Table 7-5: Baseline characteristics of the study population, stratified by ALP quartiles.  
 
ALP<=78 U/L 
(n=2751) 
ALP 79-125 U/L 
(n=2957) 
ALP 126-183 U/L 
(n=2828) 
ALP>=184 U/L  
(n=1849) 
p value  
Age yrs, mean (SD) 48.31 (13.88) 50.67 (13.86) 51.14 (14.52) 52.94 (14.87) <0.001 
Men, n(%) 1302 (47.3) 1409 (47.7) 1378 (48.7) 925 (50.0) 0.266 
BMI kg/m2, mean (SD) 26.85 (5.20) 27.43 (5.59) 28.18 (5.68) 28.64 (6.36) <0.001 
Smoking, n(%) 1075 (40.3) 1310 (45.3) 1194 (42.8) 880 (48.1) <0.001 
Alcohol >6 units, n(%) 1801 (69.1) 1788 (63.3) 1449 (54.7) 935 (53.5) <0.001 
SBP mmHg, mean (SD) 164.66 (28.23) 165.93 (29.17) 160.33 (26.96) 163.70 (27.65) <0.001 
DBP mmHGg, mean (SD) 98.04 (15.40) 98.01 (14.72) 96.8 (20.88) 96.31 (14.11) <0.001 
TC mmol/l, mean (SD) 6.00 (1.50) 6.03 (1.31) 5.80 (1.21) 5.91 (1.99) 0.002 
eGFR<60, n(%) 565 (24.1) 777 (26.0) 545 (23.2) 382 (19.6)  <0.001 
ALT IU/L, M (IQR) 22 (16-34) 24 (17-35) 23 (17-34) 24 (18-35) <0.001 
AST IU/L, M (IQR) 22 (17-28) 23 (18-28) 23 (19-29) 24 (20-30) <0.001 
GGT IU/L, M (IQR) 22 (14-36) 26 (17-43) 27 (18-46) 30 (20-49) <0.001 
Bilirubin µmol/l, M (IQR) 9 (7-12) 9 (7-12) 11 (8-14) 10 (8-13) <0.001 
Albumin g/L, mean (SD) 43.46 (4.05) 43.56 (3.76) 44.28 (3.39) 44.29 (3.59) <0.001 
SD=standard deviation, M=median, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, 
eGFR=estimated glomerular filtration rate, IQR=interquartile range, ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate transaminase, 
GGT=gamma gultamyl transpeptidase.   
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Table 7-6: Baseline characteristics of the study population, stratified by bilirubin quartiles.  
 
Bili<=7 U/L  
(n=2845) 
Bili 8-10 U/L  
(n=3348) 
Bili 10.1-13 U/L  
(n=2381) 
Bili>=13.1 U/L  
(n=2316) 
p value  
Age yrs, mean (SD) 50.88 (14.60) 51.70 (14.56) 51.37 (14.23) 50.10 (14.50) 0.587 
Men, n(%) 890 (31.3) 1448 (43.3) 1307 (54.9) 1502 (64.9) <0.001 
BMI kg/m2, mean (SD) 27.60 (6.21) 28.00 (5.78) 27.80 (5.42) 27.80 (5.67) <0.001 
Smoking, n(%) 1371 (49.3) 1497 (45.6) 970 (41.5) 906 (40.0) <0.001 
Alcohol >6 units, n(%) 1467 (54.5) 1773 (56.1) 1391 (62.1) 1425 (64.7) <0.001 
SBP mmHg, mean (SD) 166.23 (29.39) 163.81 (28.34) 163.36 (27.28) 162.17 (27.47) 0.002 
DBP mmHGg, mean (SD) 96.13 (15.42) 96.44 (14.38) 98.03 (22.46) 97.96 (13.87) <0.001 
TC mmol/l, mean (SD) 6.16 (1.88) 5.90 (1.26) 5.83 (1.16) 5.78 (1.45) <0.001 
eGFR<60, n(%) 737 (26.2) 796 (23.9) 524 (22.3) 459 (20.0)  <0.001 
ALP IU/L, M (IQR) 100 (71-165) 133 (81-190) 142 (86-193) 141 (86-189) <0.001 
ALT IU/L, M (IQR) 21 (15-30) 23 (17-33) 25 (18-36) 27 (19-40) <0.001 
AST IU/L, M (IQR) 21 (17-26) 22 (18-28) 24 (20-30) 25 (20-32) <0.001 
GGT IU/L, M (IQR) 24 (15-41) 26 (17-42) 28 (18-47) 31 (19-53) <0.001 
Albumin g/L, mean (SD) 42.98 (3.76) 43.78 (3.60) 44.22 (3.66) 44.53 (3.71) <0.001 
SD=standard deviation, M=median, BMI=body mass index, SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, 
eGFR=estimated glomerular filtration rate, IQR=interquartile range, ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate transaminase, 
GGT=gamma gultamyl transpeptidase.   
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7.3.3 Association of ALT and mortality  
Unadjusted KM time to death curves of ALT in quartiles are given in Figure 7-2 
on page 214. Time to all-cause mortality was significantly lower in quartile 1 of 
ALT compared with other quartiles (log rank p<0.001). In the Cox-PH model, ALT 
quartiles 2, 3 and 4 had significantly lower all-cause mortality in comparison to 
ALT quartile 1 after adjustment for multiple baseline confounding variables and 
final achieved SBP (Table 7-7; Model 1 on page 216).  Both CV and non-CV 
mortality show the same trend as all-cause mortality. Adding baseline total 
cholesterol (which was not available in 734 individuals with baseline ALT) to this 
model did not change the HR estimates significantly. The hazard estimates for 
IHD and stroke are presented in table 7-8 on page 217. Adjustment for other 
liver enzymes did not materially affect the results (Table 7-9 on page 218).  
There were no indications of violation of PH assumption in the log-log curves.  
 
Figure 7-2: Kaplan-Meier survival curves for ALT in quartiles  
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In the cubic spline regression Cox-PH model after incorporating all confounding 
variables, an inverse linear relationship between logALT in full range and all-
cause mortality was observed (Figure 7-3 on page 214).   In individuals younger 
than 55 years of age, ALT showed no relationship to mortality, while in older 
individuals >55 years of age (Figure 7-4 on page 215, panels A and B), ALT 
showed an inverse relationship with lower ALT associated with higher mortality 
and risk decreasing up to around 60 IU/L. In individuals BMI≤25, ALT showed 
inverse relationship to mortality, while in individuals BMI>25 (Figure 7-4 on page 
215, panels C and D), the association did not reach statistical significance.  
 
 
Figure 7-3: Regression spline Cox proportional hazard model for ALT and all-cause 
mortality.  
The ALT distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
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Figure 7-4: Regression spline Cox proportional hazard model for ALT and all-cause 
mortality (Sub-group analyses).  
The ALT distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range. A; age≤55 years, B; age>55 years, C; BMI≤25 kg/m2, D; BMI>25 
kg/m2.  
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Table 7-7: Cox proportional hazard models of liver tests and mortality.  
 
All-cause 
mortality 
CV  
Mortality 
Non-CV  
Mortality 
 
HR 95% CI HR 95% CI HR 95% CI 
ALT (Model 1)  N=2436/8677 N=1393/8677 N=1043/8677 
ALT Quartile 1 1 
 
1 
 
1 
 ALT Quartile 2 0.79* 0.71-0.87 0.80* 0.69-0.92 0.77* 0.66-0.91 
ALT Quartile 3 0.80* 0.71-0.90 0.74* 0.63-0.87 0.88 0.74-1.06 
ALT Quartile 4 0.81* 0.72-0.92 0.81* 0.69-0.95 0.83* 0.68-1.00 
AST (Model 2) N=2653/9825 N=1503/9825 N=1150/9825 
AST Quartile 1 1 
 
1 
 
1 
 AST Quartile 2 0.83* 0.74-0.93 0.86* 0.75-0.99 0.79* 0.67-0.93 
AST Quartile 3 0.83* 0.75-0.92 0.84* 0.73-0.97 0.82* 0.70-0.96 
AST Quartile 4 1.00 0.90-1.11 1.00 0.87-1.15 0.99 0.85-1.17 
GGT (Model 3)  N=1887/8572 N=1030/8572 N=857/8572 
GGT Quartile 1 1 
 
1 
 
1 
 GGT Quartile 2 1.01 0.90-1.15 0.97 0.82-1.15 1.06 0.89-1.28 
GGT Quartile 3 1.12 0.98-1.28 1.11 0.93-1.33 1.13 0.92-1.38 
GGT Quartile 4 1.27* 1.10-1.46 1.24* 1.02-1.50 1.31* 1.06-1.62 
ALP (Model 4) N=2429/9215 N=1383/9215 N=1046/9215 
ALP Quartile 1 1 
 
1 
 
1 
 ALP Quartile 2 1.03 0.93-1.13 1 0.88-1.14 1.07 0.92-1.24 
ALP Quartile 3 1.14* 1.00-1.29 1.07 0.91-1.27 1.22* 1.01-1.48 
ALP Quartile 4 1.28* 1.11-1.46 1.31* 1.10-1.57 1.25* 1.01-1.54 
Bili (Model 5) N=2510/9641 N=1394/9641 N=1116/9641 
Bili Quartile 1 1  1  1  
Bili Quartile 2 0.96 0.87-1.06 0.94 0.83-1.08 0.98 0.84-1.13 
Bili Quartile 3 0.90 0.80-1.00 0.87 0.75-1.02 0.93 0.78-1.11 
Bili Quartile 4 0.93 0.83-1.05 0.92 0.78-1.08 0.95 0.79-1.13 
*p<0.05, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline 
phosphatase, GGT=gamma-glutamyltransferase (GGT), Bili=bilirubin, CVD=Cardiovascular 
disease, Non-CVD=non-cardiovascular disease, HR=hazard Ratio, CI=confidence interval. 
All models are adjusted for age, gender, BMI=body mass index, tobacco smoking, alcohol 
use, year of first visit (epoch), baseline SBP and DBP, eGFR, and final achieved SBP.  
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 Table 7-8: Cox proportional hazard models of liver tests and IHD and Stroke mortality.  
 
IHD  
Mortality 
Stroke  
Mortality 
  
HR 95% CI HR 95% CI 
ALT (Model 1)  N=763/8677 N=341/8677 
ALT Quartile 1 
 
1 
 
1 
 ALT Quartile 2 
 
0.89 0.73-1.07 0.73* 0.55-0.96 
ALT Quartile 3 
 
0.75* 0.60-0.94 0.76 0.55-1.04 
ALT Quartile 4 
 
0.77* 0.61-0.96 0.84 0.61-1.17 
AST (Model 2) N=804/9825 N=368/9825 
AST Quartile 1 
 
1 
 
1 
 AST Quartile 2 
 
0.98 0.81-1.19 0.79 0.58-1.08 
AST Quartile 3 
 
0.77* 0.63-0.94 0.99 0.75-1.31 
AST Quartile 4 
 
0.94 0.77-1.14 1.15 0.87-1.53 
GGT (Model 3)  N=576/8572 N=231/8572 
GGT Quartile 1 
 
1 
 
1 
 GGT Quartile 2 
 
1.01 0.80-1.26 0.99 0.69-1.42 
GGT Quartile 3 
 
1.06 0.83-1.36 1.41 0.96-2.05 
GGT Quartile 4 
 
1.20 0.93-1.56 1.58* 1.05-2.38 
ALP (Model 4) N=732/9215 N=343/9215 
ALP Quartile 1 
 
1 
 
1 
 ALP Quartile 2 
 
0.96 0.81-1.15 1.09 0.85-1.41 
ALP Quartile 3 
 
1.16 0.92-1.46 0.98 0.68-1.39 
ALP Quartile 4 
 
1.38* 1.08-1.75 1.29 0.89-1.86 
Bilirubin (Model 5) N=743/9641 N=346/9641 
Bili Quartile 1  1  1  
Bili Quartile 2  0.95 0.79-1.14 1.04 0.79-1.36 
Bili Quartile 3  0.91 0.74-1.14 0.92 0.66-1.27 
Bili Quartile 4  0.91 0.73-1.13 1.13 0.82-1.54 
*p<0.05, ALP=alkaline phosphatase, ALT=alanine transaminase, AST=aspartate 
transaminase, GGT=gamma gultamyl transferase, Bili=bilirubin, IHD=ischemic heart 
disease, HR=hazard Ratio, CI=confidence interval.  
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Table 7-9: Cox proportional hazard model after accounting for other markers of liver dysfunction. 
 All-cause  
Mortality 
CV  
Mortality 
IHD  
Mortality 
Stroke  
Mortality 
Non-CV mortality 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
ALT (Model 6)  N=2203/8223 N=1251/8223 N=683/8223 N=307/8277 N=952/8233 
ALT Quartile 1 1  1  1  1  1  
ALT Quartile 2 0.78* 0.70-0.87 0.79* 0.68-0.91 0.84 0.68-1.03 0.75 0.56-1.00 0.77* 0.65-0.91 
ALT Quartile 3 0.80* 0.71-0.90 0.74* 0.62-0.88 0.72* 0.57-0.91 0.75 0.53-1.05 0.89 0.74-1.08 
ALT Quartile 4 0.84* 0.74-0.97 0.83* 0.70-0.98 0.77* 0.61-0.97 0.81 0.57-1.15 0.86 0.70-1.05 
AST (Model 7) N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
AST Quartile 1 1   1   1   1   1   
AST Quartile 2 0.87* 0.76-0.99 0.89 0.74-1.07 1.05 0.83-1.34 0.75 0.50-1.11 0.84 0.70-1.02 
AST Quartile 3 0.77* 0.67-0.87 0.83* 0.69-0.99 0.78 0.61-1.01 0.83 0.57-1.22 0.70* 0.57-0.85 
AST Quartile 4 0.94 0.82-1.08 0.99 0.82-1.20 1 0.77-1.30 1.03 0.69-1.53 0.89 0.72-1.09 
GGT (Model 7)  N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
GGT Quartile 1 1   1   1   1   1   
GGT Quartile 2 0.97 0.85-1.11 0.92 0.76-1.10 0.87 0.68-1.12 0.96 0.66-1.44 1.04 0.86-1.27 
GGT Quartile 3 1.02 0.88-1.18 0.97 0.80-1.19 0.85 0.64-1.11 1.22 0.81-1.86 1.08 0.87-1.34 
GGT Quartile 4 1.18* 1.02-1.38 1.10 0.90-1.36 0.98 0.74-1.29 1.34 0.87-2.07 1.29* 1.03-1.62 
ALP (Model 7) N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
ALP Quartile 1 1   1   1   1   1   
ALP Quartile 2 1.05 0.92-1.20 1.06 0.88-1.26 1.06 0.83-1.36 0.91 0.63-1.31 1.04 0.85-1.27 
ALP Quartile 3 1.25* 1.07-1.46 1.20 0.97-1.49 1.38* 1.04-1.84 0.78 0.49-1.26 1.30* 1.04-1.63 
ALP Quartile 4 1.61* 1.39-1.87 1.68* 1.37-2.05 1.90* 1.45-2.49 1.35 0.89-2.07 1.54* 1.23-1.92 
Bilirubin (Model 7) N=1737/8124 N=929/8124 N=508/8124 N=209/8124 N=808/8124 
Bili Quartile 1 1  1  1  1  1  
Bili Quartile 2 0.89 0.79-1.00 0.90 0.77-1.06 0.92 0.74-1.15 1.11 0.79-1.55 0.88 0.73-1.04 
Bili Quartile 3 0.81* 0.70-0.94 0.77* 0.63-0.94 0.82 0.63-1.08 0.77 0.49-1.21 0.85 0.69-1.04 
Bili Quartile 4 0.79* 0.68-0.92 0.80* 0.65-0.99 0.87 0.66-1.14 0.95 0.62-1.47 0.77 0.61-0.96 
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7.3.4 Association of AST and mortality  
Shortest survival time was observed in quartile 4 of AST in comparison to other 
quartiles (Figure 7-5 on page 219). A clear ‘U’ shaped association was observed 
with significantly lower mortality in quartile 2 (HR=0.83, 95% CI: 0.74-0.93) and 
3 (HR=0.83, 95% CI: 0.75-0.92) compared with quartile 1 (Table 7-7 on page 216) 
after adjustment for all confounding variables as in Model 2. The trend was 
similar for both CV and non-CV mortality outcomes. Incorporation of baseline 
total cholesterol (which was not available in 865 individuals with baseline AST) 
to this model did not change the HR estimates significantly. Results were similar 
when other liver enzymes were added to the model as predictor variables (Table 
7-9 on page 218).  In the cubic spline regression Cox-PH model, after 
incorporating all confounding variables, a ‘U’ shaped relationship between 
logAST and all-cause mortality was observed with significantly higher mortality 
at both ends of the distribution (Figure 7-6 on page 220).  Similar association 
was seen even in the BMI stratified analyses (Figure 7-7 on page 220). 
 
Figure 7-5: Kaplan-Meier survival curves for AST in quartiles  
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Figure 7-6: Cubic regression Cox proportional hazard model for AST and all-cause mortality.  
AST distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
 
 
Figure 7-7: Regression spline Cox proportional hazard model for AST and all-cause 
mortality (Sub-group analyses). 
AST distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range. A; BMI≤25 kg/m2, B; BMI>25 kg/m2.  
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7.3.5 Association of GGT and mortality  
In the KM analysis the shortest survival time was observed in the last quartile of 
GGT (Figure 7-8 on page 221). It had significantly higher all-cause mortality 
(HR=1.27, 95% CI: 1.10-1.46), CV mortality (HR=1.24. 95% CI: 1.02-1.50), stroke 
mortality (HR=1.58, 95% CI: 1.05-2.38) and non-CV mortality (HR=1.31, 95% CI: 
1.06-1.62) compared with quartile 1 of GGT (Table 7-7 on page 216) after 
adjustment for confounding variables as in Model 3. Further adjustment for 
other liver enzymes reduced the magnitude of HRs between mortality risk in 
quartile 1 and quartile 4 (Table 7-8 on page 217; all-cause mortality HR=1.18, 
95% CI: 1.02-1.38, CV mortality HR=1.10. 95% CI: 0.90-1.36, stroke mortality 
HR=1.34, 95% CI: 0.87-2.07, and non-CV mortality HR=1.29, 95% CI: 1.03-1.62). A 
positive linear relationship between logGGT and all-cause mortality was 
observed in the cubic regression spline Cox-PH model (Figure 7-9 on page 222).   
In individuals BMI≤25, GGT showed positive linear relationship to mortality 
(Figure 7-10 on page 222), while in individuals BMI>25 (Figure 7-11 on page 223), 
the association did not reach statistical significance. Alcohol intake (Figures 7-12 
on page 223) appears to have no effect on mortality risk associated with GGT. 
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Figure 7-8: Kaplan-Meier survival curves for GGT in quartiles  
 
 
Figure 7-9: Regression spline Cox proportional hazard model for GGT and all-cause 
mortality.  
GGT distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
 
 
Figure 7-10: Regression spline Cox proportional hazard model for GGT and all-cause 
mortality in individuals with BMI≤25 kg/m2. 
GGT distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
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Figure 7-11: Regression spline Cox proportional hazard model for GGT and all-cause 
mortality in individuals with BMI>25 kg/m2. 
GGT distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
 
 
 
 
Figure 7-12: Regression spline Cox proportional hazard model for GGT and all-cause 
mortality in alcohol users (A) and non-users (B).  
GGT distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
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7.3.6 Association of ALP and mortality  
In the unadjusted KM model the shortest survival time was observed in quartile 4 
of ALP (Figure 7-13 on page 224). While quartile 3 of ALP had 14% (HR=1.14, 95% 
CI: 1.00-1.29) excess mortality, it was 28% (HR=1.28, 95% CI: 1.11-1.46) in 
quartile 4 compared with quartile 1 after adjustment for multiple risk factors as 
in Model 4 (Table 7-7 on page 216). The pattern of risk was similar for CV, IHD, 
and non-CV mortality.  Further adjustment for other liver enzymes had the 
effect of increasing the hazard ratios for quartile 3 and quartile 4 compared with 
quartile 1, for all-cause, CV, IHD, and non-CV mortality (Table 7-8 on page 217).  
A positive linear trend in mortality with logALP was observed in the cubic 
regression spline analysis (Figure 7-14 on page 225).  While a similar positive 
linear trend was seen in individuals with BMI>25 kg/m2 (Figure 7-15 on page 
225), the association shows non-linear relationship with increase in mortality 
above the upper limit normal value of ALP in individuals with BMI≤25 (Figure 7-
16 on page 226).   
 
Figure 7-13: Kaplan-Meier survival curves of ALP in quartiles.  
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Figure 7-14: Regression spline Cox model for ALP and all-cause mortality.  
ALP distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
 
Figure 7-15: Regression spline Cox model for ALP and all-cause mortality in individuals with 
BMI>25 kg/m2. 
ALP distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
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Figure 7-16: Regression spline Cox model for ALP and all-cause mortality in individuals with 
BMI≤25 kg/m2. 
ALP distribution is in log scale. Red triangles on the horizontal axis indicate lower and 
upper limits of normal range.  
7.3.7 Association of Bilirubin and Mortality 
In the unadjusted KM model the shortest survival time was observed in quartile 1 
of bilirubin (Figure 7-17 on page 227). While the median survival time in quartile 
1 of bilirubin was 30.75 years, they were 32.09, 33.54 and 33.48 in quartiles 2, 3 
and 4 respectively. In Model 5, adjusted for baseline variables and final achieved 
SBP, bilirubin was not associated with mortality outcomes (Table 7-7 on page 
216). However, once adjustment was made for other liver enzymes, bilirubin 
quartiles 3 and 4 had significantly lower all cause (HR=0.81, 95% CI: 0.70-0.94 
and HR=0.79, 95% CI: 0.68-0.92 respectively) and cardiovascular (HR=0.77, 95% 
CI: 0.63-0.94 and HR=0.80, 95% CI: 0.65-0.99 respectively) mortality risk than 
quartile 1 (Table 7-8 on page 217).   An inverse linear relationship between log 
bilirubin and all-cause mortality was observed in the cubic regression spline Cox-
PH model (Figure 7-18 on page 227). The inverse relationship between bilirubin 
and mortality persisted irrespective of smoking status (Figures 7-19 on page 228, 
panels A and B) and BMI levels (Figures 7-19 on page 228, panels C and D).  
 
-
2.
7
1.
0
2.
7
7.
4
H
az
a
rd
 
Ra
tio
 
0
1.
5
0.
5
1.
0
2.
.
0
D
e
n
si
ty
10 32 100 316 562
Alkaline Phosphatase, IU/L  
Chapter 7 Liver Enzymes, Bilirubin and Mortality 227 
 
Figure 7-17: Kaplan-Meier survival curves for serum bilirubin in quartiles  
 
Figure 7-18: Regression spline Cox model for serum bilirubin and all-cause mortality.  
Serum bilirubin distribution is in log scale. Red triangles on the horizontal axis indicate 
lower and upper limits of normal range.  
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Figure 7-19: Regression spline Cox model for serum bilirubin and all-cause mortality (Sub-
group analyses).  
Serum bilirubin distribution is in log scale. Red triangles on the horizontal axis indicate 
lower and upper limits of normal range. A; smokers, B; non-smokers, C; BMI≤25 kg/m2, D; 
BMI>25 kg/m2.  
7.3.8 Liver enzymes, bilirubin and follow-up blood pressure  
In the GEE models, the average number of BP observations in each individual 
were 5.2. The annual reduction in SBP and DBP were 3.66 (95% CI: 3.49-3.83) 
and 1.96 (95% CI: 1.85-2.07) mmHg, respectively. The number of observations, 
number of individuals, and the GEE regression coefficients with their 95% CI in 
each model are explained in tables 7-10 to 7-12 on page 231-232. Each unit 
increase in ALT on a logarithmic scale decreased SBP by 1.94 (95% CI: 0.42-3.46) 
mmHg. Similarly each unit increase in bilirubin on a logarithmic scale decreased 
longitudinal SBP by 2.03 (95% CI: 0.29-3.78) mmHg. Each unit increase in both 
GGT and ALP on a logarithmic scale increased SBP by 2.92 (95% CI: 1.85-3.98) 
and 8.96 (7.48-10.45) mmHg, respectively. Blood pressure responses to AST 
quartiles were non-linear with maximum increase in first and last quartiles in 
comparison to quartile 2. 
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While the SBP response was more prominent in individuals over 55 years of age 
for ALT, AST and bilirubin, both ALP and GGT did not show any such differences. 
Although the SBP response to unit increase in ALT in overweight group was 
consistent with the overall response, SBP increased with unit increase in ALT in 
normal weight individuals. The SBP responses to log bilirubin and log ALT were 
prominent only in smokers and alcohol users in comparison to non-smokers and 
non-users of alcohol.  
Consistent to the SBP responses to both GGT and ALP, similar changes in DBP 
was also observed. Unit increase in GGT and ALP on a logarithmic scale 
increased follow-up DBP by 2.45 (95% CI: 1.73-3.16) and 4.03 (95% CI: 3.06-5.01) 
mmHg, respectively.  However in the stratified analyses, increase in follow-up 
DBP with GGT was seen only among individuals ≤55 years. Overall, ALT, AST and 
bilirubin did not influence follow-up DBP. In the stratified analyses the follow-up 
DBP decreased with bilirubin in overweight individuals, while it increased 
significantly with bilirubin in normal weight individuals. Similar contrasting 
results are observed in the stratified analyses based on alcohol use status (Table 
7-11 on page 231) and smoking (Table 7-12 on page 232).  
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Table 7-10: Liver enzymes and bilirubin based group average effect on longitudinal changes in systolic blood pressure.  
Variable  Overall Age≤55 Age>55 BMI≤25 BMI>25 Alcohol Users Alcohol non-users 
 GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI 
ALT  N=19367, G=3733 N=11510, G=2231 N=7857, G=1502 N=5396, G=1045 N=13971, G=2688 N=7673, G=1472 N=12156, G=2351 
logALT -1.94, -3.46; -0.42* -1.25, -3.12; 0.62 -3.27, -5.90; -0.64* 2.33, -0.88; 5.54 -3.24, -4.98; -1.51** -2.89, -5.54; -0.24* -1.39, -3.22; 0.45 
AST  N=20053, G=3868 N=11907, G=2311 N=8146, G=1557 N=5705, G=1104 N=14348, G=2764 N=8005, G=1537 N=12527, G=2425 
Q1 1.21, 0.33; 2.09* 1.12,  0.02; 2.23* 1.18, -0.26; 2.61 2.07,  0.48; 3.65* 0.82,  -0.22; 1.88 -0.49,  -1.87; 0.89 2.63, 1.51; 3.75** 
Q2 REF REF REF REF REF REF REF 
Q3 0.85, 0.01; 1.70* 1.65, 0.58; 2.72* -0.07, -1.43; 1.28 1.18, -0.43; 2.80 0.83, - 0.15; 1.82 -0.04, -1.35; 1.27 1.67, 0.60; 2.85* 
Q4 0.94, 0.07; 1.82* 1.25, 0.17; 2.32* 0.22, -1.25; 1.69 1.76,  0.03; 3.50* 0.56, -0.45; 1.58 0.34,  -1.14; 1.82 1.48, 0.41; 2.55* 
GGT  N=18083, G=3497 N=10558, G=2055 N=7525, G=1442 N=4921, G=955 N=13162, G=2542 N=7561, G=1456 N=10988, G=2132 
logGGT 2.92, 1.85; 3.98** 3.16, 1.84; 4.48** 2.80, 0.99; 4.62* 2.27, .12; 4.42* 3.03, 1.80; 4.26** 4.10, 2.27; 5.92** 2.22, 0.95; 3.51** 
ALP N=20328, G=3920 N=12050, G=2338 N=8278, G=1582 N=5743, G=1111 N=14585, G=2809 N=8108, G=1557 N=12703, G=2458 
logALP 8.96, 7.48; 10.45** 9.00, 7.24; 10.78** 9.00, 6.37; 11.65** 8.22, 5.59; 10.85 8.90, 7.09; 10.71 7.33, 4.82; 9.83** 9.76, 7.94; 11.57** 
Bilirubin N=19583, G=3779 N=11584, G=2249 N=7999, G=1530 N=5482, G=1063 N=14101, G=2716 N=7875, G=1512 N=12167, G=2357 
logBilirubin -2.03, -3.78; -0.29* -0.64, -2.80; 1.52 -3.70, -6.60; -0.80* -1.23, -4.46; 2.01 -2.61, -4.68; -0.55* -5.79, -8.53; -3.04** 0.65, -1.57; 2.87 
*p<0.05, **p<0.001**, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase, 
CI=confidence interval, REF=reference group, N=total number of observations, G=total number of individuals/groups and GEE β=generalised estimating 
equations β coefficient . All models are adjusted for age, gender, epochs, BMI=body mass index, tobacco smoking, alcohol use and eGFR CKD status.  
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Table 7-11: Liver enzymes and bilirubin based group average effect on longitudinal changes in diastolic blood pressure.  
Variable  Overall Age≤55 Age>55 BMI≤25 BMI>25 Alcohol Users Alcohol non-users 
 GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI 
ALT  N=19366, G=3733 N=11510, G=2231 N=7856, G=1502 N=5396, G=1045 N=13970, G=2688 N=7672, G=1472 N=12156, G=2351 
logALT 0.74, -0.30; 1.78 0.80, -0.65; 2.26 -1.91, -3.30; -0.53* 2.42, -0.04; 4.88 0.06, -1.05; 1.18 -0.25, -1.66; 1.16 1.48, 0.08; 2.88* 
AST  N=20052, G=3868 N=11907, G=2311 N=8145, G=1557 N=5705, G=1104 N=14347, G=2764 N=8004, G=1537 N=12527, G=2425 
Q1 0.02, -0.50; 0.55 0.24,  -0.49; 0.97 -0.38,  -1.10; 0.33 -0.01, -1.19-1.16 -0.01,  -0.55; 0.55 -0.91,  -1.60; -0.22* 0.64,  -0.09; 1.37 
Q2 REF REF REF REF REF REF REF 
Q3 0.30, -0.20; 0.80 0.42,  -0.29; 1.13 0.06, -0.62; 0.73 0.28, -0.91; 1.47 0.28, -0.24; 0.80 -0.20, -0.86; 0.45 0.76, 0.06; 1.47* 
Q4 0.44, -0.09; 0.96 0.99, 0.27; 1.70* -0.85, -1.59; -0.12* 0.92,  -0.36; 2.20 0.15, -0.38; 0.68 -0.60, -1.34; 0.14 1.02, 0.32; 1.71* 
GGT  N=18082, G=3497 N=10558, G=2055 N=7524, G=1442 N=4921, G=955 N=13161, G=2542 N=7560, G=1456 N=10988, G=2132 
logGGT 2.45, 1.73; 3.16** 3.34, 2.30; 4.38** 0.32, -0.59; 1.22 3.56, 1.91; 5.22** 1.84, 1.07; 2.62 1.57, 0.66; 2.48* 3.04, 2.05; 4.04** 
ALP N=20327, G=3920 N=12050 G=2338 N=8277, G=1582 N=5743, G=1111 N=14584, G=2809 N=8107, G=1557 N=12703, G=2458 
logALP 4.03, 3.06; 5.01** 4.65, 3.30; 5.99** 2.64, 1.33; 3.96** 5.34, 3.39; 7.28** 3.17, 2.06; 4.29** 3.19, 1.93; 4.45 4.42, 3.09; 5.77** 
Bilirubin N=19582, G=3779 N=11584, G=2249 N=7998, G=1530 N=5482, G=1063 N=14100, G=2716 N=7874, G=1592 N=12167, G=2357 
logBilirubin 0.15, -0.99; 1.29 1.37, -0.26; 3.00 -0.88, -2.32; 0.56 3.75, 1.33; 6.18* -1.53, -2.80; -0.27* -2.41, -3.80; -1.01 2.30, 0.67; 3.93* 
*p<0.05, **p<0.001**, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase, 
CI=confidence interval, REF=reference group, N=total number of observations, G=total number of individuals/groups and GEE β=generalised estimating 
equations β coefficient . All models are adjusted for age, gender, epochs, BMI=body mass index, tobacco smoking, alcohol use and eGFR CKD status.  
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Table 7-12: Liver enzymes and bilirubin based group average effect on longitudinal changes in blood pressure stratified by smoking status.  
 SBP DBP 
Variable  Smokers Non-Smokers Smokers Non-smokers 
 GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI GEE β, 95% CI 
ALT  N=8567, G=1656 N=10800, G=2077 N=8566, G=1656 N=10800, G=2077 
logALT -2.79, -5.09; -0.50* -0.97, -3.00; 1.06 1.74, -0.13; 3.60 -0.06, -1.20; 1.08 
AST  N=8898, G=1720 N=11155, G=2148 N=8897, G=1720 N=11155, G=2148 
Q1 1.34, 0.03; 2.65* 0.88,  -0.31; 2.07 0.19, -0.69; 1.07 -0.16,  -0.79; 0.46 
Q2 REF REF REF REF 
Q3 1.01,  -0.24; 2.27 0.77,  -0.36; 1.90 0.39, -0.46; 1.24 0.20, -0.39; 0.80 
Q4 1.34, 0.02; 2.65* 0.58,  -0.59; 1.75 0.75,  -0.14; 1.64 0.12,  -0.50; 0.73 
GGT  N=7998, G=1551 N=10085, G=1946 N=7997, G=1551 N=10085, G=1946 
logGGT 3.27, 1.65; 4.89** 2.62, 1.21; 4.04** 2.59, 1.25; 3.93** 2.27,  1.53; 3.01** 
ALP N=8983, G=1737 N=11345, G=2183 N=8982, G=1737 N=5743, G=1111 
logALP 11.15,  8.97; 13.34** 6.61,  4.58; 8.64** 5.05,  3.32; 6.77** 3.09,  2.02; 4.15** 
Bilirubin N=8623, G=1669 N=10960, G=2110 N=8622, G=1669 N=10960, G=2110 
logBilirubin -3.56, -6.19; -0.93* -0.90, -3.23; 1.44 2.10, 0.07; 4.14* -1.53, -2.79; -0.29* 
*p<0.05, **p<0.001**, ALT=alanine aminotransferase, AST=aspartate transaminase, ALP=alkaline phosphatase, GGT=gamma-glutamyltransferase, 
CI=confidence interval, REF=reference group, N=total number of observations, G=total number of individuals/groups and GEE β=generalised estimating 
equations β coefficient . All models are adjusted for age, gender, epochs, BMI=body mass index, tobacco smoking, alcohol use and eGFR CKD status.  
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7.4 Discussion  
In a large hypertensive cohort followed-up for more than 35 years, indices of 
liver function or injury are significant predictors of mortality.  I show that higher 
ALT and bilirubin levels (up to 4 SD from mean) are associated with lower 
mortality and lower follow-up BP, while increasing GGT and ALP are associated 
with higher mortality risk and higher follow-up BP. The mortality risk association 
of the liver tests mirror their effect on longitudinal BP change, though the BP 
effect was blunted for ALT and bilirubin in younger, non-obese or low alcohol-
intake subgroups. 
Although our findings on GGT and ALP are consistent with the current literature 
476 489 492 678-681 they contradict some of the previous findings for both ALT and AST 
654 682. ALT is a non-specific marker of liver fat, a biomarker for NAFLD and it is 
associated with diabetes, metabolic syndrome and atherosclerosis 679. There is 
inconsistency in the literature on the direction of association with ALT and 
mortality outcomes in population based studies. Although the recently published 
Ford et al study reports significantly higher mortality in the lowest quartile of 
ALT distribution, the findings were limited in the normal range of ALT and in 
older age group 487. In the current study the association with mortality and ALT 
is inverse linear in the entire range of ALT. The inverse relationship between 
ALT and mortality (all-cause, CVD and non-CVD) is independent of all other 
concomitant liver tests and is blunted in the younger subgroup (<55 years). In 
the older group (>55y years), the inverse risk appears to be driven by increased 
risk in those with lower ALT. The reason for the increased risk seen with lower 
ALT is not clear. A recent study in the elderly (>70 years) showed that the 
increased risk associated with low ALT disappeared after adjustment for frailty 
683. This indicates that ALT is more a marker of aging and frailty. The reduced 
ALT levels with increasing age would indicate that ALT may be a marker of 
functioning hepatocyte mass or sarcopenia as ALT is primarily produced by the 
liver (with a small proportion from skeletal muscle). It is therefore reasonable to 
speculate that the greater reduction in BP in this cohort of treated hypertensive 
patients with higher ALT levels may indicate better antihypertensive efficacy, as 
the majority of commonly used antihypertensive agents are pro-drugs which 
require activation in the liver. The protection offered by ALT in the treated 
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hypertensive cohort may reflect greater BP reduction in addition to protection 
offered by greater functioning hepatocyte mass. 
While AST is another enzyme associated with liver parenchymal cells, like ALT, it 
is also present in several other organ systems including cardiac muscle, skeletal 
muscle, kidneys, and brain tissue 684.  Despite strong correlation between AST 
and ALT658 the pattern of risk is different with AST showing a U-shaped 
association with all-cause, CV and non-CV mortality in contrast to ALT. 
Interestingly, both AST and ALT show increased all-cause, CV and non-CV 
mortality outcomes at the lower end of their distribution and the associations 
remain robust even after adjustment for multiple confounding factors.  
The inverse linear association of serum bilirubin and all-cause mortality observed 
in our study is consistent with the previous study reports. In a study conducted 
over half a million adults from the United Kingdom primary care research 
database (The Health Improvement Network, THIN), a 3% decrease in mortality 
was observed with 0.1 mg/dl incremental increase in bilirubin in both men and 
women 497. The anti-oxidant 672, and anti-inflammatory 685-687 properties of 
bilirubin may partially explain the biological mechanisms associated with this 
inverse relationship. Low bilirubin is also associated with conditions that 
increase CVD mortality such as hypertension 688 689, dysglycemia 690, metabolic 
syndrome 691, coronary artery calcification 692, CHD 493 494 675, peripheral arterial 
disease 675, and stroke 674 693. Bilirubin levels are strongly determined by genetic 
668and environmental influences. For example bilirubin levels are reduced in 
smokers possibly due to depletion on exposure to reactive oxygen species found 
in cigarette smoke 694 695. In the Framingham Offspring study, a prospective 
population based cohort study, the UGTA1 genotype was associated with both 
serum bilirubin and CHD 696. Individuals with the homozygous for UGTA1*28 
(genotype 7/7) in the Framingham study participants had significantly higher 
serum bilirubin concentrations and one third risk of CHD events (HR=0.30, 95% 
CI=0.12-0.74). The present study confirms the protective effect of raised 
bilirubin and shows that it is robust to smoking both by adjusting for smoking and 
by analysis stratified by smoking status indicating that confounding in unlikely to 
be a major issue. Although there may exist residual confounding due to 
unmeasured environmental factors, this is also likely to be minimal because of 
the extremely large effect of smoking on mortality. The protective effect of 
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bilirubin is also independent of other concomitant liver enzymes. Higher 
bilirubin is associated with a lower baseline BP and with greater longitudinal 
reduction in BP which suggest that the protective effect of bilirubin can be 
partly explained by BP effects. It is also likely that in the GBPC cohort of treated 
hypertensive patients, the reduction in longitudinal BP may also reflect better 
activation of antihypertensive pro-drugs, as bilirubin levels reflect hepatic 
processing capacity. One way of elucidating the mechanism would be to study 
total and unconjugated bilirubin; however the present study was limited by the 
unavailability of unconjugated bilirubin levels in this cohort. 
Both ALP and GGT are associated with increased mortality risk which is 
significant only at the higher end of the distribution. But the striking finding is 
the association of both GGT and ALP with higher longitudinal BP consistently. 
Despite a 4 mmHg annual decline in SBP related to the antihypertensive 
treatment seen in this cohort, the BP increases with both ALP and GGT. The 
magnitude of BP increase is higher with ALP than GGT. GGT has pro-oxidant 
effects due to its role in the extracellular catabolism of glutathione 697, and high 
GGT has been associated with incident diabetes 663 metabolic syndrome and 
fatty liver 681. Recent prospective studies show that high GGT is positively 
associated with increased mortality or incidence of cardiovascular disease 489 663 
678, and the present study results reflect this. However, a clear association 
between GGT and CV mortality was not observed once the effects of other liver 
tests are accounted for in the model. There is a linear increase of bilirubin with 
GGT levels and the 24% excess risk of CV mortality associated with the highest 
quartile of GGT disappears once bilirubin is included in the model. The pro-
oxidant and anti-oxidant properties respectively of GGT and bilirubin associated 
with opposite effects on CV risk when considered jointly indicates that GGT does 
not have a major independent impact on CV mortality. The mechanism by which 
ALP and GGT increase follow-up BP levels is unclear and clearly merits further 
study. 
7.5 Strengths and limitations  
The strengths of the current study include; a large cohort of nearly 10,000 
hypertensive adults, 35 years of follow-up with median survival time of 32 years, 
the ability to link liver enzymes with differing causes of mortality outcomes, 
inclusion of the entire distribution of liver enzymes (except the level suggestive 
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of obstructive liver disease), and most importantly the competence to model the 
potential non-linear association of markers of liver dysfunction on mortality 
outcomes. The exclusion of individuals without liver enzymes assessed at 
baseline from our analysis, the bias introduced by the missing covariates in the 
adjusted Cox-PH models were the major limitations. However, our results were 
consistent across multiple models with and without such variables.  
7.6 Summary  
Indices of liver function or injury independently predict mortality outcomes in 
the hypertensive population. A positive linear association was observed for both 
GGT and ALP with mortality outcomes, while it was more complex, non-linear 
and ‘U’ shaped association for AST. Both ALT and bilirubin show inverse linear 
association with mortality. These markers independently influence follow-up BP. 
These findings highlight the need for more tailored assessment of liver tests, in 
the absence of obvious liver disease, for cardiovascular risk stratification in 
hypertension management. While assessment of these additional markers help 
the physician to identify high risk groups for targeted management, addition of 
these variables  may increase the complexity on the current risk calculations. 
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8 Conclusion   
Blood pressure tops the listing of common global risk factors according to their 
population attributable fraction of mortality burden 312. Hypertension is common 
among adults, affecting at least one in four worldwide 305. It imposes a 2-3 fold 
excess risk for cardiovascular mortality compared with that of normotensive 
individuals of the same age 291. However, not all individuals with hypertension 
appear to be equally susceptible to early mortality. Current risk reduction 
strategies focus on a combination of environmental (smoking), biochemical 
(lipids), disease (diabetes) and demographic factors (age, sex) to calculate 
future cardiovascular risk 698. There are many modifications to this using social 
deprivation, albuminuria etc to enhance the prediction model 699-701. The 
absolute benefit of anti-hypertensive therapy depends not only on level of BP, 
but also on the presence or absence of additional risk factors 702. The search for 
a new biomarker or a predictor variable that is readily available and cost-
effective is therefore of special interest in hypertensive population. 
Several studies have been carried out to identify additional prognostic factors 
but these have focussed on novel biomarkers, for example B-type natriuretic 
peptides (BNP) 703 and C-reactive protien 704. While important prognostic 
information can be learned from routine blood tests that are often conducted in 
hypertension clinics, the usefulness of these markers in predicting survival has 
not previously been studied in detail. The aim of the current project was to 
explain the relationship between such inexpensive and commonly available 
markers and survival in hypertensive population.  
Altogether, five studies were conducted to assess the independent role of BP 
variability (BPV), haematocrit, serum phosphate, serum electrolytes and indices 
of liver dysfunction/injury in predicting mortality in hypertensive patients as 
part of this thesis work. The main strengths of these independent studies 
conducted were; a large cohort of nearly 15,000 hypertensive adults, a real life 
clinical settings, 35 years of follow-up with median survival time of 32 years, the 
ability to link predictor variables with differing causes of mortality outcomes, 
and adjustment for all potential confounding factors.  
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I show that both BPVSBP and BPVDBP calculated over different sequential time-
frames (of 1 to 5 years duration) are strong predictors of mortality independent 
of long-term average BP. Moreover, 60% of individuals show sustained high or low 
BPV over even longer time-frames of 6 to 9 years and this sustained BPV status is 
also a strong predictor of mortality independent of long-term average BP. From 
this study,  ARVSBP =17, calculated over any follow-up time frame greater than 1 
year and using a minimum of 3 readings more that 30 days apart, can be used as 
a threshold to define treated hypertensive patients as low or high risk. I propose 
that BPV is a prognostic marker that is independent of BP and probably captures 
a different biologic process to BP regulation. The clinical application of BPV will 
be to use a specific threshold (for example ARVSBP=17) to allow risk-stratification 
of treated hypertensive patients. Further clinical implications depend on 
whether there are interventions that can change BPV and whether these 
interventions will result in improvement in outcomes. The results indicate that 
BPV should be studied from a non-hypertension centric viewpoint to elucidate its 
pathogenic mechanisms.  
Among the biochemical parameters analysed in this thesis, the most interesting 
and novel finding is the association of serum chloride with mortality risk 
independent of sodium and other electrolytes. Serum chloride levels (<100 
mEq/L) identify high risk patients who should be targeted for more intensive 
investigation to achieve and maintain target BP. The underlying mechanism for 
this risk is unclear. A parsimonious explanation would be that serum chloride 
reflects abnormal physiology better than serum sodium, levels of which are 
perhaps more homeostatically regulated than chloride.  If other studies validate 
and extend these findings, further studies are necessary to elucidate the 
underlying mechanisms involved in the association of low serum chloride levels 
with mortality outcomes. However, as chloride measurement is part of routine 
clinical screening, our results are potentially translatable into clinical practice 
to identify hypertensive patients for more intensive investigation and BP 
management strategies. 
 
The increasing prevalence of alcohol use and obesity have focussed attention on 
abnormalities in liver function test (LFT) being early predictors of cardio-
metabolic risk. In current clinical practice, the definition of abnormal LFT is 
usually considered to be >2 SD from the mean, which triggers further 
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investigations based on the pre-test probability of liver disease. I show that 
higher ALT and bilirubin levels (up to 4 SD from mean) are associated with lower 
mortality and lower follow-up BP, while increasing GGT and ALP are associated 
with higher mortality risk and higher follow-up BP. The mortality risk association 
of the liver tests mirror their effect on longitudinal BP change, though the BP 
effect was blunted for ALT and bilirubin in younger, non-obese or low alcohol-
intake subgroups. The protective effect of ALT and bilirubin and their effect on 
longitudinal BP may reflect functioning liver mass and in addition the antioxidant 
property of bilirubin. This is the first study to show the effect of LFT on 
longitudinal BP control in treated hypertensive patients. These results need to 
be confirmed in independent studies as the usual caveats of observational 
studies apply. 
I demonstrate that Hct influences follow-up BP and it is an independent 
predictor of mortality in the hypertensive population. However, there are 
distinct differences both in terms of the strength and magnitude of the 
association of Hct and mortality between men and women that have not 
previously been known. The association of Hct and CV mortality is prominent 
among men in comparison to women, while non-CV mortality is prominently 
associated with Hct in women. Based on these findings, Hct levels should be 
taken into consideration as an important risk predictor in the assessment and 
management of hypertensive patients. However, further research is needed to 
elucidate the mechanism of this risk and to define management strategies. 
Hypertensive patients with Hct levels outside of the sex-specific low-risk 
reference ranges as identified in this study should be targeted for more 
aggressive BP and cardiovascular risk reduction treatment. 
The study of the association between phosphate and mortality demonstrates 
that elevated initial serum phosphate is an independent predictor of all-cause 
mortality in hypertensive patients. Although the association of serum phosphate 
with CV mortality is well known, especially in the CKD population, there are 
some additional novel findings in the present study. They are as follows; (a) the 
association between serum phosphate and mortality is independent of 
deprivation status, serum calcium and serum alkaline phosphatase levels and (b) 
while serum phosphate is associated with CV mortality in men, it is more closely 
associated with non-CV mortality in women. Phosphate is not currently 
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considered as a potentially modifiable risk factor for therapeutic interventions in 
hypertensive subjects. The impact of reduced intake of phosphate rich foods on 
serum phosphate level and mortality outcomes is not known. It is therefore 
reasonable to propose dietary intervention studies that target reduced intake of 
phosphate rich foods. The role of aggressive BP and cardiovascular risk reduction 
treatment in individuals with high serum phosphate also needs to be tested.  
There have been significant changes in the management of hypertension in the 
past two decades. Several hypertension management guidelines have been 
updated with new emerging data mainly from clinical trials. However, in 
community settings less than 50% of hypertensive patients are achieving the 
recommended systolic BP goals 323 705. Although there are several reasons for this 
underachievement, co-morbidities are often suggested as one of the main 
reasons for less intensive anti-hypertensive therapy and poor BP control. The 
studies conducted as part of this thesis in real life settings suggest that 
haematocrit, serum electrolytes and markers of liver dysfunction or liver injury 
significantly influence follow-up BP levels. These are novel findings and need to 
be confirmed in an independent population, and their cumulative effect on 
survival needs to be assessed using receiver operator characteristics curve (ROC) 
analysis or other reclassification methods such as integrated discrimination 
improvement (IDI) 706 to show if these add any additional information to improve 
the predictive potential of existing algorithms. However, the results with follow-
up BP are applicable to clinical practice, as they can enable clinicians to target 
the patients for more intensive management. If individuals with a specific set of 
serum markers require more intensive BP therapy to achieve treatment goals, 
monitoring of these variables in individuals with hypertension will help the 
physician to titrate the drugs more efficiently to achieve the desired level of BP 
control. Some of these markers may also have a role in resistant hypertension 
that needs to be investigated further. 
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